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RÉSUMÉ 
Streptococcus suis est un important pathogène porcin bactérien causant principalement des 
septicémies, des méningites, des endocardites et l'arthrite. Des 35 sérotypes connus, le sérotype 2 
est le plus fréquemment isolé et associé à la maladie. S. suis est aussi reconnue comme étant un 
agent de zoonose. Les humains peuvent être infectés via par des petites coupures ou abrasions aux 
mains par ce pathogène lors de manipulations avec de la viande ou des carcasses de porc infectées. 
L'infection humaine peut être sévère et causer des méningites, des septicémies, des endocartides, la 
surdité (consequence de la méningite) et éventuellement la mort. 
La pathogénèse de l'infection causée par S. suis n'est pas encore bi~n définie et plusieurs 
étapes sont probablement impliquées. Les mécanismes qui permettent à S. suis de se disséminer à 
partir des amygdales (le réservoir chez l'animal) ne sont pas bien compris. Il est admis que 
l'aptitude d'une bactérie à adhérer aux tissus de l'hôte est une étape critique de la plupart des 
infections microbiennes. Cette adhésion est considerée comme la première étape à une colonisation 
des muqueuses et peut aussi être la première étape à l'invasion des cellules de l'hôte, processus qui 
peut mener aux bactérémies ou aux septicémies. Un des types d'adhésines bactériennes les plus 
connues et les plus étudiés sont les protéines liant la fibronectine. De plus, la plupart des protéines 
liant la fibronectine décrites pour différents pathogènes ont été suggérées comme cibles potentielles 
de vaccins afin de prévenir l'infection bactérienne. En effet, il a été décrit que les anticorps liant ces 
protéines de surface ont la double activité de bloquer l'adhérence et d'augmenter la opsono-
phagocytose. 
À ce jour, trois types de protéines liant la fibronectine ont été identifiés chez les 
streptocoques: i) la famille MSCRAMM, renfermant un motif LPXTG médiant la liaison de cette 
proteine à la surface des bactéries par des sortases, ii) les protéines liant la choline et qui n'ont pas 
de motif LPXTG mais qui possèdent des répétitions liant la choline qui interagissent avec la 
phosphorylcholine des acides lipotéichoiques des bactéries à Gram positif et finalement, iii) un 
nouveau groupe de protéines nommé « anchorless » qui ne possèdent pas de motif LPXTG ou des 
répétitions liant la choline. Les mécanismes utilisés par ce dernier type de protéine pour être exporté 
à la surface de la bactérie sont encore inconnus. 
Comme S. suis est un pathogène extracellulaire qui adhère probablement aux composants 
de la matrice extracellulaire (ECM) lors des différents étapes de la pathogénèse, les principaux 
objectifs de ce travail étaient: i) d'étudier l'adhésion de S. suis sérotype 2 aux plus importants 
composants de la ECM, ii) d'identifier et de caractériser les adhésines impliquées dans l'adhésion 
de S. suis sérotype 2 aux protéines de l'ECM, plus particulièrement à la fibronectine, iii) de 
déterminer le rôle de ces adhésines dans la pathogénèse de l'infection causée par S. suis sérotype 2 
et finalement, iv) d'étudier l'activité protectrice de ces adhésines. 
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Nous démontrons pour la première fois que S. suis sérotype 2 peut lier spécifiquement les 
composantes majeures de l'ECM, comme la fibronectine et différents types de collagène. Alors que 
S. suis ne peut lier directement le collagène de type IV des membranes basales, il a le potentiel 
d'adhérer à cette protéine par un nouveau mécanisme en utilisant lafibronectine liée à sa surface 
comme pont. Cette propriété pourrait s'avérer être un nouveau mécanisme de colonisation et 
d'évasion immune de S. suis. La forte inhibition de l'adhésion de S. suis à la fibronectine et au 
collagène lorsque traité aux protéases et à la chaleur indique que ces mécanismes de liaison sont 
médiées surtout par des protéines. De plus, ces travaux démontrent que l'adhésion de S. suis à la 
fibronectine et au collagène est principalement de type sortase-indépendant, indiquant que la plupart 
des adhésines impliquées dans ces adhésions, contrairement à ce qui a été préalablement décrit pour 
d'autres streptocoques, ne sont pas des adhésines de la famille MSCRAMM. 
Lors de nos efforts pour mieux comprendre la pathogénèse de l'infection causée par S. suis, 
nous avons identifié et caractérisé une nouvelle protéine liant la fibronectine. Cette protéine a été 
identifiée comme étant une a-énolase (SsEno). La séquence en acides aminés de cette protéine 
démontre une absence de motif LPXTG ou de répétition liant la choline, classant cette protéine dans 
le nouveau groupe désigné protéines « anchorless » et attestant que l'activité des protéines liant la 
fibronectine de S. suis n'est pas reliée aux MSCRANIMs. À ce jour, la principale fonction décrite 
pour les énolases bactériennes de surface est une activité de liaison au plasminogène. Par contre, 
nous avons décrit pour la première fois que l'énolase de surface de S. suis n'a pas seulement une 
grande affinité pour le plasminogène mais aussi une affinité semblable pour la fibronectine. De 
plus, nous avons montré que cette protéine multifonctionnelle est aussi une protéine de choc 
thermique qui a aussi une activité de liaison aux IgG. Fonctionellement, nous avons prouvé que 
cette protéine est une nouvelle adhésine de S. suis qui participe à la capacité d'adhésion et 
d'invasion de cette bactérie via-à-vis les cellules endothéliales, indiquant que SsEno pourrait être 
une molécule clé dans la pathogénèse de l'infection causée par ce pathogène. Ces caractéristiques, 
incluant la grande immunogénicité de cette protéine chez le porc, fait de SsEno un candidat 
intéressant pour un vaccin contre les infections à S. suis. Par contre, les résultats obtenus dans ces 
travaux démontrent que, malgré que cette protéine induit une bonne réponse immunitaire, SsEno ne 
confère pas une protection contre les l'infection à S. suis. 
En resumé, ces travaux ont permis d'identifier une nouvelle adhésine importante de S. suis 
qui pourrait participer dans différentes étapes de la pathogenèse de cette bactérie comme l'évasion 
par la bactérie du système immunitaire de l'hôte et l'entrée de la bactérie dans le système nerveux 
central par les cellules endothéliales formant la barrière hémato-encéphalique. 
Mots clés: S. suis, MEC, fibronectine, enolase, IgG, HSP, adhésion, invasion, cellules 
endothéliales, vaccin 
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SUMMARY 
Streptococcus suis is an important bacterial pathogen of pigs that mainly causes septicemia, 
meningitis, endocarditis, and arthritis. Of the 35 known serotypes, serotype 2 is the most frequently 
isolated and associated with disease. S. suis is also a zoonotic agent. Humans can be infected with 
the pathogen while handling infected pig carcasses and meàt through exposed cuts and abrasions on 
their hands. Human infections may be severe, with meningitis, septicemia, endocarditis, and 
deafness as possible outcomes of infection. Death can also occur. 
The pathogenesis ofthe infection caused by S. suis is not clear and many steps are probably 
involved. The mechanisms that enable S. suis to disseminate from the tonsils (animal reservoir) 
throughout the animal are not weil understood. It is commonly believed that the ability of bacteria 
to adhere to host tissues is a critical step in the onset of most microbial infections. This adhesion is 
the first step for the colonization of mucosal surfaces and may also be the first step before the 
invasion of host cells, a process that may lead to bacteremia and sepsis. One of the most known and 
studied bacterial adhesins are the fibronectin-binding proteins. In addition, most of the fibronectin-
binding proteins described up to now for different pathogens have been suggested as potential 
vaccine targets for preventing bacterial infections since antibodies against these surface proteins are 
believed to have the dual activity of both adherence blocking andopsonic function. 
Up to now, three types of streptococcal fibronectin-binding proteins have been identified: i) 
the MSCRAMM family, containing an LPXTG motif that mediates bacterial surface binding by 
sortases, ii) the choline-binding proteins that lack the LPXTG motif but contained choline-binding 
repeats which interact with the phosphorylcholine ofthe lipoteichoic acid of Gram positive bacteria, 
and finally iii) the new denominated "anchorless" proteins which do not possess LPXTG motif or 
choline-binding repeats. The mechanism used by this type of proteins to be exposed to the surface 
of bacteria is still unknown. 
As S. suis is primarily an extracellular pathogen and it presumably adheres to components of 
the extracellular matrix (ECM) to initiate an infection, the main objectives of this work were: i) to 
study the adhesion of S. suis serotype 2 to sorne of the most important ECM proteins, ii) to identify 
and characterize the adhesins involved in the adhesion of S. suis serotype 2 to the ECM proteins, 
specially to fibronectin, iii) to determine the role of these adhesins in the pathogenesis of the 
infection caused by S. suis serotype 2 andfinally, iv) to study the protective activity of these 
adhesins. 
We have demonstrated for the first time that S. suis is able to specifically bind to major 
constituents of the ECM such as fibronectin and different types of collagen. Interestingly, while S. 
suis is not able to bind directly to basement membrane collagen type IV, it has the potential to 
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adhere to this protein via a surface-bound fibronectin mechanism. This property might represent a 
novel mechanism of colonization and immune evasion. The dramatic reduction in binding observed 
after protease and heat-treatment of S. suis to both, fibronectin and collagen, indicates a prote in-
mediated binding mechanism for these adhesions. In addition, this work also demonstrates that the 
adhesion of S. suis to fibronectin and collagen is mostly sortase-independent, which indicates that 
most of the adhesins involved in these S. suis adhesions, in contrast with what it has been described 
early for other streptococci, are not adhesins from the MSCRAMM family. 
In our continued effort to understand the pathogenesis of the infection caused by S. suis, we 
have identified and characterized a predominant S. suis fibronectin-binding prote in identified as an 
a-enolase (SsEno). Its amino acid sequence shows the absence of LPXTG motif or choline-binding 
repeats, including this prote in in the new denominated "anchorless proteins" and corroborating that 
the fibronectin-binding activity of S. suis are not related with MSCRAMMs. Up to now, the major 
function described for surface bacterial enolases is a strong plasminogen-binding activity. However, 
we have demonstrated for the first time that S. suis surface enolases have not only a high affinity for 
plasminogen but also a similar high affinity for fibronectin. In addition, the multifunctional SsEno 
is a heat-shock prote in that also has IgG-binding activity. We have also shown that this protein is a 
new S. suis adhesin that participates in the adhesion to and invasion ofthis bacterium to endothelial 
cells, indicating that SsEno cou Id be a key molecule in the pathogenesis of the infection caused by 
this pathogen. These features, including the high immunogenity of this protein in pigs, made of 
SsEno an interesting candidate for a vaccine against S. suis infections. However, results obtained in 
this work demonstrated that, although this prote in elicits a good immune response, SsEno did not 
confer protection against experimental S. suis infection. 
In conclusion, this work has permitted to identify a new and important S. suis adhesin 
which can participate in the different steps of the pathogenesis of the infection caused by this 
bacteria including its evasion of the host immune system and its entry to the CNS through the 
microvascular endothelial ce Ils forming the blood brain barrier. 
Key words: S. suis, ECM, fibronectin, enolase, IgG, HSP, adhesion, invasion, endothelial 
cells, vaccine 
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Streptococcus suis is a major swine pathogen that mainly causes sèpticemia, meningitis, 
endocarditis, and arthritis. Of the 35 known serotypes, serotype 2 is most frequently isolated and 
associated with disease. It has been proposed that two serotypes (serotypes 32 and 34) be excluded 
from S. suis species and re-designated as Streptococcus orisratti. S. suis, especially serotype 2, has 
also been described as an important zoonotic agent that affects people in close contact with infected 
pigs or pork-derived products. Indeed, an important number of cases of human disease with a high 
rate of mortality in China were directly linked to a concurr~nt outbreak of S. suis infection in pigs. 
Little is known about S. suis virulence factors. The capsule polysaccharide (CPS) is a 
critical virulence factor given that unencapsulated isogenic mutants are completely avirulent and 
rapidly cleared from the circulation in pig and mouse infection models. However, non-virulent 
strains are also encapsulated, indicating that virulence of this pathogen is a multifàctorial process. 
Another critical S. suis virulence factor is the new described OFS (opacity factor serum), since 
experimental infections of piglets with an isogenic ofs mutant strain revealed that OFS is necessary 
for S. suis serotype 2 virulence. OFS carries the typical structural elements of MSCRAMMs, thus it 
has been speculated that OFS functions as an adhesin and, in particular, that the C-terminal repeats 
of OFS bind fibronectin. However, no detection of any fibronectin-binding activity was found for 
the recombinant OFS. Other potential virulence factors have also been described in S. suis, 
including a hemolysin (suilysin), a 136-kDa muramidase-released protein (MRP), a 110-kDa 
extrace\1ular factor (EF) protein, Sao, a hyaluronidase, a superoxide dismutase, various proteases 
and different adhesins. 
The pathogenesis of S. suis infection is not fully understood and Iikely involves many steps. 
The pathogen is able to spread systemically from the palatine and pharyngeal tonsils, that are both 
potential portaIs of entry for S. suis, resulting either in general septicemia or infections of specifie 
organs (e.g. endocarditis, meningitis, arthritis), followed frequently by death. However, the 
mechanisms that enable the pathogen to disseminate throughout the animal and colonize different 
tissues are not weil understood. It has been demonstrated that S. suis is able to bind to and, in sorne 
cases, invade endothelial and epithelial cells of human and porcine origin. However, the S. suis 
adhesins and the host receptors involved in these interactions are still unknown. 
Host extraceUular matrix (ECM) proteins are used as ceH receptors by many pathogens. The 
ECM is a stable macromolecular structure underlying epithelial and endothelial cells and 
surrounding connective tissue cells. Its composition varies among different organs, but the main 
components are fibronectin, collagen, elastin, laminin and glycosaminoglycans. Pathogen binding to 
these ECM proteins might have many consequences that influence their pathogenicity. On one hand 
these adhesions can mask the microbial surface and thereby interfere with antigen presentation and 
provide an overall immune evasion strategy. On the other, it can serve as a bridge b-etween the 
bacterium and host cel! surface wh en ECM proteins bind to their natural receptor on host cell 
3 
surfaces such as integrins. Adhesion of pathogen to these integrins via ECM proteins is usually the 
first step in colonization of tissues but also in penetrating into the body through activation of host 
cell cytoskeleton. In fact, this activation pennits bacterial invasion of host cells and can be used by 
pathogens to cross sorne host barriers. While it has been demonstrated that various streptococci 
specifically bind to host ECM and that these interactions play a role in disease pathogenesis, little is 
known about the ability of S. suis to bind to ECM proteins and the adhesins involved in these 
adhesions. Only a fibronectin-fibrinogen-binding (FBPS) protein has been proposed as a 
contributing factor in the colonization of organs due to its binding to ECM proteins of host cells. 
However, interactions between S. suis and ECM proteins have never been studied before. 
The majority of pigs that have undergone infections caused by S. suis develop a solid 
immunity indicating that the immune response elicited by the infection is protective. This feature is 
of fundamental importance for the development of an efficient vaccine to eradicate the S. suis 
diseases around the world. Sorne of the S. suis virulence factors described above have been 
investigated in vitro and in vivo as suitable candidates for a S. suis vaccine. However, up to now, ail 
these efforts to prevent pigs and human infections have failed. As bacterial virulence is detennined 
by a wide variety of factors that influence bacterial attachment, penetration into tissue, and the 
escape from host, different bacterial ECM-binding proteins have been suggested as potential 
vaccine targets for preventing bacterial infeètions because antibodies against these surface proteins 
are believed to have the dual activity ofboth adherence blocking and opsonic function. 
From this knowledge, our work hypothesis is that adhesion of S. suis type 2 to ECM 
proteins represent a key step in the pathogenesis of the infection caused by this pathogen. The result 
of this adhesion is bacterial dissemination from tonsils to bloodstream and bacterial penetration 
across sorne of the host barriers, such as the blood brain barrier (BBB), which is responsible, at least 
in part, for the development of S. suis infections. In addition, we hypothesize that antibodies against 
the adhesins involved in those adhesions protect host from S. suis infections by preventing bacterial 
attachment to cells and by functioning as opsonic antibodies. 
General aim: To study S. suis serotype 2 interactions with ECM proteins 
Specifie objectives: 
1. To study the adhesion of S. suis serotype 2 to sorne of the most important ECM proteins 
II. To identify and characterize the adhesins involved in the adhesion of S. suis serotype 2 
to the ECM proteins 
III. To detennine the role ofthese adhesins in the pathogenesis of the infection caused by S. 
suis serotype 2 
IV. To study the role ofthese adhesins as a potential vaccine candidates 
II. LITERA TURE REVIEW 
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1. Streptococcus suis 
1.1. Introduction: 
Streptococcus suis is a major porcine pathogen worldwide. It is one of the most important 
agents of swine meningitis (152). In addition, it is also responsible of other important diseases in 
pigs such as meningo-encephalitis, septicemia, arthritis, endocarditis, pericarditis, polyserositis, 
rhinitis, and abortion (152). S. suis. is also considered as an opportunistic pathogen or a secondary 
invader in pneumonia cases because it is commonly isolated from the respiratory tract of sick pigs 
in combination with other recognized respiratory pathogens (116, 151). Furthermore, S. suis is a 
zoonotic agent related with cases of human meningitis, endocarditis, septicemia and toxic-shock-
like syndrome (152). S. suis infection in hum ans is considered as an occupational disease as most of 
the infected persons were in close contact with infected pigs or with infected carcasses (152). 
Biologically, S. suis is a Gram-positive bacteria, motionless, ovoid coccus, that can stay 
singly, in pairs or, in some occasions, in short chains (124). Ail the known strains are a-hemolytic 
on sheep blood agar, and many strains can also produce ~-hemolysis on horse blood agar (353). 
Biochemically, S. suis is a chemo-organotroph microorganism, with a fermentative and facultative 
anerobic metabolism (184). 
1.2. History: 
The first case of S. suis infection was reported in Netherland in 1951 by Jansen and Van 
Dorssen (171). Bacterial isolation in the affected piglets (1-6 months old) demonstrated that these 
animaIs carried hemolytic streptococci bacteria in brainand other internaI organs (171). Some years 
later, in 1954, Field et al. observed a similar process in which the affected animais were not only . 
piglets but also adult pigs (103). Isolation of bacteria demonstrated that the pathogens responsible 
were also alpha-hemolytic streptococci. In 1963, De Moor described similar alpha-hemolytic 
streptococci, also isolated of septicemic pigs, which were different biochemically and serologically 
from the streptococcal species described at that moment (80). Erroneously, he placed the identified 
strains in the new serologic groups R, S, RS and T, following the nomenclature of Lancefield (80). 
Three years later, Elliott suggested that De Moor's group S was similar to his pyomiositis (PM) 
Streptococcus which possessed the wall antigen of the group D of Lancefield, the lipoteicoic acid, 
and he proposed the name Streptococcus suis serotype 1 for this new species (92). In 1975 Windsor 
and Elliott isolated other porcine streptococci which corresponded to De Moor's group R. They 
named these bacteria S. suis serotype 2 (394). Isolates reacting with antisera against both serotypes 
1 and 2 were designated as serotype 1/2, which corresponded to the originally denominated RS 
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group by De Moor. Between 1983 and 1995, 32 new serotypes based on capsular antigens were 
described, out ofa total number of35 serotypes (123,124, 149,284). 
The first time that S. suis was officially described as a new species was in 1987 by Kilpper-
Balz and Scheleifer (184). They demonstrated, using hybridation studies, that the serotypes of this 
new species have genetic homogeneity although they are genetically unrelated to other members of 
the group D of Lancefield. 
The phyl6genetic diversity of S. suis serotypes was studied later by two inde pendent 
research groups using the comparison of 16 rRNA gene sequence (63) and a variable region of the 
chaperonin 60 gene (52). Results showed that 32 of 35 reference strains had a nucleotide sequence 
similarity which ranged between 93 and 100%, and fell into a major group comprising three 
clusters. Comparison with nucleotide sequence from other streptococci indicated that, with the 
exception of serotypes 32, 33 and 34, S. suis reference strains did not cluster with any other 
Streptococcus species in the genus. It has recently been proposed that serotypes 32 and 34 be 
excluded from S. suis species and re-designated as Streptococcus orisratti (154). However, there is 
no indication suggesting that members of serotype 33 should be transferred to another species. 
The number of untypeable isolates is, in general, relatively low. Most of the times, these 
isolates are recovered from sporadic cases of disease and it seems that there is no justification at the 
present time for the characterisation of new capsular types (147). 
1.3. Distribution 
Among the 35 serotypes described, the serotype 2 has always been considered the most 
virulent and the most frequently isolated serotype from diseased animaIs (128). However, the 
situation may be different depending the geographical location and also, throughout time. For 
example, the percentage of S. suis serotype 2 strains isolated from diseased animais in Canada 
decreased in the last years and remained relatively low compared with those reported in. sorne 
European countries, such as France, Italy and Spain, where most of isolates recovered from 
diseased animais belong to serotype 2 (39, 396). Under specific circumstances, sorne strains 
belonging to other serotypes of S. suis appear highly virulent, as it is the case for serotype 14 in UK 
(145), serotypes 1/2 (unpublished observations M.Gottschalk) and 5 (71) in Canada and serotype 9 
in central Europe (396). 
Serotype 2 is considered the main cause of serious infections in humans, especially 
in people in close contact with swine or pork products. S. suis does not usually cause outbreaks of 
human infection. However, after the first S. suis human case described in Denmark in 1968 (20), 
sporadic cases have been reported in many countries that have intensive swine industry. To date, 
most of the human infections have occurred in northem Europe and Asia (223). The total number of 
cases worldwide is weIl over 400 (223). China, Thailand, and the Netherlands are responsible for 
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69%, Il % and 8% of the total cases reported, respectively (223). Mysteriously, only few cases 
have been reported in Canada and USA. This is probably the consequence of a serious diagnostic 
problem in laboratories working with human medicine. In fact, most of these laboratories would 
probably misidentifY an isolate of S. SUlS as enterococci, Streptococcus pneumoniae, Streptococcus 
bovis, viridans group streptococci or even Listeria spp. (152). In many cases, the initial Gram stain 
diagnosis of the cerebrospinal fluid (CSF) specimen is considered as pneumococcal meningitis. 
1.4. S. suis infections 
Streptococcus suis is a well-recognized worldwide swine pathogen of emerging clinical 
significance in most countries with intensive swine industry. However, important cases of S. suis 
infections in humans have also been reported in the last years. 
1.4.1: In swine 
The first S. suis case reported in pigs was in Netherlands in the 50's (171). After that, it has 
been observed that S. suis is a worldwide cause of a variety of porcine infections being the most 
commons septicemia, arthritis, endocarditis, meningitis, pericarditis, rhinitis and abortion, among 
others (152). 
Although S. suis is commonly isolated from the respiratory tract of pigs, it is unclear if it is 
also responsible of another illness like pneumonia because S. suis is usually isolated in sick pigs 
with other recognized respiratory pathogen like Pasteurella multocida, Actinobacil/us 
pleuropneumoniae, Haemophilus parasuis, Bordetella brochiseptica and others. Thus, it is 
commonly believed that S. suis could behave as an opportunistic pathogen when other pulmonary 
pathogens are found in lungs (384). However, sorne controversy appears when pure cultures of S. 
suis are isolated in cases ofswine pneumonia (116, 151). In contrast, in cases ofmeningitis, S. suis 
is the only microorganism recovered From the brain, and thus is considered a primary pathogen 
(90). 
1.4.1.1. Clinicat signs 
The earliest sign of S. suis infection is usually a rise in rectal temperature to as high as 
42.5°C (152). This may occur at the beginning without any other obvious clinical sign. This high 
temperature is accompanied by a detectable bacteremia or pr~:mounced septicemia (152). If pigs 
don't receive any treatment, these symptoms may persist for up to 3 weeks. During this period, 
there is usually fluctuation in body temperature and variable degrees of inappetence, depression, 
and shifting lameness (68). In sorne cases, pigs may be found dead without any premonitory signs 
(152). In cases of septicemia, S. suis is isolated from a great variety of organs like spleen, li ver, 
heart, lung and brain where there are inflammatory lesions, without a typical pattern (302). Infected 
pigs that resist septicemia generally have gross lesions in the central nervous or respiratory system, 
but not in both (302). In cases of meningitis, the most consistent clinical signs are the neurological 
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on es like lateral recumbence, paddling, convulsions, ataxia. and opisthotonus (353). The 
predominant lesions found in a pig infected with this pathogen are neutrophilic meningitis and 
chorioiditis, with hyperemic meningeal blood vessels, fibrinopurulent or suppurative epicarditis and 
suppurative bronchopneumonia(98, 302, 321). Evidence of encephalitis, oedema and congestion of 
the brain may also be present (353). In addition, the choroid plexus may have disruption of the 
plexus brush border and fibrin and inflammatory cell exudates may be present in the ventricles 
(353). These microscopic lesions do not seem to be serotype-associated (302). 
Sorne of the pigs with the acute form of the disease survive, resulting in healthy carriers or 
alternatively the infection becomes chronic. In chronic disease lameness and residual nervous signs 
such as otÎtis interna might be evident, as weil as chronic arthritis signs (225, 302). 
1.4.1.2. Transmission 
The main S. suis reservoirs seems to be the swine (152). The most common tissues 
colonized by S. suis in healthy pigs are the tonsils and nasal cavities, from where it can disseminate 
throughout the animal without exhibiting any clinical feature (24, 71, 85, 155). Different carrier 
rates from 0 up to 100% in the upper respiratory tract have been reported (19,69,255). This carrier 
status in tonsils might persist ev en after treatment with penicillin (353). Sorne carrier animaIs will 
remain healthy carriers, whilst other, will sooner or later develop clinical signs (128). Pigs of any 
age can be infected with S. suis, but susç:eptibility generally decreases with age following weaning 
(152). Outbreaks are usually attributed to the introduction of a carrier into the herd (152). However, 
within a carrier herd, outbreaks can occur especially at young and stress predisposed animais (152). 
Several ways for the transmission of S. suis between animais in a herd have been suggested: 
i) piglets born to sows with genital colonization (13), ii) respiratory transmission via aerosols by 
nose to nose contact (38), Hi) oral transmission by contact with a source of infection and, iv) 
transmission via the nasal, genital or alimentary tract (353). 
It has been demonstrated that faeces, dust, water and feed may become secondary sources 
of infection in which bacteria can persist for short or long periods (353). In addition, vectors of S. 
suis such as flies and mice can also play a role in disease transmission (97). 
1.4.1.3. Diagnosis 
Diagnosis of S. suis infections Îs generally based on i) clinical signs, ii) age of animaIs and 
Iii) macroscopic les ions (152). Confirmation of the S. suis infections is achieved by i) the isolation 
of the infectious agent and il) the typical microscopic lesions in tissues (152). 
Since S. suis is a normal inhabitant of the upper respiratory tract of pigs and may be 
recovered from lungs of healthy pigs, it is important to isolate this pathogen in other tissues, 
overcoat in case of septicemia, because, as mentioned above, it is important to interpret wjth caution 
the presence of S. suis in the respiratory tissues,. Once isolated, identification of bacterial isolates as 
S. suis can be done by different tests (see point 1.5) 
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1.4.1.4. Treatment 
The choice of the best antibacterial agent against S. suis infections must be based on several 
criteria such as i) the susceptibility of the organism, ii) the type of infection and iii) the mode of 
administration (152). In fact, it has been demonstrated that S. suis is highly susceptible to several 
antibiotics. 
A study in which the antimicrobialsusceptibility of S. suis strains isolated from diseased 
pigs to 10 compounds Iicensed in veterinary medicine was carried out recently in Europe (398). The 
antimicrobial agents included in the tests were ceftiofur, cefquinome, enrofloxacin, florfenicol, 
gentamicin, penicillin, spectinomycin, tetracycline, tilmicosin and 
trimethoprim/sulphamethoxazole. The isolates that were tested were collected in seven European 
countries and represent the ma st common serotypes involved in clinical disease (396). Results 
showed that 100% of the strains tested were sensible ta ceftiofur, cefquinome, enrofloxacin, 
florfenicol and penicillin. Only 1.3% of the strains were found ta be resistant to gentamicin, 3.6% to 
spectinomycin and 6% ta trimethoprim-sulphamethoxazole. In contrast, high levels of resistance 
were observed for tetracycline (75.1 %) and tilmicosin (55.3%) (398). It is important ta remark that 
variations in antimicrobial usage from one country ta another, variations in methodology and 
differences in serotypes tested may contribute to apparent differences in antimicrobial susceptibility 
wit~in the countries. These results suggest that we have ta be careful in the treatment of S. suis 
infections and that antibiotics have to be used only in cases where sensibility tests have shown that 
S. suis is sensitive (152). 
Up ta now, the prompt recognition of the early clinical signs of streptococcal meningitis 
followed by immediate parenteral treatment of affected pigs with an appropriate antibiotlc is 
currently the best method to maximize pig survival (353). In addition, adjunctive therapy with an 
anti-inflammatory agent is recommended for treatment of S. suis meningitis in pigs (13). Treatment 
can also be administered via the drinking water or in medication feed. However, due ta the spread 
features of the disease, treatment needs to be started very quickly and as it has been explained, pigs 
in early stage of infection may be difficult ta detect (152). 
1.4.1.5. Prognosis 
Although morbidity rarely exceeds 5%, it can reach more than 50% in cases of poor 
hygiene and/orconcurrent disease (353). Once a herd is infected, mortality is usually low (0-5%) 
with . appropriate treatment at the beginning of the infection. However, it can approach 20% in 
untreated or wrongly treated herds (71). 
1.4.2: In humans 
The first cases of severe human meningitis and s~psis due to S. suis capsular type 2 
occurred between 1968 in Denmark (20). Since these cases, many other cases have occurred around 
the world in the most diverse places like in the Netherlands, Denmark, Italy, the United Kingdom, 
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France, Spain, Portugal Sweden, Ireland, Austria, Hungary, Hong Kong, Japan, Argentina, 
Belgium, Germany, Taiwan, Canada, Singapore, Croatia, Thailand and China (152). Except for two 
human S. suis infection cases caused by serotype 1 (although not serologically confirmed), two 
cases of septicemia caused by §erotype 14 and one case caused by serotype 4 ail other human S. suis 
infections are attributed to serotype 2 (190, 389). 
ln Hong Kong and Vietnam, S. suis has been identified as one of the most common 
causes of meningitis in adults (162, 229). In Canada, there are not any recorded cases earlier than 
1982, and the first case in Quebec was diagnosed in 1996 (243). ln China, an outbreak of the 
disease in humans caused by S. suis serotype 2 with higher than usual human morbidity and 
mortality was reported in Sichuan province in 2005 (223). During the Sichuan outbreak, a total of 
204 human cases, with 38 fatalities, have been reported (223). 
1.4.2.1. Clinical signs 
Human infections with S. suis are most frequently manifested as purulent meningitis, but 
cases of septic shock with multiple organ failure, endocarditis, pneumonia, arthritis, and peritonitis 
have also been reported (223). Differences in clinical signs among pa,tients infected with S. suis 
have been observed. In the acute form of meningitis, symptoms include high fever, headache, chili s, 
nausea, vomiting, and vertigo, followed by one or more of the following: hearing loss, walking 
ataxia, coma, neck stiffness, petechia, articular pain, peripheral and facial paralysis, severe myalgia, 
ecchymosis, rashes, and rhabdomyolysis (110, 233, 311, 362). In the acute form of toxie septic 
shock, besides high fever, chills, headache, vomiting, vertigo, and abdominal pain, other clinical 
signs were also observed, such as hypotension, tachycardia, liver dysfunction, subcutaneous 
hemorrhage (purpura fulminans), disseminated intravascular coagulation, acute renal failure, and 
acute respiratory distress syndrome (110,236,389). Hearing loss is the most common sequela after 
recovery from purulent meningitis, whereas death often follows septic shock (223). 
1.4.2.2. Transmission 
Most of the infected persons are adults in good health who have had direct contact with pigs 
and/or their excrements (113). That indicates that S. suis infection in human can be considered as an 
occupational disease (223). It has been proposed that high exposure to S. suis may lead to a 
colonization of the upper respiratory tract without producing any health consequences. Only in 
sorne cases, predisposing factors such as splenectomy, alcoholism, diabetes mellitus and 
malignancy may influence disease progression (l18, 161,389). 
Although S. suis can colonise hurnan upper respiratory tract, the route of entry used for this 
pathogen in most of the cases is the skin (243). S. suis can use sorne smaU injury or minor abrasions 
as a route of entry and to disseminate to the different organs producing the associated diseases 
described above (243). However, other cases were reported where the route of entry is not 
designated because the person who contracted the infection had never been in direct contact with 
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pigs (152). There are sorne reported cases where the illness is related to raw pork or uncooked pig's 
blood consumption, and the route of entry could be the oral or respiratory ones, but this hypothesis 
has not been demonstrated yet (110). 
1.4.2.3. Diagnosis 
As for pigs, presumptive diagnosis ofhuman S. suis infection is based on clinical signs and 
microscopic les ions. Confirmation of infection is achieved by isolation of the infectious agent arid 
the recognition of microscopic les ions in tissues. Epidemiology history, such as information about 
direct contact with sick pigs, is very useful for final confirmation. In addition to clinical 
information, the initial routine laboratory examination is essential for diagnosis offhis disease (236, 
311 ). 
Patients infected with S. suis display elevated white blood cell counts at 13.8-26.6xl09fL 
(81-95% neutrophils) and high C-reactive prote in concentrations of 130-236 mgIL (normal value 
<10 mg/L) (236, 311). In sorne cases, high activities of alanine aminotransferase and aspartate 
aminotransferase were detected because of liver damage (236). Examination of patient's CSF 
usually revealed turbidity, accompanied by polymorphonuclear pleocytosis (white blood cell count 
of 1.25-3.24 xl 09 /L), and very low concentrations of protein and glucose (236, 311). Gram stain of 
CSF, blood, and sometimesjoint fluid, can show pairs or short chains of Gram-positive coccoids. 
1.4.2.4. Treatment 
As explained before, S. suis is sensitive to many antibiotics. Once the infectious agent of S 
suis is verifie d, antibiotic treatment, accompanied with other associated treatments, is very effective 
in humans (223). Therapeutic treatment varies between patients, depending on the clinical signs. 
After confirmation of infection, patients are commonly treated with penicillin G, accompanied by 
one or more other antibiotics including ceftriaxone, gentamicin, chloramphenicol, and ampicillin 
(223). 
Additional intensive supportive care and treatments, such as maintenance of blood glucose 
concentrations at 4--6 mmol/L, selective digestive-tract decontamination, strategies for prevention 
of iatrogenic infection, and intravenous immunoglobulin against shock were required (14). 
1.4.2.5. Prognosis 
In general, most of the cases in humans have a positive prognosis with an early diagnostic 
of the disease and the appropriate treatment. However, septic shock syndrome may le ad to severe 
damage of organs, including liver, kidneys, and circulatory system, and therefore, mortality can be 
high (more than 70%) despite adequate treatments (223). It is usual that, as occurs in swine 
infections, infected pers ons have a loss (total or partial) of hearing. The incidence of this sequel in 
this type of meningitis is higher than with others meningitides (20, 225). 
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1.4.3: In other species 
S. suis has also been isolated from a wide range of other animal species such as 
cows, cats, dogs, horses and birds among others (192). Different serotypes (112, 2, 3, 4, 5, 9, 16, 18, 
20, 26, 31 and 33) as weil as some non typable strains have been isolated from these species. In 
fact, reference strains from capsular type 20 and 31 were isolated from diseased ca Ives, and the 
reference strain from serotype 33 from a diseased lamb (63). In aIl these species, S. suis produce 
similar diseases than in pig specially meningitis, abortion and bronchopneumonia (192). The 
probability that S. suis can be transmissible from domestic pigs to other wild animaIs such as wild 
boars has been studied since different cases of wild boars infected with S. suis have been reported 
(30, 153, 192, 311). 
1.5. Identification and detection 
The first test used for the identification of S. suis is the hemolytic test on blood agar. AlI S. 
suis strains produce narrow zones of ex-hemolysis on sheep blood agar plates. In addition, many S. 
suis strains are also able to produce ~-hemolysis on horse blood agar plates (333). 
Several biochemical tests can also be used to identifY S. suis. The biochemical 
identification of S. suis has been performed with a number of commercial multitest kits such as the 
Index and API systems (224, 375), in addition to conventional tests including growth and 
fermentation in phenol red broth containing 0.1 % agar and 1 % lactose, trehalose, sorbitol, raffinose, 
or inulin, hydrolysis of hippurate, and sensitivity to optochin (98). 
Various parameters have been proposed for the biochemical identification of S. suis 
including i) growth in 6.5% NaCI (s. suis is able to grown in anaerobic or aerobic conditions, but is 
unable to grow in 6.5 % NaCI solution) (184), ii) acetoin production [the Voges-Proskauertest, that 
appears to be the most reliable test for differentiating S. suis from S. bovis (148)], and iii) acid 
production from trehalose and salicin [S. suis is able to produce acid when grown in presence of 0-
glucose, sucrose, lactose, maltose, salicin, trehalose and inulin (283)] (148). 
However, these biochemical characteristics are so variable that identification is often 
difficult and may require combination of biochemical reactions, followed by confirmative 
serotyping (90). The latter method is based on capsular polysaccharide antigens by use of one or 
more of the following techniques: capsular reaction (122-125), capillary precipitation (124) or a co-
agglutination test (249). Most laboratories have adopted the coagglutination technique. Since the 
majority of the typeable strains belong to serotypes 1-8 and 112, it is advisable for diagnostic 
laboratories to only use antisera corresponding to these serotypes and to send the non typeable 
isolates to a reference laboratory (150, 155). It is important to note that some isolates cross-react 
with more than one antiserum using the coagglutination or the capsular reaction tests. The most 
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notable cross-reactions are with antisera against serotypes 1 and 2 which corresponds to strains of 
serotype Yl, and sometimes, sorne strains of serotype 1 can cross-react with antiserum of serotype 
14 (124, 128). 
Today, PCR is also a rapid technique used to detect specific serotypes or strains of S. suis in 
animal carriers, or to identify strains obtained from infected or healthy pigs, or ev en sick human 
beings for clinical diagnosis or epidemiological studies. PCR based on the S. suis-specific 16S 
ribosomal RNA (rRNA) region and a species-specific probe (serotypes 1-31) targeting 16S rRNA 
gene can be used to identify S. suis strains (46, 299). A PCR procedure based on a 688 bp fragment 
within the glutamate dehydrogenase gene (gdh) of S. suis serotype 2 was also reported to efficiently 
amplify a specific fragment from ail S. suis strains tested (265). A multiplex PCR assay was also 
developed for this purpose (265). Type 2 and II2-specific PCR has also been established for 
detection of S. suis type 2 in human infection (233). 
Additionally, immunocapture mcthod (125), fluorescent antibody techniques (76, 278), 
whole-cell antigen-based indirect ELISA (307), and purified capsular polysaccharide antigen-based 
indirect ELISA (84) are other techniques used to identify this pathogen. 
1.6. Virulence factors 
As Salyers and Whitt desctibed in 1994, a virulence factor denotes a bacterial product or 
strategy that contributes to virulence or pathogenicity (318). In the case of S. suis, where most of the 
studies about virulence factors have been carried out with serotype 2, this definition is not so easy 
applied. There is a lot of controversy between different authors referring to S. suis virulence, but ail 
authors agree on one point: there exist two types of S. suis capsular type 2 strains, the virulent and 
the avirulent one. The presence of virulence factors in a strain does not indicate that it is a virulent 
strairi since two strains with the same virulent factors can be totally opposite in his virulence. ' 
Different studies can designate field strain as virulent or avirulent based on i) the animal 
state: healthy or sick, ii) the presence of virulent factors and iii) the infection experimental model 
depending on the use of different strains of mice, preinfected piglets or the age of the pigs (152). In 
addition, it is also true that the results of the experimental infections of pigs with S. suis depend on 
the status of the animal, the volume of the inoculum, the route of infection, and the presence of S. 
suis as a normal microorganism of the upper tract respiratory of the animal previous to the infection 
(152). 
Different studies proposed that the most important candidates to be virulence factors in S. 
suis are the polysaccharide capsule (CPS), the serum opacity factor (OFS), the proteins MRP 
(muramidase-released prote in) and EF (extracellular factor), the hemolysin (suilysin), the IgG 
binding protein, hemagglutinins, FBPS (fibronectin binding p~otein) and other proteins briefly 
mentioned in this review. Recently, a 2-D gel approach combined with mass spectrometry identify 
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373 proteins probably inolved in the pathogenesis of S. suis (173). Most of the identified proteins 
were located in the cytoplasm and were involved in energy metabolism, protein synthesis, and 
cellular processes. Among the different prote in spots processed, 87 spots representing 77 proteins 
were successfully identified in which sorne virulence-associated proteins of S. suis were found, 
including arginine deiminase, omithine carbamoyl-transferase, carbamate kinase, muramidase-
released protein precursor, extracellular factor, and suilysin (173). Enolase and endopeptidase have 
been proposed as putative virulence-associated factors in this study (173). 
1.6.1: The polysaccharide capsule (CPS) 
Many microorganisms synthesize exopolysaccharides, this is, polysaccharides excreted 
outside the microbial cel!. In sorne cases, these polymers, composed of repeating units of simple 
sugars, remain attached to the outer surface of the bacterium, and then, they are referred to as 
capsules. Exopolysaccharide production is usually associated with increased virulence as they may 
function as adhesins, recognition molecules, resistance to antibiotics and by favouring the 
camouflage of the pathogen against the host immune response. The thickness of the capsule and its 
polyanionic charge are responsible for the limitation of the entry of different molecules and ions 
inside the bacteria, protecting them from the exterior (268). On the other hand, the capsule protects 
bacteria from phagocytosis by reducing opsono-phagocytosis processes mediated by host defence 
ce Ils (for example, macrophages and neutrophils) (333). Moreover, production of capsular material 
can prevent the interaction between the C3b component of the complement system and the 
phagocytic ce Ils (345) and it has been demonstrated that the presence of sialic acid in the capsule is 
also been associated with the binding of factor H, which prevents deposition of the C3b component 
on bacterial antigens (298). In addition, the negative charge that it confers to the bacteria can 
repulse the phagocytic cells which are also negative in charge (12). Furthermore, the limited 
immunogenicity of many bacterial polysaccharides, the mimicry of hostantigens or active induction 
of T suppressor ce Ils may contribute to the success of encapsulated bacteria as pathogens (64). 
S. suis possesses a rigid cell associated polysaccharide capsule, with a molecular weight of 
310 kDa, that excludes India ink (284). S. suis serotype 1 capsule is composed of five sugars: 
galactose, glucose, N-acetyl glucosamine, N-acetyl galactosamine and sialic acid. Type 2 capsule 
composition differs only in one sugar: rhamnose instead of N-acetyl galactosamine (95). As for 
other bacteria, the sialic acid present in the capsule of S. suis has been proposed to be an important 
sugar involved in the pathogenesis of the infection caused by this bacterium. Arends and Zanen 
suggested that virulence of S. suisserotype 2 could be related to the presence of sialic acid in the 
capsular material (20). However, further information about the structures and composition of 
capsules in other serotypes is, so far, unknown. 
To better understand the role of the capsule as a virulent factor, the production of non-
encapsulated mutant strains of S. suis type 2 was done. Studies with these mutants showed that the 
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capsule is an important virulence factor of S. suis since the non-encapsulated isogenic mutants were 
shown to be avirulent in swine and mouse models of infections (6~, 346). Different studies 
demonstrated that the probable cause for this avirulence is the fact that these mutants are easily 
phagocytosed in vitro by porcine and mouse phagocytes such as monocytes, macrophages and 
neutrophils (32, 57, 61, 332) which prevent bacterial dissemination and, as consequence, its 
delivery to the target organs. In fact, it can be affirmed that the presence of the capsule is really 
necessary for a good infection cycle of the microorganism and for its capacity to cause disease. 
However, as explained before, the capsule can hide sorne important adhesins, involved in sorne 
steps of the infection, promoting a decrease in the virulence of this pathogen. It has been 
demonstrated that S. suis capsule is up-regulated du ring growth in intraperitoneal chambers in rats 
and pigs (61, 297) and also after cultivation in liquid media supplemented with serum (392). This 
regulation of capsule expression could be a strategy used by S. suis to promote infection and seems 
to represent a corn mon feature among other streptococcal and bacterial species, such as 
Streptococcus pyogenes and Haemophilus influenzae (136, 352). 
1.6.2. The cell wall 
The cell wall of S. suis has also been proposed as an important virulence factor. Several 
studies have been shown that the cell wall or its components such as the lipoteicoich acid (L T A) 
contribute to exacerbate the host inflammatory response to infection (129, 152). However, the 
structure and composition of S. suis L T A are poorly known. It has been proposed that L T A from S. 
suis may have a backbone structure similar to that of Group A streptococcal teichoic acid, but with 
differences in the attachment of glucosyl substituents (94). Besides its involvement in inflammation, 
L TA may also play a direct role in S. suis virulence. Indeed, a recent study has shown that 
inhibition of the adherence of S. suis to porcine BMEC can be obtained by pre-incubation of the 
cells with purified LTA (379). In addition, it has been proposed that S. suis may D-alanylate its 
L T A and that a high ratio of D-alanine to glycerol phosphate in this molecule may be important for 
the interaction of this pathogen with host cells (105). In our laboratory we have recently generated, 
by allelic replacement, a I1dltA mutant in a virulent S. suis serotype 2 field strain and the 
contribution of lipoteichoic acid (L TA) D-alanylation to the virulence traits of this swine pathogen 
and zoonotic agent was evaluated. Absence of LTA D-alanylation resulted in increased 
susceptibility to the action of cationic antimicrobial peptides (107). In addition, and in contrast to 
the wild type strain, the MitA mutant was efficiently killed by porcine neutrophils and showed 
diminished adherence to and invasion of porcine brain microvascular endothelial cells (107). 
Finally, the I1dltA mutant was attenuated in both the mouse and porcine models of infection, 
probably reflecting decreased ability to escape immune clearance mechanisms and impaired 
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capacity to traverse across the ho st barriers (107). The results of this work suggest that L T A 0-
alanylation is an important factor in S. suis virulence (107) 
1.6.3. MRP and EF 
MRP (muramidase-released protein) is a 136 kDa cell wall associated protein, which can 
also be released to the culture supernatant by bacteria, whereas EF (extracellular factor) is a 110 
kDa extracellular prote in (382). Up to now, five EF variant genes were identified in serotype 2 
strains as weil as a smaller (MRPs) and a larger (MRP*) variants (l17, 347, 382, 383). Both 
proteins were first identified as potential virulent factors of S. suis serotype 2, because most of the 
strains that. caused diseases in Europe are MRP and EF positives (354, 381, 382). However, this 
hypothesis was rapidly discarded when, as observed later, most of the North American virulent 
strains that produce disease in animais do not express MRP and EF (126). 
To the present, although the genes encoding the two proteins were c10ned and 
characterized, their function in the pathogenicity of the S. suis infection remains unclear (347,348). 
Sorne findings indicate that MRP cou Id be an adhesin becausethe anti-MRP serum is able to inhibit 
the S. suis adherence to sorne cells (363). However, although it has also been shown that a particular . 
region in the MRP aminoacid sequence is very similar to a fibronectin-biriding prote in of 
Staphylococcus aureus, binding to fibronectin cou Id not be confirmed at present (348). It has been 
recently demonstrated that mrp gene expression levels were dramatically upregulated both in vitro 
and in vivo corrobor~ting that mrp upregulation in the initial stage of infection may play a role in 
adhesion (363). In contrast, the efgene functions differently than the mrp. In most organs, it was not 
notably upregulated until 48 or 72 h post infection suggesting that EF may play a different role 
during infection (363). 
To verify the virulence potential of MRP and EF, Smith et al. infected newborn pigs with 
isogenic mutant strains for the expression of both proteins (349). Results showed that mutants that 
lacked EF and MRP were still as virulent as the wildtype strains suggesting that the proteins 
themselves do not contribute to the pathogenicity of the bacteria. An alternative explanation for 
these results is that the virulence associated with S. suis is a multifactorial process in which 
particular functions can be fulfilled by redundant or alternative factors, which means that, in 
absence ofMRP and EF, other virulence factors can take over their functions. This hypothesis cou Id 
explain why sorne North American strains are virulents although not possessing these proteins. 
1.6.4: Hemolysin (Suilysin) 
Hemolysin is a form of exotoxin protein produced by bacteria which causes lysis of red 
blood cells in vitro. As explained above, visualization of hemolytic effect of this toxin in red blood 
cells in agar plates facilitates the categorisation of sorne pathogenic bacteria such as S. suis. 
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Hemolysin activity IS nonnally associated with pathogenicity and virulence 10 many bacterial 
specles. 
It was in 1994 that Jacob et al. identified for the first time a 54 kDa S. suis hemolysin (167). 
One year later, Gottschalk et al., described another S. suis hemolysin of 65 kDa (130). Different 
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posterior studies corroborated that these two S. suis hemolysins were really the same one and that 
the difference in the molecular weight was caused by the different techniques used for their 
purification (130). This S. suis hemolysin, named suilysin, belongs to the family oftoxins known as 
thiol-activated toxins or more recently named as antigenically related cholesterol-binding cytolytic 
toxin (332). This name refers to the fact that ,these toxins do not bind to membranes that do not 
contain cholesterol or a closely related sterol (263). ln fact, interaction with cholesterol also occurs 
in the absence of any other lipids, i.e. with the pure sterol in solution or suspension (89), and, as 
occurs for suilysin (57), leads to inhibition of Iytic activity (290). Other hemolysins which have 
corn mon characteristics with suilysin are pneumolysin (s. pneumoniae), listeriolysin (Listeria spp.) 
and streptolysin (s. pyogenes). These thiol-activated toxins fonn discrete, oligomeric pores in 
membranes containing cholesterol (40). The pores produced by these toxins are exceptionally large, 
assuming an internai diameter of up to 30 nm and comprising around 50 monomer subunits (40). 
The ring-shaped, non-covalently bonded oligomers have been visualized by electron microscopy 
(89) before being functionally characterized as transmembranal pores. ln the case of suilysin, the 
pores fonned in membranes are about 7 nm (130). 
Suilysin has a cytotoxic effect in vitro on epithelial (199, 261), endothelial (62, 378) and 
immunecells (32, 57, 336), suggesting that this S. suis toxin could play a role in damaging and 
penetration of different cells and tissues and, in consequence, in the pathogenesis of the bacteria. 
Moreover, suilysin triggers cytokine expression by human and porcine monocytes (221). 
To verify the role of suilysin during infection, sly isogenic mutants have been produced and 
tested in animal trials. Different results have been observed. Allen et al. reported that sly mutant 
was avirulent in a mouse infection model (10). However they also reported that the same mutant 
was only slightly attenuated in a porcine model of systematic infection. ln addition, Lun et al. 
documented that three suilysin mutants showed no attenuation in a porcine challenge experiments 
(221). In addition, as for MRP and EF, this toxin is mainly present in European and Asian strains 
which imply that, by itself, it can not be considered as a critical virulence factor. However, due to 
the multifactorial process involving S. suis pathogenesis, this protein cou Id, in combination with 
other factors, be considered as important for the development of the diseases produced by this 
bacterium. 
1.6.5. Hemagglutinins 
8acterial adhesins mediate strong and specific adhesion of bacteria that are colonizing 
epithelia or invading tissues. The oligosaccharide chains of glycoproteins and glycolipidsare ideal 
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receptors for bacterial attachment, and the heterogeneity of oligosaccharide structures and the 
specificity of bacterial lectin-like adhesins provide bacterial attachment to different cell types of the 
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body. S. suis proteins that possess sugar-specific adherence activities for galactose, N-
acetylgalactosamine and sialic acid have been identified by inhibition of hemagglutination (196). 
On one hand, Haataja et al. reported that galactose-binding strains of S. suis recognise the Galal-
4Gal sequence that is present in the pl and pk blood group antigen structures (139). Furthermore, 
they showed that S. suis is able to bound to trihexosylceramide (Gb03) but not to globoside (Gb04) 
or Forssman glycolipid (Gb05). Gb03 is expressed on the surface of erythrocytes as weil as in many 
pig and human tissues, and might represent the receptor .for galactose binding strains in pig 
pharyngeal epithelium (139). Until now, only a galactose-binding protein of 18 kDa with an 
isoelectric point of 6.4 has been identified in S. suis (218). This adhesin was subtyped in Po (which 
adhesion to galactose is inhibited only by galactose) and PN (which activity is inhibited by galactose 
and N-acetyl-galactosamine). These two adhesin variants have the same N-terminal peptide 
sequence indicating that they are closely related (366). On the other han d, the cell-binding 
specificity of sialic acid-recognizing strains of S. suis was also investigated by Tikkanen et al. 
(366). They demonstrated that treatment of human erythrocytes with sialidase or mild periûdate 
abolished hemagglutination of S. suis. Hemagglutination inhibition experiments with sialyl 
oligosaccharides indicated that S. suis possesses an adhesin for this sugar and that the adhesion 
involved preferred the sequence NeuNAc alpha 2-3Gal beta.I-4Glc (366). Howèver, up to now, the 
adhesin involved in this process has not been identified. 
1.6.6~ Albumin-binding protein and GAPDH 
The binding capacity of S. suis serotype 2 to albumin was also investigated be~ause it has 
been demonstrated that the adhesion of S. suis to this plasma protein increase its virulence (294). 
This study indicated that a 39-kDa protein was responsible for the interaction with albumin. 
However, since different surface molecules have been described to possess an albumin binding 
activity in other streptococci (344), the possibility that other cellular components could also 
contribute to this activity in S. suis cannot be ruled out. This theory was supported by the fact that 
an avirulent strain that produces a thicker capsular material showed a higher binding to albumin 
than other virulent strains with thinner capsule (297), suggesting that capsular material cou Id also 
be involved in this binding activity (294). 
Interestingly, poste ri or genetic studies demonstrated that the N-terminal sequence of this 
39-kDa prote in of S. suis possesses a high degree ofhomology with the glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) of group A streptococci indicating that in fact, this 39 kDa protein is the 
GAPDB of S. suis (47). Recombinant GAPDH from S. suis was found to possess functional 
GAPDH enzymatic activity after the purification. In addition, adherence assay with S. suis and 
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porcine tracheal rings pre-incubated with this recombinant GAPDH showed a significant reduction 
in the adhesion of S. suis to tracheal rings suggesting that this protein could be involved in the first 
steps of the bacterial adhesion to host cells (47). To verify the role ofthis protein in the virulence of 
S. suis, mutants defective in the expression of this protein were constructed and tested for their 
adhesion to tracheal ce Ils and porcine tracheal rings (47). Results showed a reduction in their 
binding capacity compared with the wild type strain, indicating that this protein is localized in the 
surface of the bacteria and that it seems to play an important role in bacterial adhesion. However, 
the fact that this protein is also present in the non-virulent strains of this pathogen confinns again 
the multifactorial character of the pathogenesis ofthis pathogen. 
1.6.7: IgG binding protein 
Another protein isolated, purified and characterized from S. suis serotype 2 as a potential 
virulence factor is a 52 kDa IgG-binding protein. This IgG-binding protein has been found 
associated with the cell surface, but it has been demonstrated that it can also be released in a soluble 
fonn during bacterial growth (35, 342, 343). In addition, it represents a common antigen found in 
ail strains of S. suis serotypes tested, including the non-virulent ones, detennining that this factor 
alone does not participate in virulence (35,342, 343). The role of this protein is unknown at time. 
However, its IgG-binding activity suggests that it may play a role in the evasion of the host 
defenses. 
Sorne years later, studies on the presence of stress or heat shock proteins (HSP) in S. suis 
using polyclonal and monoclonal antibodies directed against different bacterial heat shock proteins 
identified a new protein with an apparent molecular mass of 60 kDa. As for the 52 kDa IgG-binding 
protein, this HSP was identified on the surface of ail S. suis serotypes. Posterior sequence analysis 
deinonstrated that this protein was in fact the identified 52 kDa IgG-binding protein indicating that 
this protein, in addition of its IgG-binding activity is also member of the 60 kDa heat shock protein 
family (34, 35). The difference on the molecular weight in both studies was probably due to the 
different purification methods used. 
1.6.8: Fibronectin-fibrinogen-binding protein (FBPS) 
Many important virulence factors are environmentally regulated and are induced at specific 
stages of the infection process (228). To identify these genes in S. suis, the group of de Greef et al. 
c10ned promoters and their downstream sequences that are "on" during experimental S. suis 
infection of piglets (79). Twenty-two in vivo-selected (ivs) genes were found (79). Two of the ivs 
genes were directly linked to virulence since homology to genes in the database that encode for 
known virulence factors was found (79). One of them showed homology to genes encoding 
fibronectin- and/or fibrinogen-binding proteins of Streptococcus gordonii andS. pyogenes (73). 
The jbps gene was shown to be present in ail known serotypes of S. suis (except serotypes 
32 and 34 that, up to date, can be described as S. orisratti instead of S. suis), as weil as in ail known 
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phenotypes of serotype 2. However, the expression of FBPS in ail serotypes and phenotypes was not 
studied indicating that although ail straiqs, except for serotypes 32 and 34, possess the jbps gene, 
maybe not ail strains express FBPS.· 
A considerable number of fibronectin-binding proteins of various bacterial species have 
been shown to be important virulence factors (177). The role of FBPS in the pathogenesis of S. suis 
was studied in an experimental infection model in piglets. Since the authors were unable to 
determine a 50% lethal dose for the mutant strains, they decided to compare the virulence of the 
isogenic FBPS mutant with that of the wild-type S. suis strain in a competitive infection assay in 
piglets (78). Data obtained clearly showed that the mutant strain was capable of colonizing the 
tonsi\ as efficiently as the wild-type strain indicating that FBPS is not invo\ved in the colonization 
of the tonsil (78). However, results also indicated that FBPS does play a role in the colonization of 
specific organs, since joints and the CNS were more efficiently colonized by wild-type than by 
mutant bacteria (78). Unfortunately, the se authors never evaluated the adhesion capacity of the 
FBPS mutant to fibronectin. In addition, de Greef et al., also demonstrated that FBPS reacted with a 
convalescent-phase serum of a pig that survived an S. suis infection indicating that FBPS is 
immunogenic in pigs and corroborating that FBPS of S. suis is expressed under in vivo conditions 
(78). In addition, another recent study has demonstrated thatjbps expression was upregulated in ail 
organs 24 h postinfectionindicating thatjbps could act as an adhesin and that high initial expression 
levels were critical for virulence (363). 
1.6.9. Serum opacity factor 
Recently, Baums et al., identified a gene of S. suis, named ofs (29), which encodes a prote in 
homologous to other streptococcal fibronectin-binding proteins su ch as FnBA of Streptococcus 
dysgalactiae (237) and SOF of S. pyogenes (72) As OFS carries the typical structural elements of 
MSCRAMMs (see at point 2.3.1), it has previously been speculated that OFS functions as an 
adhesin and in particular that the C-terminal repeats of OFS bind fibronectin. However, no detection 
of any fibronectin-binding activity was found for the recombinant OFS (29). The lack of detectable 
fibronectin-binding might be explained by significant differences between the repetitive sequences 
ofOFS and the fibronectin-binding repeats of FnBA (237) and SOF (29). 
On the other hand, it has been demonstrated that, as for SOF of S. pyogenes (72), OFS also 
confers surface-associated serum opacification activity (29). This activity has not been proven to be 
essential for virulence, and probably, other as-yet-unknown functions of OFS might be involved in 
pathogenesis (29) since experimental infections of piglets with an isogenic ofs mutant strain 
revealed that OFS is a major virulence determinant in S. suis serotype 2 (29). These results are in 
accordance with the attenuation of virulence in an SOF knockout S. pyogenes mutant described 
previously by Courtney et al. (72) and corroborate that, in addition of the CPS, OFS is another 
proved virulence factor for S. suis. 
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A recent study using PCR screening and sequencing analysis of OFS from 108 S. suis 
isolates from diseased and healthy pigs, and hum an patients shows that besides the ofs gene 
reported before (designated type 1), there were three more allelic variants of ofs (designated types 2 
to 4) (361). Type-l and type-2 ofs genes encode functional OFS and as consequence opacified horse 
serum. In contrast, type-3 ofs was interrupted by a point mutation and type-4 ofs was disrupted by 
either insertion of an IS element or genetic rearrangement, and therefore did not show serum 
opacification activity (361). These results suggest that OFS could contribute to the virulence of only 
sorne S. suis isolates. 
1.6.10. Surface antigen one (Sao) 
A S. suis surface protein reacting with convalescent-phase sera from pigs clinieally infected 
by S. suis type 2 was also identified (216). The apparent Il O-kDa protein, designated Sao, exhibits 
typieal features of membrane-anchored surface proteins of gram-positive bacteria (see point 2.3.1), 
such as a signal sequence and an LPXTG membrane anchor motif (216). In spite of high identity 
with the sequenced genomes of S. suis Canadian strain 89/1591 and European strain PIn, Sao does 
not share significant homology with other known sequences. However, a conserved avirulence 
domain that is often found in plant pathogens has been detected (216). A recent characterisation of 
S. suis Sao demonstrate that there are, at least, three allelic variants of saD gene, namely sao-S, sao-
M, and sao-L based on the different lengths of the genes (approximately 1.5, approximately 1.7, and 
approximately 2.0 kb, respectively) (100). These differences were determined to be caused by 
heterogeneity within the number of C-terminal repeat sequences, whieh had been seen as a 
pathogenicity-related domain in the plant pathogen, Xanthomonas oryzae (100). Electron 
mieroscopy using a Sao-specific antiserum confirmed the surface location of this protein on S. suis. 
In addition, the Sao-specific antibody reacts with celllysates of 28 of 33 S. suis serotypes and 25 of 
26 serotype 2 isolates in immunoblots, suggesting that this protein is highly conserved in S. suis 
species (216). However, although the immunization of piglets with recombinant Sao elicits a 
significant humoral antibody response, the antibody response was not retlected in protection of pigs 
that are intratracheally challenged with a virulent strain before this work (216). 
1.6.11. SalKlSalR 
As explained before, recent large-scale outbreak of human S. suis serotype 2 epidemic in 
China characterized by a toxie shock-Iike syndrome has been described in the last years. Studies of 
the epidemic strains responsible of these outbreaks revealed the presence of a newly predieted 
pathogenieity island (PAl). Further bioinformatics analysis identified a unique two-component 
signal transduction system ·Iocated in this PAl, whieh is orthologous to the SalKiSalR regulatory 
system of Streptococcus sa/ivarius (215). Knockout of salKR eliminated the lethality of these 
strains in experimental infection of piglets (215). Functional complementation of salKR into the 
isogenie mutant AsalKR restored its pathogenicity (215). 8actericidal assays demonstrated that the 
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mutant was more susceptible to polymorphonuclear leukocyte-mediated killing than its parental 
strain. In addition, colonization experiments showed that the &alKR mutant could not colonize any 
susceptible tissue of piglets when administered alone (215). These findings suggest that SalKiSalR 
is requisite for the full virulence of ethnie Chinese isolates of highly pathogenie S. suis serotype 2, 
thus providing experimental evidence for the validity of this bioinformatically predieted PAl and' 
confirming that SalKiSalR can be considered as a novel virulence factor of S. suis. 
1.6.12. Enzymes 
1.6.12.1. Hyaluronate Iyase 
The hyaluronate Iyase is a secreted protein that degrades hyaluronic acid (HA) into an 
unsaturated disaccharide (11). HA is a high-molecular-weight polysaccharide consisting of 
repeating disaccharide units and is a fundamental component of the extracellular matrix and 
capsular material (205). Many gram-positive bacteria able to adhere to HA are able to cause 
infection at the mucosal and skin surfaces of humans and animaIs (217). It is proposed that a 
decrease in viscosity due to HA depolymerization increases the permeability of connective tissues, 
which increases the ability of bacteria to spread and contributes to subsequent virulence (217). 
Human tissues known to contain HA include the blood, brain, liver, umbilical tissue, and skin (205). 
Members of several streptococcal species are known to produce hyaluronate Iyase (163, 
230), and research indieates that this lyase may be important in pathogenesis. In the case of S. suis it 
has been showed that although the hyl locus is present in virtually ail S. suis isolates, only about 
30% of isolates express an active protein (185). The gene, in corn mon with many encoding 
streptococcal surface proteins, has a variable 5' end evolving by the generation of point mutations, 
insertions or deletions, and recombination events and a more conserved 3' end (185). Despite these 
observations suggesting thecorresponding protein is subject to host immune surveillance, the lack 
of activity in many virulent field isolates, often associated with the disruption of the hyaluronidate 
Iyase open reading frame, suggested that hyaluronidate Iyase is not an important virulence factor of 
S. suis (185). However, a recent study revealed that although hyl mRNA levels were very low in 
vitro, it reaches a significant level in vivo whieh led to hypothesise that it is possible that sorne host 
factors are required for hyl gene expression and that this protein could be an important virulence 
factor for S. suis (363) 
1.6.12.2. Arginine deiminase 
In addition to ail these potential S. suis virulence factors two cell wall-associated proteins of 
S. suis that were induced by a temperature shift from 32°C or 37°C to 42°C have been identified 
(395). Amino-terminal sequence analysis of the two proteins indicated homologies to an omithine 
carbamoyl-transferase (OCT) and to the streptococcal acid glycoprotein from S. pyogenes, an 
arginine deiminase (AD) recently proposed as a putative virulence factor (82, 83). Cloning and 
sequencing of the respective genes of S. suis, adiS and oetS, and their adjacent upstream and 
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downstream regions revealed that they were c1ustered together with two additional open reading 
frames (ORFs). The first ORF (orf-2) showed 59.8% homology to a gene encoding a hypothetical 
cytosolic protein, and the second ORF (ekS) showed 70.1 % homology to a carbamate kinase of S. 
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pyogenes. Thus, it was conc1uded that the genes adiS, oelS, and ekS make up the AD system (ADS) 
of S. suis (395). 
The ADS catalyzes the conversion of arginine to ornithine, ammonia, and carbon dioxide 
and concomitantly generates 1 mol of ATP per mol of arginine consumed and comprises three 
major enzymes, the AD, the OCT, and the CK. In oral streptococci and S. pyogenes, the ADS seems 
to provide protection against acidic stress by the production of ammonia (55, 82). Furthermore, it 
has been shown that the AD of S. pyogenes is involved in adhesion to and invasion of epithelial cells 
(82, 232). In the case of S. suis it has been proposed that the ADS enables S. suis to overcome 
oxygen and nutrient starvation and to tolerate acidic environments (135). Thus, the ADS might 
facilitate S. suis survival within the different niches of the host and thereby probably contributes to 
S. suis pathogenesis. However, future investigations are needed to c1arify the importance of the 
ADS for S. suis infections. 
1.6.12.3. Superoxide dismutase 
Although S. suis is considered a facultative anaerobic metabolism bacteria (184), its 
metabolism is always fermentative with glycolysis serving as the principal energy-yielding 
pathway. Despite this, and despite the usual lack of hem proteins by this bacterium, growth under 
aerobic conditions is always associated with the consumption of oxygen (17). Oxygen consumption 
is due primarily to the activities of flavoprotein NADH oxidases and, depending on the oxidase, the 
reduced product may be H20, H20 2, or O2- (51, 365). It has been demonstrated that S. suis 
possesses NADH oxidases capable of reducing oxygen to toxic H20, H20 2, or O2- (258). Cellular 
damage mediated by these reactive oxygen species can be minimized through the dismutation of 
O2- by means of superoxide dismutase enzyme (SOD) or a high intracellular concentration of 
manganese. It has been demonstrated that S. suis produces a MnSOD (200). The activity of this 
SOD was influenced by the availability of manganese, and when the organisms were grown under 
manganese-limited conditions, by the availability of iran; however, the extent to which this IS 
relevant in vivo is not known (258). 
Different studies demonstrated that S. suis appears to be well equipped for its existence as 
an aerotolerant anaerobe (258). It requires manganese, but not iron, for growth, produces a MnSOD 
to eliminate O2 - and reduce cellular damage via Haber-Weiss reactions, and in the absence of 
catalase, and perhaps peroxidase, may be able to exc1ude iron to minimize cellular damage 
associated with H20 2 and the Fenton reactions (258). Finally, the lack of an iron requirement may 
also benefit the organism in vivo in that unlike other organisms, it would not be subject to, and 
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indeed might bene fit from, one of the major host defence mechanisms, namely, the withholding of 
iron from invading pathogens (258). 
1.6.12.4. Proteases 
Proteases are important virulence factors for a variety of microbial pathogens and may 
contribute to tissue degradation and perturbation of the host defence system (226). It has been 
reported that S. suis produces four major proteases (arginine aminopeptidase, chymotrypsin-Iike, 
caseinase, and dipeptidyl peptidase IV (DPP IV)( 176). 
The Arg-aminopeptidase of S. suis was found to be both extracellular and cell-associated 
prote in and showed a molecular mass of approximately 55 kDa. In bacteria, arginine residues 
released by the action of Arg-aminopeptidases on peptides may be catabolized via the arginine 
deiminase pathway resulting in the production of ATP and other essential metabolic precursors as 
explained before (74). S. gordonii has also been reported to produce an extracellular Arg-
al1).inopeptidase (121). It was hypothesized that the Arg-aminopeptidase of S. gordonii cou Id c1eave 
the arginine residues at the N-termini of substance P and bradykinin thus inactivating their 
biological function (121). This inactivation could result in the uncontrolled contraction of smooth 
muscle at the infection site and a change in local vascular permeability. This phenomenon may also 
apply to S. suis but further studies are needed to evaluate this hypothesis. 
A strong cell-associated caseinase activity was also detected in ail strains of S. suis serotype 
2. This caseinase activity may have a nutritional function and can also participate in the maturation 
of precursors as demonstrated in other bacteria (368). For instance, the caseinase of Aeromonas 
salmonicida participates in the processing of a hemolysin precursor produced by this bacterium 
(368). Since S. suis also produces a hemolysin (167), the caseinase activity may play a similar role 
in its maturation. However, this caseinase function has not yet been studied for S. suis. 
A cell-associated chymotrypsin-like activity, belonging to the c1ass of serine proteases, was 
detected only in virulent European S. suis strains as was also noted for the suilysin (hemolysin). 
Femandez-Espla et al. (102) reported the purification of a cell wall-anchored chymotrypsin-Iike 
enzyme from Streptococcus thermophilus. Interestingly, this protease shares several characteristics 
(serine protease, substrate specificity, optimum pH and temperature) with the S. suis chymotrypsin-
like activity identified in this study. However, the function ofthis protease is still unknown. 
Finally, a DPP IV activity was also found in the culture supematant and on the cell surface 
of S. suis. The optimum activity observed at pH 8 corresponds to that· of other DPP IV and 
homologues previously characterized (331). Inhibitors specific for DPP IV (diprotin A and DPP IV 
inhibitor 1) were highly effective in inhibiting the DPP IV activity of S. suis. This activity is also 
present in mammals on activated T ce Ils (CD26) and in a soluble form in plasma where it regulates 
bioactive peptides Iike neuropeptide Y and cytokines (178, 239). Various species of Lactococcus 
(234), Lactobacil/us (242) and Streptococcus (120, 242) have been found to possess this activity 
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and the genes have been cloned and characterized. The OPP IV of Porphyromonas gingivalis is 
considered a virulence factor since a mutant lacking this activity did not cause as much damage as 
the wild-type strain in an animal model (195). However, its role in S. suis is unknown. 
Further studies are required to investigate the pathogenic role(s) of ail these four S. suis 
proteases since up to now the exact function ofthese proteins is still unknown. 
1.7. The pathogenesis of S. suis infection 
Knowledge on the pathogenesis of S. suis infection is still restricted. Studies on this subject 
are almost limited to. S. suis serotype 2 and only concem the development of swine meningitis. 
Knowledge of S. suis infections to humans is even more limited than in pigs. However, the recent S. . 
suis outbreak in Asia has accelerated the study of the pathogenesis ofthis bacteria in humans (223). 
Many question marks remain unclear (Fig. 1). It seems that S. suis infection represent a 
very complex process in which ho st, bacterial and environmental factors dictate the course of the 
interaction. Several steps are believed to be central in the production of disease: i) colonisation and 
invasion of the respiratory epithelium, ii) blood dissemination and phagocytosis resistance, iv) 
inflammation and v) penetration of the endothelial barrier of the target tissues (59, 128). 
1. 7.1. Colonisation and invasion of the respiratory epithelium 
How bacteria present at low numbers on mucosal surfaces are able to traverse the first 
mucosal barriers to develop disease is still unknown. In fact, bacteria would need to breach mucosal 
epithelia in the upper respiratory tract to reach the bloodstream. 
To pass through the cells, S. suis has first to adhere to respiratory epithelial barrier. Several 
studies have shown that S. suis is able to adhere to different epithelial cell lines, including those of 
porcine (261) and human origin (199), to pig tissues such as pharyngeal epithelium (139) or to 
porcine lung sections (127). To mediate these processes, different structures, such as bacterial 
adhesins seem to be important, however, the exactly molecules involved are still unknown. 
The hypothesis that sorne adhesins are responsible for this adhesion is corroborated by the 
fact that adherence of S. suis to epithelial cells is considerably reduced in the presence of capsule 
which can hide adhesins (199) These results suggested that, as occurs with other capsulated 
bacteria, host cell adherence of S. suis depends on the state of encapsulation of bacteria (259, 314). 
Tt has been hypothesised that encapsulation is down-modulated early in the infectious process in 
order to avoid interfering with colonization, but, in contrast, encapsulation is up-modulated during 
bacteremia, where it appears to confer a selective advantage for the pathogen (352). Although it is 
known that in S. suis expression of the capsule is modulated by environmental signais (33, 297), 
modulation of capsule expression upon the infectious stage has not been proved yet for S. suis. 
After adhesion to ho st epithelial cells, S. suis has to invade these cells to cross the epithelial 
barrier. Sorne controversy has been observed in the capacity of S. suis to invade or not epithelial 
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cells. Although Lalonde et al. published that S. suis is not able to invade epithelial cells and Norton 
et al. declared that S. suis invade epithelial cells "as a rare event" (261), a more recent study 
demonstrates that different non-typable strains were able to invad~ epithelial cells (33). Since these 
studies have been carried out with cell monolayers, studies using respiratory epithelial cells 
monolayers in a Trans-weIl system cou Id finally resolve this controversy. 
Another approach that can be used by S. suis to cross epithelia barriers is the use of 
suilysin. As explained above, suilysin is a member of thiol-activated cytolysin family of hef!1olysins 
(167). The roles of these toxins in pathogenesis of bacteria are varied and not fully understood. 
However, it has been demonstrated that they aIl lyse eukaryotic cells that contain cholesterol. In the 
case of S. suis it has been demonstrated that suilysin expressing S. suis strains are able to damage 
the epithelium using this pore-forrning toxin, which was shown to play a cytotoxic effect in vitro on 
a wide range of cell lines (199, 261), and might favour tissue invasion. However, this is not seen 
with sui1ysin-negative strains. 
S. suis also produces other molecules that could help bacteria to cross these epithelial cells 
destroying the integrity of the barriers. One ofthese molecules is the enzyme hyaluronate lyase (11) 
which is able to degrade HA. HA, also called hyaluronane or hyaluronate,. is a non-sulfated 
glycosaminoglycan distributed widely throughout epithelial tissues. It is one of the main 
components of the extracellular matrix (ECM) and contributes significantly to cell proliferation and 
migration. The degradation of HA by S. suis hyaluronate lyase could perrnitthe enhancement of 
invasion and the spread of the bacteria during infection by destruction of the ECM (11). In addition, 
S. suis also possesses plasminogen-binding molecules such as GAPDH (174). This molecule is able 
to capture plasminogen from host plasma and once converted to plasmin (175) bacteria become 
arrned with the broad substrate spectrum proteolytic potential of plasmin that can be used to 
facilitate bacterial penetration through biological membranes such as the respiratory epithelium 
barrier. 
FinaIly, a way to circumvent the epithelial barrier would be the so called "Trojan horse 
theory". This theory suggested that bacteria are taken up directly in the tonsil by. monocytes, 
allowing the bacteria to travel intracellularly from tonsils to bloodstream (393). However, this 
theory is not very plausible for S. suis because i) S. suis is not able to survive for long time inside 
these cells (348) and ii) it has been shown that, because of the presence of capsule, only a low 
number of monocytes contain intracellular bacteria and most of the bacteria remain attached 
extracellularly (334, 393). These results indicate that S. suis is probably not able to travel 
intracellularly, but in contrast it could travel extracellularly (393). This new theory was ca lied 
"modified Trojan horse the ory" and suggested that bacteria are able to cross barriers and 
disseminate towards bloodstream or target organs not inside the ce lis but in close association with 
them (128). 
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1.7.2. Blood dissemination and phagocytosis resistance 
As explained above, the strategies proposed by "Trojan horse" theories might help bacteria 
not only to cross the epithelial barrier but also to disseminate in blood, and even to reach the target 
tissues by exploiting the monocytes. However, most studies carried out during the last decade 
suggest that bacteria migrate in blood as free bacteria since a high level of bacteremia usually 
precedes the onset ofbacterial meningitis (393). 
Once in the blood, bacteria have to resist the immune system. The first leukocytes recruited 
to sites of infection are the neutrophils (386). Neutrophils are a type of white blood cel! or leukocyte 
which form an early !ine of defence against bacterial infections (386). They are the most numerous 
type of leukocytes and belong to a group called phagocytes. They are part of the innate immune 
system and are involved in the intlammatory response (386). Neutrophils are produced in huge 
numbers in response to infection, trauma or other stimuli. Once in place, they eliminate the invading 
bacteria and other noxious substances; usually dying in tlie process themselves. One of the methods 
they use to kill invaders is called phagocytosis which involves engulfing and digesting the "enemy" 
cell (386). 
It has been demonstrated that neutrophils play an important role in innate immunity against 
S. suis because i) they are detected during the early stages of S. suis infection, H) are significantly 
increased in pigs infected with a virulent strain, and Hi) are usually predominant in lesions caused 
by this pathogen (317, 320, 350, 381). A recent study carried out in our laboratory corroborated that 
neutrophils play an important role in host defence against S. suis infection since they are able to 
rapidly phagocyte most of the bacteria in presence of specific antibodies and complement (57). 
However, under non-immunised serum conditions, the capsule protects bacteria from neutrophil-
mediated killing whereas non-encapsulated mutants were efficiently killed under the same 
conditions. Quessy et al. (297) also showed that an increase in capsular material thickness after in 
vivo bacterial growth is accompanied by increased resistance to killing by swine neutrophils. 80th 
studies corroborate the role ofCPSas an important virulence factor of S. suis. Since neutrophils are 
the predominant cell type in swine blood, the ability of CPS ,to effectively protect S. suis from 
killing by these phagocytes may explain, at least in part, its survival capacity in blood (221). 
However, some avirulent strains also possess capsule which demonstrate that other factors are also 
important in the bacterial resistance in blood. It has been demonstrated that virulent strains that 
express EF, MRP and suilysinare more resistant to phagocytosis and killing by neutrophils that 
virulent strains that lack these factors (32, 57). Particularly, the lack of suilysin seems to be, at least 
in part, responsible for the higher susceptibility to killing by leukocytes. The principal reason is 
that, as established for other cell types, suilysin is also toxic for neutrophils (32, 57). However, it 
has also been probed that suilysin also interferes with complement which can protect, at least in 
part, S. suis from the immune, system (32, 57). It is important to remark that, although weil 
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capsulated strains possessing the mentioned virulence factors are able to resist phagocytosis, these 
strains are rapidly phagocytèd and c1eared from the circulation by neutrophils in the presence of 
complete serum and specific antibodies against this pathogen, confirming the important role of 
opsonic molecules (complement and antibodies) in the phagocytosis process of these immune 
system cells. 
As explained above, neutrophils have been found to be the first leukocytes at the onset of 
the disease, but after few hours, neutrophils start to die and other immune system ce Ils consisting of 
mainly monocytes and lymphocytes take their place in the protection of the host (350). Monocytes 
are produced by the bone marrow from hematopoietic stem cell precursors called monoblasts. These 
cens circulate in the bloodstream for about one to three days and then typically move into tissues 
throughout the body. They constitute between three to eight percent of the leukocytes in the blood. 
As neutrophils, monocytes are also responsible for phagocytosis of foreign substances in the body. 
Monocytes can perform phagocytosis using intermediary (opsonising) proteins such as antibodies or 
complement that coat the path?gen, as weIl as by binding to the microbe directly via pattern-
recognition receptors that recognize pathogens (324). Studies of phagocytosis and killing of S. suis 
by murine and human monocytes/macrophages showed similar results as those obtained with 
neutrophils .. Studies carried out by different techniques such as viable count, bacterial staining or 
flow cytometry showed that virulent strains of S. suis are not (or almost never) phagocyted by 
porcine and human monocytes/macrophages in non opsonic conditions (48, 61, 222, 316, 338). 
These results corroborate that the capsule is the major resistance molecule against phagocytosis and 
killing by these leukocytes and that, as also occurs with neutrophils, specific-antibodies against this 
pathogen enhance the phagocytosis of S. suis. However, the increased of phagocytosis of S. suis by 
these leukocytes in presence of complement is controversial. Sorne studies have shown that 
complement alone does not help leukocytes to phagocyte S. suis (316, 346) but that it is important 
in the phagocytosis of the non-encapsulated mutant (222). However, on the other hand, it has been 
demonstrated that deactivated serum significatively increase the phagocytosis of S. suis by porcine 
and mice phagocytes (48, 61) which means that sera components other than complement are 
important for the phagocytosis o~ S. suis by the host immune system. 
1. 7 .3. Septicemia 
The pathogenesis of S. suis infection is poorly understood (128). There is evidence, 
however, that the immune system may play an important role in both the development of and 
protection against disease. Paradoxically, the failure to control this inflammatory cascade may be at 
the origin of c1inical manifestations. Several inflammatory and infectious diseases are associated 
with the overproduction of proinflammatory cytokines and chemokines, and the recruitment and 
activation of different leukocyte populations are a hallmark of acute inflammation (322). These 
cytokines are believed to mediate responses associated with c1inical deterioration, multiorgan 
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system failure and death from septic shock (385). It has been reported that S. suis serotype 2 is able 
to interact with leucocytes of porcine origin in a whole-blood system, inducing the upregulation of 
the proinflammatory mediators TNF-a, IL-l~, IL-6, IL-8 and MCP-l (337). In addition, S. suis also 
provokes the release ofTNF-a, and lL-6 by murine macrophages (335) and TNF-a, IL-6, IL-l, IL-8 
and MCP-l by human monocytes (336). The activation of these cytokines is CDl4 and TLR2 
dependent and the major S. suis component responsible of the production of these cytokines is the 
cell wall (132, 337). Moreover, it has also been described that suilysin also promotes the production 
of TNF-a by human monocytes and IL-6 by alveoliu macrophages and porcine monocytes (221). 
The TNF-a, IL-l and IL-8 cytokines are considered as essentials for the initiation of the 
inflammation but also for the leukocytes recruitment (128, 335). These feed-back positive signais 
produce an overproduction of cytokines that can conclude with the apparition of sorne important 
clinical signs in the ho st such as septicemia and finally death. 
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Fig. 1. Summary of the 
knowledge and proposed 
hypotheses for the different steps 
involved in the pathogenesis of 
meningitis of S. suis. S. suis 
interacts with the epithelial cell 
layers of the upper respiratory tract 
and penetrates to blood circulation. 
Sly+ strains may use toxicity and 
invasion to reach the bloodstream, 
while Sly- strains are still 
uncertain. S. suis could also be 
directly uptaken by blood ce Ils and 
enter to the bloodstream within 
circulating cells. Bacteria could 
travel in bloodstream associated to 
these clood cells (bound and/or 
intracellular) or as free bacteria, 
resulting in bacteremia or 
septicemia. Free bacteria would 
enter the CNS after increasing BBB 
permeability, via direct cell toxicity 
(Sly+ strains), indirectly via local 
cytokine production or via other 
unknown(s) mechanism(s). Local 
cytokine production could also 
increase CAMs expression and 
leukocyte migration, that in tum 
"open the door" to free bacterial 
trafficking. On the other side, blood 
cells-associated bacteria would 
enter the CNS via the "Trojan 
horse" (bacteria inside celIs) or 
"modified" Trojan horse (bacteria 
adhered to ce lIs) mechanism 
favoured by activated phagocyte 
cytokine release. Figure adapted 
from (128) 
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1.7.4. Meningitis 
In the event, for unknown reasons, that bacteria fail to cause acute fatal septieemia, S. suis 
is able to reach the central nervous system (CNS) through mechanisms that are only partially 
understood. To reach the CNS bacteria are facing the blood brain barrier (BBB). This consists of 
two levels: a barrier between blood and brain arises at the cerebral capillary endothelium and a 
barrier between blood and cerebrospinal fluid (CSF) at the choroid plexus epithelium. The BBB is 
characterised by restrieted permeability on both sides of the layer due to the presenèe of tight 
junctions between endothelial cells of cerebral vessels and epithelial cells of the choroid plexus 
(372). Bacterial adherence to brain mierovascular endothelial cells (BMEC) can consequently lead 
to invasion, toxieity and/or increase in permeability. Most meningeal bacteria such as group B 
streptococci, S. pneumoniae and Escherichia coli are ableto adhere to and invade brain BMEC 
(259,372). In the case of S. suis it has been reported that this bacterium is able to adhere to human 
and porcine BMEC (62, 378). In addition, a recent study using a mutant lacking sortaseA showed 
that this mutant had reduced capacity to adhere to and invade porcine brain microvascular 
endothelial cells compared to the wild-type strain indicating that adhesins of the MSCRAMMs 
family (see point 2.3.1) are, at least in part, responsible for this adhesions (380). Interestingly, 
invasion was proved only for the porcine cells, but not for the human cells, although both humans 
and pigs develop S. suis meningitis (62, 378). Moreover, it has been demonstrated that S. suis can 
resist up to seven hours inside porcine BMEC whieh could indieate a possible way to cross the 
BBB. In addition, toxins such as suilysin were shown to be toxie for cells forming BBB in vitro (62, 
378). This cytotoxicity might produce functional alteration and increased permeability of BBB, 
which can help bacteria to penetrate across the endothelial barrier (320) but also the choroid plexus 
epithelial cells (364). In contrast, suilysin negative strains might rely on other mechanisms than 
toxicity to get access to the CNS (128). It has been hypothesised that after adherence to BMEC or 
leukocytes, S. suis might stimulate production of arachidonic acid, PGE2, MMP9 and 
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proinflammatory cytokines resulting in alteration of BBB permeability (87, 175, 176, 337). The 
local production of proinflammatory cytokines by mieroglial cells, endothelial cells, and migrating 
leukocytes upon contact with bacteria is currently regarded as the initial step for the development of 
meningitis. Several cytokines and chemokines (especially, TNF-a, IL-l, IL-8) are known to up-
regulate the expression of cell adhesion molecules (CAMs), su ch as selectins and integrins, which 
allow transmigration of leukocytes through the barriers (128). The observed cytokine-inducing 
activity of S. suis may have significant biologieal relevance since it has been demonstrated that 
these cytokines can be generated in the blood. For example, in the monocyte-associated theory 
(Trojan horse or "modified"), cytokine release by activated phagocytes after interaction with S. suis 
might, in turn, activate endothelial cells and increase both cell and bound (or intracellular) bacterial 
trafficking. On the other side, if the free circulating bacterial theory is considered, S. suis could 
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directly, or indirectly (via local cytokine release) stimulate the expression of CAMs and non-
infected leukocyte transmigration across the barriers. In this case, migrating leukocytes "open the 
do or" for bacterial trafficking to different organs. 
Once inside the BBB, S. suis is be able to survive and multiply in the cerebrospinal fluid 
and then cause damage to the CNS including brain oedema, increased intracranial pressure, and 
cerebrovascular insults provoking the meningitis. 
1.8. Vaccines against S. suis 
As explained before, S. suis infections can be treated by antibiotics. However, the antibiotic 
resistance found in sorne of the strains and the fact that it is essential to start the treatment at the 
beginning of the infection to avoid bacterial transmission between pigs in -the herds, show the 
importance of the development of new strategies. In the last years, different types of vaccines have 
been developed or are presently under investigation. However, up to now, the results obtained are 
not very encouraging. 
The idea of creating a vaccine against S. suis infections appears when Elliot et al. showed 
that' the transfer of serum from convalescent piglets resulted in complete protection against 
subsequent S. suis infection (92). These results indicate that sorne S. suis- antigens are able to 
produce a specific immune response able to prevent subsequent S. suis infections. Sorne years later, 
Holt and colleagues (159, 160) identified, by using sera raised against different fractions of S. suis 
type 2, six major surface antigens of 44, 78, 86,94, 130 and 136 kDa which were not recognized by 
serum from unprotected animais. They demonstrated that sera against the 94 kDa protein protected 
mice against challenge with a live, virulent strain of S. suis type 2. However, that study also showed 
that the serum raised against the 78 kDa protein inhibited the protective effect of the 94 kDa 
antiserum. Although the 94 kDa protein conferred protection in mice, its use as a possible subunit 
vaccine to control S. suis type 2 infection in pigs is not possible because it would require 
elimination of the 78 kDa antigen. Moreover, it is not known whether this protein is produced by 
other serotypes and will therefore be cross-protective, or whether it is serotype specific. Antibodies 
against the other surface proteins identified in that study were variably opsonic, but none was 
protective. 
Quessy and colleagues also reported a protective effect agliinst heterologous challenge to 
mice with virulent strains of S. suis type 2 of a 110 kDa protein purified from a culture supematant 
of S. suis type 2 (295). However, this protein was never characterized sufficiently to determine its 
usefulness as a possible subunit vaccine. 
In another effort to search for a S. suis protein(s) that can be used as a vaccine candidate, 
Okwumabua et al. constructed and screened a gene library with a polyclonal antibody raised against 
the whole-cell protein of S. suis type 2 (264). A clone that reacted with the antibody was identified 
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and characterized. The amino acid sequence of this protein shared homology with sequences of 
unknown function from other streptococci. They demonstrated that pigs immunized with this 
recombinant 38-kDa protein mounted antibody responses to the prote in and were completely 
protected against challenge with a strain of a homologous serotype, a wild-type virulent stralry of S. 
suiS type 2, suggesting that it may be a good candidate for the development of a vaccine against S. 
suis infection. However, it is has never been demonstrated that this protein is protective against 
other S. suis serotypes. 
On the other hand, vaccination strategies using known potential virulence factors such as 
purified suilysin (168) or MRP and EF (397) from S. suis serotype 2 have been shown to protect 
pigs from homologous and heterologous serotype 2 strains. However, and as explained before, a 
substantial number of virulent strains in sorne geographic regions do not express these proteins and, 
this feature impede the use of these proteins as an U1;liversal vaccine. 
Another S. suis critical virulence factor tested as vaccine was the CPS. However, its poor 
immunogenicity also impedes the use of this molecule as a vaccine (93). S. suis capsule 
biosynthesis has not yet been fully elucidated. In two subsequent studies, the S. suis serotype 2 cps2 
was identified as an important gene for capsule biosynthesis and non-encapsulated mutants were 
generated by disruption ofthis gene (346). However, a recent study showed that inactivation of the 
ara operon in S. suis serotype 2 also resulted in an unencapsulated phenotype (106). As one of the 
several approaches that may be used to elicit protective immunity against this bacterium is 
vaccination with a live, attenuated strain of S. suis, the use of these mutants was tested. Results 
obtained with both mutants were variable. The study using the unencapsulated I1cps2 mutant as live 
vaccine showed that this mutant failed to provide protection to pigs against the homologous 
serotype 2 parent strain (346) and that, as consequence, this strain is not usefull as a vaccine. In 
contrast, vaccination with the unencapsulated ara mutant provided a relatively good protection level 
against a challenge with the homologous serotype 2 parent strain. However, this protection was not 
100% effective and, in addition, it has not been tested against other S. suis serotypes, which impede, 
for the moment, its use as a effective vaccine (106). 
Repeated injections with other virulent, avirulent, or formalin-killed virulent S. suis type 2 
also gave variable results. Live avirulent strains protected against serotype 2 challenge in pigs (157, 
158, 296) but did not eliminate already established organisms or prevent the establishment of 
carriers (158). Single immunization with formalin-killed virulent type 2 organisms resulted in a 
good opsonizing response, although this did not always correlate with protection (157). In addition, 
passive protection studies in mice using the same formalin-killed strain showed protection with 
serum from hyper-immunized pigs but none with serum from piglets (42). Kebede and colleagues 
also tested the protective value of temperature-sensitive mutants of S. suis and only homologous 
protection was achieved (182). Finally, Foster and colleagues evaluated the use of a streptomycin-
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dependent mutant of S. suis type 1/2 as a vaccine. Although homologous protection was achieved, 
the vaccine failed to protect completely against S. suis type 2 (112). 
At present, the most used vaccines in the field are the inactivated commercial autogenous 
vaccines, but results have been inconsistent (142, 203). Simonson et al. described that the use of 
commercial bacterins (STREP BACT-TM) are highly effective to confer passive and active 
immunisation against serotype 1 and 2 of S. suis. However, this protection is limited since other 
serotypes can also produce infections (41). 
Up to now, an effective vaccine able to prote ct pigs or humans against ail virulent serotypes 
of S. suis does not exist. However, several research groups are now working hard to find new 
antigenic S. suis surface antigens, present in aIl the S. suis serotypes, that cou Id finally confer a 
successful protection against this pathogen. 
As explained before, bacterial virulence is determined by a wide variety of factors that 
influence bacterial attachment, penetration into tissue, and the escape from host. Up to now, 
different bacterial ECM-binding proteins have been suggested as potential vaccine targets for 
preventing bacterial infections because antibodies against these surface proteins are believed to 
have the dual activity of both adherence blocking and opsonic function (109). 
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2. Bacterial adhesion to Extracellular Matrix: 
2.1. Extracellular matrix 
2. 1. 1 General composition 
A major portion of tissues is extracellular space that is filled by a network of 
macromolecules secreted by the cellular components within the tissue. ECM is present to sorne 
degree in ail tissues" even blood where the plasma might be considered the matdx, but is a 
functional determinant in connective tissues (9). The matrix is mainly composed of structural and 
adhesive proteins. 
2.1.1.1. Structural ECM components 
The principal structural components of the eukaryotic ECM are coUagens that form 
different types of interstitial or basement membrane networks, including fibril-forming collagens 
(collagen types l, II, and III) and the two-dimensional collagen type IV network. For further 
,organization of the ECM, additionalcollagenous glycoproteins, proteoglycans, hyaluronan, and 
many other components, such as growth factors and proteases, become assoeiated with interstitial or ' 
basement-membrane ECM, giving rise to their specialized structure and function at different 
locations in the body (9). 
The main portion of interstitial ECM is produced and deposited by different 
connective tissues cells and determines the specifie character of each tissue or organ (9). 
Consequently, the tropism of pathogenic microorganisms is determined by the local composition of 
this complex network ofhost-derived factors. 
2.1.1.1.1. Collagen 
Co lIagen is found in ail of the connective tissues, such as dermis, bones, tendons, and 
ligaments, and also provides the structural integrity of ail of our internai organs (53). Therefore, 
because of its wide distribution throughout our bodies, it represents one of the most abundant 
naturally occurring proteins (376). 
There are close to 20 different types of collagen (246). Each one of these collagens is 
encoded by a specific gene. The predominant form is Type 1 collagen. This fibrillar form of 
collagen represents over 90 percent of our total collagen and is composed of three very long protein 
chains. Each chain is referred to as an "Alpha" chain. The .amino aeid sequence of each chain often 
follows the pattern Gly-X-Pro or Gly-X-Hydroxyproline, where X may be any amino acid residues. 
In collagen, G1y is required at every third position because the assembly of the triple helix puts this 
residue at the interior (axis) of the helix, where there is no space for a larger side group than 
glycine's single hydrogen atom. For the same reason, the rings of the Pro and Hyp must point 
outward. These two amino acids thermally stabilize the triple helix. This amino acid sequence 
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pennits that the three Alpha chains are wrapped around each other to fonn the final triple helical 
structure called a collagen monomer. This configuration imparts tremendous strength to the prote in. 
Basically all of the collagen types (131) share this triple-helical molecular structure. 
However, the various other types of collagens have slightly different amino acid compositions and 
provide other specific functions in our bodies (131). Type II collagen is the fonn that is found 
exc\usively in cartilaginous tissues. It is usually associated with proteoglycans or "ground 
substance" and therefore functions as a shock absorber in our joints and vertebrae. Type 1lI collagen 
is also found in our skin as weil as in blood vessels and internai organs. In the adult, the skin 
contains about 80-percent Type 1 and 20-percent Type 1II collagen. ln newboms, the Type III 
content is greater than that found in the adult. It is thought that the supple nature of the newbom 
skin as well as the flexibility of blood vessels is due in part to the presence of Type III collagen. 
During the initial period of wound healing, there is an increased expression of Type III collagen 
(70). Type IV collagen is found in basement membranes and functions as a filtration system. 
Because of the complex interactions between the Type IV collagen and the noncollagenous 
components of the base ment membrane, a meshwork is fonned that filters cells as weil as molecules 
and light. Finally, Type V collagen is found in essentially all tissues and is associated with Types 1 
and III. In addition, it is often found around the perimeter of many ce Ils and functions as a 
cytoskeleton. 
The biosynthetic pathway responsible for collagen production is very complex (291). Each 
specific collagen type is encoded by a specific gene. The messenger RNA for each collagen type is 
transcribed from the gene and undergoes many processing steps to produce a fInal code for the 
specific collagen type. A precursor fonn of collagen called procollagen is produced initially (31). 
Procollagen contains extension proteins on each end called amino and carboxy procollagen 
extension propeptides. These nonhelical portions of the procollagen molecule make it very soluble 
and therefore easy to move within the cell as it undergoes further modifications. The first 
modification to take place is the very critical step of hydroxylation of selected proline and lysine 
amino acids. Specific enzymes called hydroxylases are responsible for these important reactions 
fonning hydroxyproline and hydroxylysine (254). After that, sorne of the newly fonned 
hydroxylysine amino acids are then glycosylated by the addition of sug~rs, such as galactose and 
glucose (16) by the galactosyl or glucosyl transferases enzymes. This glycosylation step imparts 
unique chemical and structural characteristics to the newly fonned collagen molecule that influence 
fibril size (187). 
As explained above, when the procollagen peptides are intact, the molecule is about 1,000 
times more soluble than it is at a latter stage when the extension peptides are removed (292). This 
high degree of solubility allows the procollagenmolecule to betransported, by means of specialized 
structures called microtubules, within the cell and finally secreted into the ext~acellular spaces (86). 
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Once secreted, specialized enzymes called procollagen proteinases remove both of the extension 
peptides from the ends of the molecule and give the typical insolubility to the collagen (202). It is 
also in the extracellular spaces where the rest of post-translational modifications take place. The 
triple helical collagen molecules line up and begin to form fibrils to finally form the collagen fibers. 
This step is called crosslink formation and is promoted by another specialized enzyme called lysyl 
oxidase (27). This last reaction places stable crosslinks within (intramolecular crosslinks) and 
between the molecules (intermolecular crosslinks) giving the tremendous strength to the collagen 
fibers present in the tissues. 
2.1.1.1.2. Laminin 
In addition to the network-forrning collagen IV, the mature basement membranes also 
con tain other abundant structural components. Larninin is the most abundant noncollagenous 
protein in the basement membrane and is responsible for stability (407). 
Up to now, eleven different genes encode the eleven chains of the larninin protein family 
(al-S, ~1-3, and yl-3). This a-, 13-, or y-chain denornination is based on sequence identity and 
protein dornain organization. There is sorne evidence that a fourth ~-chain could exist, but its 
existence is currently unc1ear (210). The a-chain averages 400 kDa in size and 160 nm in length. 
The ~-chain averages 215 kDa in size and 60 nm in length. Finally, the y-chain averages 205 kDa in 
size and 40 nm in length respectively. 
Structurally, larninin are formed by heterotrimeric chains that resemble a three-pronged fork 
(Fig 2). The C-terrnini of the a-, ~-, and y-chains form the "handle" of the larninin fork. The three 
"prongs" are the short arms oflarninin that emerge from the coiled-coil domain (210). 
a-chain (400 kDa) 
Integrin and 
entactin 
Binding site 
collagen 
Binding site 
a-helical 
coiled coil 
y-chain 
(205 kDa) 
Heparan sulphate 
Binding site 
Fig 2: Diagram of the Laminin fork structure composed of three different chains: a, ~ and y. Figure 
adapted from (371) 
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Laminin plays an essential role in basement membrane formation due to multiple 
interactions with itself and other components. Laminins contain binding sites for other cell 
components such as integrins, heparin sulphate, proteoglycans, dystroglycan, nidogen, and lutheran 
(Fig 2). These adhesions permit that laminin influence multiple functions of adjacent cells inciuding 
adhesion, proliferation and differentiation (247, 367). 
Laminin assembly is a complex process that up to now is not completely understood. It 
seems that once in the Golgi apparatus, ionic interactions favor ~'Ydimer formation, which is then 
stabilized and secreted upon incorporation of the (X-chain (260, 371). The point of intersection of the 
three chains is stabilised by disulfide bridges (280). In addition, the rod or "handle" of the fork is 
stabilized by a heptad repeats. These heptad repeats allow for hydrophilic, charged, and 
hydrophobie stabilization of the trimer. (371). Much like type IV collagen, laminin seems to be able 
to self-assemble in basement membranes into a honeycomb-like polymer. This self-assembly of the 
heterotrimeric laminins into oligomers is a process dependent of calcium and is attributed to the 
globular domain of each chain (Fig 2), although the mechanism remains elusive (281, 371, 408). 
2.1.1.1.3. Elastin 
Many vertebrate tissues, such as skin, blood vessels, and lungs, need to be both strong and 
elastic in order to function. A. network of elastic fibers in the ECM of these tissues gives them the 
required resilience so that they can recoil after transient stretch (276). Long, inelastic collagen 
fibrils are interwoven with the elastic fibers to limit the extent of stretching and prevent the tissue 
from tearing. 
The main component of elastic fibers is elastin, a highly hydrophobie protein (about 750 
ammo acids long), which, like collagen, is unusually rich in proline and glycine but, unlike 
collagen, is not glycosylated and contains sorne hydroxyproline but no hydroxylysine (319). 
The elastin protein is composed largely of two types of short segments that alternate along 
the polypeptide chain: i) the hydrophobie segments, which are responsible for the elastic properties 
of the molecule, and ii) the alanine- and Iysine-rich a-helical segments, which form cross-links 
between adjacent molecules (319). Each segment is encoded by a separate exon. There is still 
controversy, however, concerning the conformation of elastin molecules in elastic fibers and how 
the structure of these fibers accounts for their rubber-like properties. The most accepted theory is 
that elastin polypeptide chain adopts a loose "random coi!" conformation, and it is the random coil 
structure of the component molecules cross-linked into the elastic fiber network that allows the 
network to stretch and recoillike a rubber band (319). 
Elastin synthesis goes through several steps similar to those observed in the collagen 
formation: gene transcription, alternative splicing of pre-mRNA, mRNA translation, hydroxylation 
of sorne proline residues of the tropoelastin, secretion of tropoelastin molecules in the extracellular 
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space, synthesis of cross-links with Iysinonorleucine, desmosine and isodesmosine, that gives 
insolubility and elasticity of elastin, and finally, deposition of this elastin on the microfibrillar 
scaffold (166). 
As explained above, elastic fibers are not composed solely of elastin. The elastin core is 
covered with a sheath of microfibrils, each of which has a diameter of about 10 nm (315). 
Microfibrils are composed of a number of distinct glycoproteins, including the large glycoprotein 
fibrillin, which binds to elastin and is essential for the integrity of elastic fibers. Microfibrils are 
thought to be important in the assembly of elastic fibers. They appear before elastin in developing 
tissues and seem to form a scaffold on which the secreted elastin molecules are deposited. As the 
elastin is deposited, the microfibrils become displaced to th~ periphery of the growing fiber 
stabilizing it (315). 
2.1.1.2 Adhesive glycoproteins 
Upon vessel wall injury, particularly at sites of wound healing, initial adhesion of 
platelets to the exposed subendothelium and subsequent plate let aggregation are dependent on 
adhesive glycoproteins present in the subendothelial cell matrix as weil as those stored inside 
plate lets and secreted during this initial phase of hemostatic plug formation (9). In addition to their 
strong attachment-promoting activity, residing predominantly in the Arg-Gly-Asp (RGD)-
containing epitope and being the predominant recognition site for integrins, these multifunctional 
proteins are of major importance in the initial adherence phase of pathogens (9). 
2.1.1.2.1. Fibronectin 
Fibronectinis one of the most important ECM proteins because it has numerous functions 
that ensure the normal functioning of life. One of its more notable functions is its role as a 'guide' in 
cellular migration pathways in mammalian development, particularly the Neural Crest (ectoderm 
cells that will develop into skin pigment cells as weil as sorne bones of the skull). Moreover, 
fibronectin also helps maintain the shape of cells by lining up and organizing intracellular 
cytoskeleton by means of receptors. In addition, it helps stabilize the attachment of ECM to cells by 
acting as binding sites for cell surface receptors. More generally though, fibronectin helps create a 
cross-linked network within the ECM by having binding sites for other ECM components (355). 
Fibronectin can be found in two different forms (227). The blood plasma fibronectin, which 
is a soluble form, composed of two 250 kDa subunits joined together by disulfide bonds and the 
cellular fibronectin, The latter insoluble form, that was formerly called cold-insoluble globulin, is 
synthesized by the cells that form the ECM and is formed by a large complex of cross-linked 
subunits. Each fibronectin subunit is folded into a series of functionally distinct domains separated 
by regions of flexible polypeptide chain (Fig 3). The domains in tum consist of smaller modules, 
each of which are serially repeated and usually encoded by a separate exon, suggesting that the 
fibronectin gene, like the collagen genes, evolved by multiple exon duplications (227). All isoforms 
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of fibronectin are encoded by a single large gene that contains about 50 exons of similar size. 
Transcription produces a single large RNA molecule that can be a1tematively spliced to produce the 
various isoforms of fibronectin (227). 
30kOa 40kOa 20kOa 
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Fig 3: Diagram ofthe fibronectin structure. Figure adapted from www.bbioo.com 
When fibronectin is treated with a low concentration of a proteolytic enzyme, the 
polypeptide chain is eut in the connecting regions between the domains, leaving the domains 
themselves intact. One can then show that one of its domains binds to collagen, another to heparin, 
and the last one to specifie receptors on the surface of various types of cells (Fig 3) (227). Synthetic 
peptides corresponding to different segments of the cell-binding domain have been used to identify 
a specifie tripeptide sequence (Arg-Gly-Asp, or RGD) (227). This RGD sequence is not confined to 
fibronectin . It is also found in a number of extracellular proteins, including, for example, the blood-
c10tting factor fibrinogen. RGD sequences are recognized by several members of the integrin family 
of cell-surface matrix receptors. Each integrin, however, specifically recognizes its own small set of 
matrix molecules, indicating that tight binding requires more than just the RGD sequence (360). 
Unlike fibrillar collagen molecules, which can be made to self-assemble into flbrils in a test 
tube, fibronectin molecules assemble into fibrils only on the surface of certain cells (285). This is 
because additional proteins are needed for fibril formation, especially fibronectin-binding integrins 
(227). The fibronectin fibrils on the cell surface are highly stretched and under tension. The tension 
is exerted by the cel! and is essential for fibril formation (227). The fibronectin fibrils are usually 
aligned with adjacent intracellular actin stress fi bers. In fact, intracellular actin filaments promote 
the assembly of secreted fibronectin molecules into fibrils and influence fi bri 1 orientation. The 
interactions between extracellular fibronectin fibrils and intracellular actin filaments are mediated 
mainly by integrin transmembrane adhesion proteins. The contractile actin and myosin cytoskeleton 
thereby pulls on the fibronectin matrix to generate tension. As a result, the fibronectin fibrils are 
stretched, exposing a cryptic (hidden) binding site in the fibronectin molecules that allows them to 
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bind directly to one another. In addition, the stretching exposes more binding sites for integrins. In 
this way, the actin cytoskeleton promotes fibronectin polymerization and matrix assembly (227). 
2.1.1.2.2. Vitronectin 
Vitronectin is present in normal plasma at concentrations of 200 to 400 ~g/ml and 
constitutes 0.2-0.5% of total plasma protein (28). Previous data suggests that the liver is a major 
site of vitronectin biosynthesis (339). A second circulatory pool of vitronectin is contained within 
platelets. This rapidly releasable intracellular form accounts for only 0.8% of the circulating 
vitronectin pool (275). A high level of vitronectin rnRNA is present in the liver. However, many 
other organs including brain, heart, skeletal muscle, lung, uterus, testis and thymus were also found 
to contain vitronectin rnRNA (339). 
The molecular weight of human vitronectin is 75 kDa. It circulates as a single-chain (75 
kDa) and as a two-chain (10 and 65 kDa) form under reducing conditions. Under non-reducing 
conditions, the N-terminal 65 kDa and C-terminal 10 kDa fragments are linked by a single disulfide 
bond (369) (fig 4). 
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Fig 4: Diagram of the vitronectin structure. Figure adapted from www.haemtech.com 
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Vitronectin contains three glycosylation sites that contribute approximately 30% of its 
molecular mass. The complete open reading frame of vitronectin encodes for 459 amino acids 
preceded by a signal peptide of 19 amino acids in length (328). The vitronectin gene consists of 
eight exons and seven introns, resulting in a 1.7 kb transcript with no indication for alternative 
splicing (289). 
Vitronectin is a conformationally labile molecule (fig 4). This lability likely plays a large 
role in regulating its function. Formation of complexes with plasminogen activator inhibitor-I (PAI-
1), thrombin-antithrombin 1II, or complement C5b-C9 induces conformational changes within 
vitronectin exposing its heparin binding domain. Interestingly, conformation al changes are not 
limited to the heparin binding domain and also occur in the N-terminal half of the molecule 
including the somatomedin B domain (289). This region of the vitronectin molecule contains a high 
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affinity binding domain forPAI-1 (340) and an Arg-Gly-Asp (RGD) amino acid sequence. A highly 
acidic region (aa 53-64) containing sulfation sites (tyrosine residue 56 and 59), a putative 
crosslinking site (amino acid 93), and a collagen binding domain occurs adjacent to the RGD 
sequence (165). Due to its RGD sequence, vitronectin plays a key role in the attachment of cells to 
their surrounding matrix. Vitronectin is anchored to the extracellular matrix by its collagen binding 
and glycosaminoglycan (GAG) binding domains. The carboxy-terminal region of vitronectin (aa 
332-348) accommodates its plasminogen binding domain (191). A cluster of basic amino acids 
containing two consensus heparin binding sites occurs downstream of this region. This site is 
particularly exposed in vitronectin multimers engaged in specific binding interaction with collagen 
(type 1), osteonectin, and PAI-l (191). 
Vitronectin has been implicated as a regulator of many diverse physiological processes 
including coagulation, fibrinolysis, pericellular proteolysis, complement dependent immune 
response, cell attachment and spreading (341). Vitronectin is involved in fibrinolysis due to its 
ability to stabilize the active conformation of PAI-l and bind the urokinase receptor. Vitronectin is 
also involved in immune defense via interaction with the terminal complex of complement and in 
haemostasis via heparin binding which neutralize antithrombin III inhibition of thrombin and factor 
Xa (289). 
2.1.1.2.3. Fibrinogen and fibrin 
Fibrinogen is a soluble glycoprotein found in the plasma, with a molecular weight of 340 
kDa (88). Fibrinogen has a biological half-life of about 100 h and is synthesized predominantly in 
the liver (141). As a clotting factor, fibrinogen is an essential component of the blood coagulation 
system, being the precursor of fibrin (179). However, at the 'usual' plasma levels of 1.5 to 4.5 gll, 
its concentration far exceeds the minimum concentration of 0.5-1 gli necessary for haemostasis 
(179). 
The fibrinogen molecule is a hexamer consisting of two identical sets of three polypeptide 
chains (a., ~, and y) he Id together by disulfide bonds (146) (Fig 5). Synthesis of the protein in 
hepatocytes is under the control of 3 genes (one for each chain) located within 50 kilobases (kb) on 
chromosome 4 (180). 
Fibrinogen resembles fibronectin in that fibrinogen also contains many important functional 
binding regions, including heparin binding domains on the N-terminal ~ chain (404), platelet 
recognition sites (143) and ICAM-1 binding sites (18). Other important sites on fibrinogen include 
the Arg-Gly-Asp (RGD) sites (115) which, as explained above, are necessary for integrin ligation 
permitting adhesion of endothelial ce Ils to provisional matrix through specifie integrins. 
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Fig 5: Diagram of the fibrinogenlfibrin structure. Figure adapted from (293) 
Processes in the coagulation cascade (Fig 6) activate the zymogen prothrombin to 
the serine protease thrombin, which is responsible for converting fibrinogen into fibrin (134). 
Thrombin causes a limited proteolysis of the fibrinogen molecule, during which fibrinopeptides A 
and B are released from the N-terminaJ regions of the a and ~ chains, respectively (Fig 5). These 
fibrinopeptides, which have been sequenced in many species, may have a physiologic role as 
vasoconstrictors and may aid in local haemostasis during blood clotting. ln addition, fibrinogen 
fragments also function as chemotactic factors for inflammatory cell infiltration (390). Thrombin is 
also responsible for the activation of the fibrin-stabilizing factor, which in its activated form is a 
transpeptidase catalyzing the formation of epsilon-(gamma-glutamyl)-lysine crosslinks in fibrin to 
form a clot (325). Together with vitronectin and other adhesion proteins, the fibrin clot constitutes 
the majority of the initial provisionaJ ECM network for sealing a wound site, thereby protecting this 
area against infiltration by opportunistic, infectious microorganisms (204). 
On the other hand, fibrinolysis is the process wherein a fibrin clot, the product of 
coagulation, is broken down (238). Its main enzyme plasmin cuts the fibrin mesh at various places, 
leading to the production of circulating fragments that are cleared by other proteases or by the 
kidney and liver (56). Plasmin is produced in an inactive form, plasminogen, in the liver. Although 
plasminogen cannot cleave fibrin, it still has an affinity for it, and is incorporated into the clot when 
it is formed (56). Plasminogen contains secondary structure motifs known as kringles, which bind 
specifically to lysine and arginine residues on fibrin(ogen). When converted from plasminogen into 
plasmin, it functions as a serine protease, cutting C-terminal to these lysine and arginine residues 
(56). Tissue plasminogen activator (t-PA) and urokinase are the agents that con vert plasminogen to 
the active plasmin, thus allowing fibrinolysis to occur (238). t-PA is released into the blood very 
slowly by the damaged endothelium of the blood vessels, such that, after several days (when the 
bleeding has stopped), the clot is broken down. This occurs because plasminogen becomes 
entrapped within the clot when it is formed; as it is slowly activated, it breaks down the fibrin mesh. 
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t-PA and urokinase are themselves inhibited by plasminogen activator inhibitor-l and plasminogen 
activator inhibitor-2 (PA1-1 and PAI-2) (238). In contrast, plasmin further stimulates plasmin 
generation by producing more active forms of both tPA and urokinase (238). On the other hand, 
alpha 2-antiplasmin and alpha 2-macroglobulin inactivate plasmin. Plasmin activity is also reduced 
by thrombin-activable fibrinolysis inhibitor, which modifies fibrin to make a less pote nt cofactor for 
the tPA-mediated plasminogen activation (238). 
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Fig 6: Coagulation cascade of proteins. Figure adapted from (293) 
2.1.1.2.4. Thrombospondin 
Thrombospondin is a high-molecular weight, heparin-binding glycoprotein that was 
initially termed "thrombin-sensitive protein" based upon its release by thrombin-activated platelets 
(25, 26). Thrombospondin is one of the most abundant proteins in the platelet a-granule (77, 359). 
Structurally, thrombospondin is a 450,000 Da molecular weight glycoprotein (208) consisting of 
three, identical, disulfide-Iinked polypeptide chains (206). Thrombospondin is not an exclusive 
product of platelets and megakaryoctes. 1t can be also synthesised by endothelial cells (252), 
fibroblasts (170), monocytes and macrophages (169), and osteoblasts (308). 
Over the last decade it has become c1ear that platelet-derived thrombospondin, or 
thrombospondin 1 (TSPl) as it is now known, is a member of a family of at least five proteins, 
every one of which exhibits a distinct tissue distribution. 1t is sometimes referred to as the subgroup 
A thrombospondins which also contains thrombospondin 2 (TSP2). Subgroup B thrombospondins 
comprise the other members of the family: thrombospondins 3 to 5 (TSP3-5) which are 
homopentameric with smaller subunit masses than TSP] or TSP2 (44). 
44 
Ali TSPs (Fig 7) have in common a region of about 650 amino acids at the carboxy-
terminal end of their subunits. These ami no acids are organised into domains or repeats that bind 
calcium and a range of extracellular molecules, and possess sorne cell attachment properties (3). 
The amino-terminal domain binds heparin and is thus also called the heparin binding domain (96). 
Following this domain, TPS has a collagen-binding domain that permit adhesion of this protein to 
the ECM and a set of domains, known as type 1 or properdin domains, that are anti-angiogenic 
(327). Subgroup B thrombospondins lack type 1 domains, do not inhibit angiogenesis and have 
variable amino-terminal domains. Type 2 domain, also termed epidermal growth factor- (EGF-) like 
repeats, is found after the type 1 domain and is variable in number. At the carboxy-terminal domain, 
TSPs contain the RGD motif important for the binding of this protein to the cell. 
1 
s 
1 
RGD 
repeals 
Fig 7: Diagram of the thrombospondin structure. Figure adapted from www.haemtech.com 
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Differences 10 structure and in tissue distribution between TSPs indicate that their 
physiological roles are likely to differ. Nevertheless, TSPs do have a number of analogous 
activities. For instance, both proteins bind calcium and heparin. However, these latter interactions 
represent only a fraction of their binding repertoire. Studies with platelet thrombospondin (TSP 1) 
de mon strate that the protein interacts with components of platelets and of the clotting and 
fibrinolytic systems including fibrinogen, thrombin, plasminogen and osteonectin (67, 140, 206, 
214). These findings raise the possibility that thrombospondin might promote platelet aggregation 
and clotting (207, 269). Another group of interactions between subgroup A thrombospondins and 
extracellular components are those involving structural and adhesive proteins. Mumby and 
colleagues reported that TSPI could bind type V collagen, laminin and fibronectin. Subsequently, 
evidence emerged that TSPI can also bind collagen types I-IV (253). Following studies concerning 
the molecular interactions of TSP1, Lahav and coworkers suggested that the protein plays a role in 
extracellular matrix (ECM) assembly (198). 
Despite the complexity of TSPs interactions at the molecular level and their sometimes 
bewildering consequences on cellular behaviour, distinct multiple roles for the proteins in biological 
processes are starting to come to light. Thus, although the two proteins have major functions in 
development, it seems that it is in tissue formation during adult life where TSPs have a more overt 
impact (3). In normal adults TSPs appear to play a role in continued tissue turnover as evidenced by 
45 
their tightly controlled post-natal expression (44). For example, TSP1 is prominent in basement 
membranes, and at the base of epithelia in sorne adult human tissues (2, 67). It is conceivable that 
the role of the protein in these locations is related to collagen fibrillogenesis and/or cell 
differentiation (3). In addition, TSPs are also required for "normal" cutaneous wound healing. 
TSP1, derived from plate lets and the monocytic ce Ils of the intlammatory response, appears early in 
repair and is involved in coagulation and the provisional matrix, cell recruitment, apoptosis of 
damaged cells, protease modulation and TGF,8 activation (7, 45). Conversely, TSP2 emanates from 
wound fibroblasts and so emerges later than TSP1 in repair. TSP2 seems to regulate angiogenesis 
and collagenous matrix assembly during healing (45, 197). 
2.2. Bacterial adhesion to extracellular matrix protein (ECM) 
An essential step in successful colonization and production of disease by microbial 
pathogens is their ability to adhere to ho st cell surfaces. A1though different pathogens can adhere to 
nearly any site in the body, each pathogen usually colonizes one or a few particular sites in the ho st 
(391). The choice of host cell surface that a pathogen can adhere to is large. The mammalian cell 
surface contains many proteins, glycoproteins, glycolipids, and other carbohydrates that could 
potentially serve as a receptor for a bacterial adhesin. Additionally, the ECM provides a rich source 
of glycoproteins to which many pathogens bind (9). 
As explained above, the ECM is the extracellular part of animal tissue that usually provides 
structural support to the cells. The ECM inc1udes the interstitial matrix, present between various 
ce Ils (in the intercellular spaces), and the basement membrane (356). Basement membranes are 
sheet-like depositions of ECM on which various ce Ils rest. ECM is intimately linked and determines 
a variety of cellular systems, cellular shape, orientation, differentiation, and metabolism (9). 
Furthermore, the time-depending modification and rebuilding of ECM at different parts in the body 
is essential for intlammation and wound healing. At these sites, the provisional ECM may provide 
bacterial entry and colonization, whereas intact tissues or epithelia are mostly protected against 
bacterial infection by a variety of adhesive and mucoidal components (391). However, sorne 
pathogens can use bacterial toxins to cause tissue damage by destruction of host ce Ils, an as 
consequence, exposure of the ECM. Once exposed, bacteria can bind these ECM proteins via its 
adhesins (391). 
Bacterial adhesins for ECM proteins are usually proteins, either located at the tip of a 
scaffold-Iike structure on the bacterial surface (called fimbria) or anchored in the bacterial 
membrane bu.t surface exposed (nonfimbrial or afimbrial adhesins) (391). 1t is becoming apparent 
that the molecular machinery needed to build pili or to transport an afimbrial adhesin to the 
bacterial surface is often conserved. Despite this conservation, the receptor specificity of the 
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adhesin is dictated by a portion of the adhesin exposed at the pilus tip or on the bacterial surface 
(391 ). 
The bacterial binding to ECM proteins 'can have many consequences. On one hand these 
adhesions can mask the microbial surface and thereby interfere with antigen presentation and 
. provide an overall immune evasion strategy. On the other, it can serve as a bridge between the 
bacterium and host cell surface when ECM proteins bind to their natural receptor on host cell 
surfaces (391) (Fig. 8). One of these natural receptors is integrins. Adhesion of pathogen to these 
integrins via ECM proteins is usually the first step in penetrating into the body through activation of 
host cell cytoskeleton (Fig. 8). This activation permits bacterial invasion to ho st cells and can be 
used by pathogens to cross sorne host barriers (391). 
2.3. Bacterial fibronectin-binding proteins 
Pathogenic bacteria often use adherence to and invasion of eukaryotic ce Ils for 
colonization, evasion of immune defence and survival, as weil as to cause disease in the host (l72). 
Many Gram-positive bacteria express specific cell-surface components called adhesins that mediate 
their adherence to host cells, thereby facilitating not only colonization but also invasion (391). Most 
ofthese adhesins and invasins function by binding to various components of the extracellular matrix 
(ECM), particularly fibronectin (172). Many Gram-positive bacteria that interact with fibronectin 
have been identified (330). As explained before, fibronectin is a multi-functional protein that is 
abundant in the circulation and at various extracellular sites (227). As it can bind to both host cells 
and bacteria, it is considered an essential binding molecule for bacterial adherence. Moreover, via 
its interaction with integrins, fibronectin can also play a role in triggering the signal transduction 
events that lead to bacterial invasion of eukaryotic ce Ils (330). 
Up to now, three different types offibronectin-binding proteins have been described 
for Gram-positive bacteria (65): i) microbial surface components recognizing adhesive matrix 
molecules (MSCRAMMs), ii) choline-binding proteins and finally iii) anchorless-proteins. 
Several Gram-positive bacteria, including streptococci and staphylococci, specifically bind 
to fibronectin using several different adhesins with highly homologous recognition motifs. These 
adhesins are anchored on the bacterial surface via an LPXTG motif and known as microbial surface 
components recognizing adhesive matrix molecules or MSCRAMMs (177). 
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Fig 8. Schema tic model indicating how binding of multiple Fn molecules to FnBPs attached to 
the bacterial cell surface might result in integrin clustering on the host celJ surface and 
subsequent uptake of bacteria. Figure adapted from (373) 
2.3.1. MSCRAMMS 
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The MSCRAMMs exhibit structural features typical of other cell wall-anchored proteins of 
Gram-positive bacteria (177) (Fig 9). A putative signal sequence involved in transport of the 
proteins through the cytoplasmic membrane by the Sec-dependent transport of the protein is located 
at the N terminus of these proteins. Following the signal sequence, MSCRAMM contain a domain, 
called A domain, that up to now has no known biological activity and the B domain that contain the 
fibronectin-binding repeats. The C-terminus is composed of: (i) a conserved LPXTG motif which is 
required for ace urate sorting and anchoring of the proteins to the cell wall; (ii) a hydrophobie 
membrane-spanning region; and (iii) a tail of positively-charged residues which remain in the 
cytoplasm. 
Signal 
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binding 
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Fig 9: Diagram of the MSCRAMMs structure. Image adapted from (279) 
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Once the protein has been transported to the cel! surface, the LPXTG motif is cleaved 
between the Thr and Gly residues. The carboxyl group of the Thr residue is then linked to a free 
amino group of a branched peptide within the peptidoglycan cel! wall (326, 370). Finally, a proline-
rich stretch of residues, thought to span the peptidoglycan layer of the cell wall, is commonly found 
on the N-terminal side of the LPXTG motif in these proteins. The enzyme responsible for 
catalyzing ,these reactions has been named 'sortase'. Sortase is a multifunctional protease-
transpeptidase that has been shown to specifically cleave the LPXTG sequence in a prote in and to 
catalyze the transfer of the processed prote in to the free amino group of pentaglycine cross-bridges 
in peptidoglycans (277). Genes homologous to srtA, a sortase-encoding gene, are found in a variety 
of Gram-positive bacteria whose genome sequences have been entered in a database (235, 271), 
suggesting that the sortase-mediated mechanism is a universal strategy of Gram-positive bacteria 
for displaying proteins on the microbial surface. However, there is usually more than one srtA 
homo log in each genome, and the number of srtA homologs .varies depending on the species (271). 
S. suis possesses five srt homologs: srtA encodes sortase, which anchors surface proteins with an 
LPXTG motif to the cell wall, while the functions of the other four homologs (the srtBCD cluster 
and srtE) remain unknown (267). The genetic organization of the srtA region was found to be 
conserved among S. suis strains (267). Although in sorne strains the srtAs showed strong sequence 
divergence, their functions were verified to be overlapping by genetic complementation, indicating 
the functional conservation of srtAs during the evolution of these strains (267). These results 
indicate the importance of a srtA-mediated cell wall sorting system for displaying proteins on the 
surface of S. suis. 
2.3.2. Choline-binding proteins 
Another mechanism of anchoring on the surface, distinct from LPXTG mediated 
attachment, is used by many surface proteins of different pathogens. Pneumococci have a series of 
surface-exposed proteins that attach to bacteria through this specific choline binding motif (36). The 
principal particularity of these proteins is that they do not possess the carboxy-terminal hydrophobic 
domain or charged tail, and also lack the LPXTG motif. These proteins, called choline-binding 
proteins, have modular structures consisting of a C-terminal choline binding module that is usually 
followed by a flexible linker peptide built from a proline-rich segment and finally by a functional N-
terminal module (36). The choline binding module consists of several (usual!y around 10) repeat 
regions of usually approximately 20 amino acids. These modules have been identified to bind to 
terminal choline residues of teichoic or lipoteichoic acid structures present on the surface of 
S. pneumoniae and serves as an anchoring device to pneumococci for the se proteins (36). The 
choline-binding protein motif has also been found among the surface proteins of other bacteria like 
Clostridium acetobutyticum, Clostridium difficile, Streptococcus mutans, and Streptococcus downei 
(403). However, up to now, no choline-binding prote in has been described for S. suis. 
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2.3.3. Anchorless-proteins 
Several Gram-positive ce Il-surface proteins with adhesive and invasive functions have been 
described that contain neither a signal peptide nor an LPXTG motif nor choline-binding repeats 
(65). The exact mechanism used by these proteins to be exported to the surface of bacteria is still 
unknown. However, a possible mechanism by which these anchorless proteins are displayed on the 
bacterial surface has been suggested by Bergmann et al. (37) who identified the anchorless surface-
displayed a-enolase in S. pneumoniae. Although the described bacterial enolases have not the 
ability to bind fibronectin, it has been proposed that ail the anchorless proteins, including the 
fibronectin-binding proteins, used a similar mechanism to be secreted to the surface of bacteria. 
Bergmann et al. suggested that this prote in is secreted by autolysis and can reassociate by 
interacting with receptors on the surface of pneumococci. However, another study suggested that 
the secretion of the Listeria monocytogenes enolase is SecA2-dependent (213). Further research is 
required to identify the real mechanism used by these anchorless proteins to be secreted at the 
surface of the cell. 
Fibronectin-binding anchorless proteins have biological functions as adhesins and invasins 
(65). Moreover, other biological activities have also been described for these proteins. For example, 
the S. aureus anchorless fibronectin-binding protein Eap (extracellular adherence prote in) mediates 
diverse biological functions, including adherence and immunomodulation, thus contributing to S. 
aureus pathogenesis (144). Other example of these anchorless proteins is the fibronectin-binding 
protein PavA from S. pneumoniae, which was described by Holmes et al. (156). PavA is localized 
on the pneumococcal cell surface, despite the lack of conventional secretory or cell-surface-anchor 
signais. PavA binds to immobilized fibronectin and has been suggested to be involved in 
pneumococcal cell adhesion and to be essential for virulence (156). Another example is the 
fibronectin-binding prote in FBP54 from S. pyogenes, which shows 67% homology to PavA, and 
neither contain the anchor features common to surface proteins of Gram-positive bacteria (73). As 
for the other described anchorless-fibronectin-binding protens FBP54 seems to play a role in the 
pathogenesis of the infection caused by S. pyogenes. Up to now, no fibronectin-binding anchorless 
protein of S. suis has been identified. 
2.4. S. suis adhesion to ECM proteins 
Although it has been demonstrated that ECM proteins are important host receptors for 
bacterial adhesins and that most of the bacterial ECM-binding proteins contribute to the 
pathogenesis of bacteria, little was known, before this work, about the capacity of S. suis to adhere 
to the se ho st proteins. In fact, only three works have been published about the adhesion of S. suis to 
the proteins forming the ECM or about the S. suis adhesins involved in these processes. 
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The first one, realised by De Greef et al. in 1991, identified by "in vivo selected genes" the 
only fibronectin-fibrinogen-binding protein (FBPS) described for S. suis (78, 79). They showed that 
thejbps gene was present in ail known serotypes of S. suis [except for serotypes 32 and 34 that up to 
now can be considered as S. orisratti (154)], as weil as in ail three phenotypes of serotype 2. 
However, the expression of FBPS in ail serotypes and phenotypes was not studied (78). Therefore, 
it is possible that although ail strains, except for serotypes 32 and 34, possess the jbps gene, not ail 
strains express FBPS. The gene encoding FBPS was cloned and sequenced,i and it has been showed 
that recombinant FBPS was able to adhere to human fibronectin and fibrirlOgen (78). In addition, 
using an isogenic mutant for this protein, it was demonstratt~d that FBPS is involved in the 
colonization of the organs specific for an S. suis infection in piglets, but notin the colonization of S. 
suis on the tons ils of piglets (78). The second work describes a 52 kDa IgCii-binding protein (343). 
The characterisation of this protein, identified by Serhir et al. in 1993, demonstrated that it not only 
reacts with a large variety of IgGs and with human IgA, but also with other human plasma proteins 
including fibronectin (342). Finally, the last work about the adhesion of S. suis to fibrinogen has 
been recenty published (43). Bonifait et al. showed that supplementing the culture medium with 
fibrinogen induced biofilm formation by S. suis in a dose-dependent manner wich indicates that S. 
suis is able to bind fibrinogen to its surface and produce this biofilm (43). Moreover, this biofilm-
grown S. suis were shown to be much more resistant to penicillin G than planktonic cells( 43). 
In addition to these adhesins, other proteins with high homology with other bacterial 
fibronectin-binding proteins have been described for S. suis. In 1993, the gene encoding the 
muramidase-released protein (MRP) was cloned and sequenced (348). Its analysis demonstrated 
that this protein contains a particular region within the amino acid sequence with high similarity 
with a fibronectin-binding protein of S. aureus. However, binding of MRP to human fibronectin 
cou Id never be confirmed (348). In 2006, Baums et al., also identified a gene of S. suis, named ofs 
(29), which encodes a protein with high homology to other streptococcal MSCRAMM fibronectin-
binding proteins such as FnBA of S. dysgalactiae (237) and SOF of S. pyogenes (72). However, 
although OFS has a MSCRAMM typical structure, no detection of any fibronectin-binding activity 
was found for the recombinant OFS (29). The lack of detectable binding might be explained by 
~ignificant differences between the repetitive sequences ofOFS and the fibi"onectin-binding repeats 
of FnBA (237) and SOF (29) which are considered as the fibronectin-binding structure of these 
proteins. 
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3. Enolase 
3.1. Glycolysis 
3.1.1. Introduction 
Glycolysis is a metabolic pathway by which a 6-carbon glucose (Glc) môlecule is oxidized 
to two molecules of pyruvic acid (Pyr) (257). The word glycolysis is derived from Greek yÀV1(VÇ 
(sweet) and Àvmç (rupture). It is the initial process of most carbohydrate catabolism, and it serves 
three principal functions: i) the generation of high-energy molecules (A TP and NADH) as cellular 
energy sources as part of anaerobic and aerobic respiration, ii) production of pyruvate for the citric 
acid cycle as part of aerobic respiration and iii) the production of a variety of six- and three-carbon 
intermediate compounds, which may be removed at various steps in the process for other cellular 
purposes (257). 
As the foundation of both aerobic and anaerobic respiration, glycolysis is the archetype of 
universal metabolic processes, known and occurring (with variations) in many types of cells in 
nearly ail organisms. Glycolysis, through anaerobic respiration, is the main energy source in many 
prokaryotes, eukaryotic cells devoid of mitochondria (e.g. mature erythrocytes) and eukaryotic cells 
under low oxygen conditions (e.g. heavily exercising muscle or fermenting yeast) (257). 
In eukaryotes and prokaryotes, glycolysis takes place within the cytosol of the cell. In plant 
cells sorne of the glycolytic reactions are also found in the Calvin-Benson cycle which functions 
inside the chloroplasts. The wide conservation includes the most phylogenetically deep rooted 
existant organisms and thus it is considered to be one of the most ancient metabolic pathways (309). 
3.1.2. History 
The most common and well-known type of glycolysis is the Embden-Meyerhof pathway. 
The tirst formai studies of the glycolytic process were initiated in 1860 when Louis Pasteur 
discovered that microorganisms were responsible for fermentation (329), and in 1897 when Eduard 
Buchner found that certain cell extracts cou Id cause fermentation (189). The next major 
contribution was from Arthur Harden and William Young in 1905 who determined that a heat 
sensitive high molecular weight subcellular fraction (the enzymes) and a heat insensitive low 
molecular weight cytoplasm fraction (ADP, A TP and NAD+ and other cofactors) were required 
together for fermentation (194). The details of the pathway itselfwere determined by 1940, with a 
major input from Otto Meyerhof (194) and sorne years later by Louis Leloir (193). The biggest 
difticulties in determining the intricacies of the pathway were due to the very short lifetime and low 
steady-state concentrations of the intermediates of the fast glycolytic reactions. 
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3.1.3. Glycolysis phases (257) 
The breakdown of the six-carbon glucose into two molecules of the three-carbon pyruvate 
occurs in ten steps (Fig JO), the first five of which constitute the preparatory phase. In these 
reactions, glucose is first phosphorylated at the hydroxyl group on C-6 (step 1). The glucose 6-
phosphate thus formed is converted to fructose 6-phosphate (step 2), which is again phosphorylated, 
this time at C-I, to yield fructose 1,6-bisphosphate (step 3). For both phosphorylations, ATP is the 
phosphoryl group don or. Fructose 1,6-bisphosphate is split to yield two three-carbon molecules, 
dihydroxyacetone phosphate and glyceraldehyde 3-phosphate (step 4); this is the "Iysis" step that 
gives the pathway its name. The dihydroxyacetone phosphate is isomerized to a second molecule of 
glyceraldehyde 3-phosphate (step 5), ending the first phase of glycolysis. In this preparatory phase 
of glycolysis the energy of A TP is invested, raising the free-energy content of the intermediates, 
and the carbon chains of ail the metabolized hexoses are converted into a common product, 
glyceraldehyde 3-phosphate. 
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Fig 10. The two phases of glycolysis. Figure adapted from (257) 
The energy gain cornes in the payoff phase of glycolysis. Each molecule of glyceraldehyde 
3-phosphate is oxidized and phosphorylated by inorganic phosphate (not by ATP) to form 1,3-
bisphosphoglycerate (step 6). Energy is then released as the two molecules of 1,3-
bisphosphoglycerate are converted to two molecules of pyruvate (steps 7 through 10). Much of this 
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energy is conserved by the coupled phosphorylation of four molecules of ADP to A TP. ,The net 
yield is two molecules of A TP per molecule of glucose used, because two molecules of ATP were 
invested in the preparatory phase. Energy is also conserved in the payoff phase in the formation of 
two molecules ofNADH per molecule ofgluç;ose. 
3.2. Enolase 
3.2.1. Introduction 
Enolase. was discoveredin 1934 by Lohman and Mayerhof while they were studying the 
conversion of 3-phosphoglycerate to pyruvate in muscle extracts (219). The enzyme a-enolase (2-
phospho-d-glycerate hydrolase, EC 4.2.1.11) catalyses the conversion of 2-phospho-D-glycerate 
(PGA) to phosphoenolpyruvate (PEP) by elimination of 1 molecule of water in thecatabolie 
direction in the second half of the Emden Mayerhoff-Pamas glycolytie pathway (257) (Fig lOB). In 
the other direction, ocurring during gluconeogenesis, the same enzyme catalyses the reverse 
reaction, the hydration of PEP to PGA (257). To be highly active, enolase requires certain divalent 
metal ions. The natural cofactor for this enzyme is magnesium. In presence of magnesium, enolase 
imparts its high activity, whieh classify this enzyme among the enzymes called metal-activated 
metalloenzymes (402). Enolase reaction also occupies a key position in the metabolic pathway of 
fermentation in general and the glycolytie pathway, in particular, and hence this enzyme is 
ubiquitously present in abundance in the biologieal world (402). 
3.2.2. Distribution 
Ali enolases are composed of two identical subunits, and have a molecular weight in the 
range of 82-100 kDa (272). In mammals and humans, there are three inde pendent genetie loci, a, p 
and y, that encode for three isozymes: i) a-enolase, that is found in a variety of tissues including 
liver, ii) ~-enolase, that is almost exclusively found in muscle tissues and finally iii) y-enolase, that 
is found in neuron and neuroendocrine tissue (282). Several earlier studies have determined from 
their chromatographie and immunological studies that neuron/brain-specific enolase can be found in 
heterodimerie forms such as aa, ap, pp, ay and TI (108, 181, 312). As yet ~y heterodimerie 
isoenzyme has not been found, although experimentally it has been isolated from its individual 
homodimeric counterparts (306). Rider and Taylor (305, 306) and Merkulova et al. (241) described 
that the proportions of isoenzymes aa, pp and ap in heart and skeletal muscle of rat varies during 
embryonic development. In both tissues, aa isoenzyme predominates in the fetus stage however 
this isoenzyme is replaced by ap and pp types in adult heart and by pp type in adult muscle. These 
researchers also showed that the aa isoform is found in liver, brain, spleen, adipose tissue and 
kidney. 
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3.2.3. Primary and secondary structure of a-enolase 
It has been known since 1971 that a-enolase exist in a dimeric form (351). This structure 
was confirmed in the 80's and early 90's by X-ray crystallography. The results corroborate the 
dimeric form ofthis enzyme in which both identical subunits are facing each other in an antiparallel 
fashion. Each subunit of enolase is made up of two domains: the smaller N-terminal and the larger 
C-terminal domains (351). 
Crystal structure of a-enolase from S. pneumoniae suggests that this enolase, and probably 
ail the bacterial enolases, presumably form an octamer instead of a dimer under ail physiological 
conditions, whether cytoplasmically located or presented on the surface of the bacterium (91). 
3.2.4. Enolase activity 
Warburg and Christian (388) and Utter and Werkman (374) observed for the first time the 
IOn requirement of this enzyme. Since then, several groups have studied the importance and 
mechanisms of metal ion activation of the enolase enzyme (402). Six divalent metal ions -
magnesium, manganese, zinc, cadmium, cobalt and nickel - were found to activate enolase (50). 
Among these, although magnesium is a naturally occurring metal activator, the binding of enolase 
with magnesium is much weaker than with zinc (50). Thus, according to the definition of Valle, 
enolase qualifies as a metal-ion-activated enzyme complex rather than a typical metalloenzyme in 
which the metal is firmly bound. The role of Mg2+ in the enolase activity is twofold since it 
possesses two types of binding sites which contribute to catalysis (99). The first site is ca lied 
conformational. It induces conformational changes in the active site and enables binding of a 
substrate or its analogues. Once firmly bound, the second magnesium ion binds to the second site 
and serves as a required component of the catalytic apparatus. The relative activation strength 
profile of binding of metal ions in the enolase activity is Mg2+ > Zn2+ > Mn2+ > Fe(IIi+ > Cd2+ > 
C02+, Ni2+, Sm3+, Tb3+ (50, 402). Irrespective of which of these metal ions binds, the studies on 
yeast enolase have shown that metal ion binding in the catalytic site is always weaker when 
compared with that in the conformational site. Thus, although Ca2+, Tb2+ and Sm3+ do not activate 
enolase, they bind to enolase much tighter than Mg2+ (49). 
3.2.5. Mechimism of enolase activity (272) 
Enolase catalyzes the elimination of OH- from C3 of a discrete enolate intermediate which 
is created by removal of a proton from C2 of 2-PGA by a base in the active site in a stepwise 
manner (209). 
When 2-PGA binds to a-enolase, it interacts with Gln167, Lys396 and both essential 
divalent cations (Mg2+), and as a result the carboxyl group of PGA is rotated and neutralized. A 
large movement of theloop Ser36-His43 (36Ser-Gly-Ala-Ser-Thr-Gly-Val-His43) and a smaller 
movement of the loops Ser158-Gly162 and Asp255-Asn256 then result into the coordination of 
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backbone carbonyl and si de-chain hydroxyl of Ser39 with catalytic Mg2+. This movement appears 
to close the active site. The loops, Va1l53-Phe169 and Ser250-Gly277, th en move together, 
allowing His 159 to donate a proton to the phosphoryl of PGA. The interaction of protonated 
phosphoryl of PGA with Arg374 and catalytic Mg2+ th en results in ovemeutralization of the 
negative charge on phosphoryl and the lowering of and hence bringing of carbon-2 pKa of PGA 
into the physiological range. The movement of Lys 345 closer to Arg374 lowers the pKa of its E-
ammonio group, which loses its proton and accepts one from the C2 of PGA. Finally, the proton 
shared by Glu168 and Glu211 forms a hydrogen bond to the PGA hydroxyl group. This proton is 
then transferred from the carboxylate to the hydroxyl group, making H20 and PEP. In the reserve 
reaction (hydration reaction), the water held by Glu 168, Glu211 and His373 is deprotonated by one 
of the carboxylates, and the resulting OH- adds to C3. At the same time, a proton from the E-
ammonio group of Lys345 adds to C2, resulting in the elimination of the double bond between C2 
and C3 (209). 
3.2.6 Enolase superfamily 
The Enolase superfamily is a paradigm of superfamilies whose members catalyse different 
reactions retaining a common mechanistic strategy. This superfamily was discovered by Babbitt et 
al. on the basis of the fundamental structure and the conserved amino acid residues of the catalytic 
site (23). Enolase superfamily comprises 16 enzymes which catalyze 11 different reactions. AIl the 
members of this family catalyze the initial metal-assisted abstraction of the a proton from a carbon 
adjacent to a carboxylate group, resulting in a stabilized enolate anion intermediate. The fate of this 
intermediate anion is then determined by the different active-site architecture, catalyzing a variety 
of chemical reactions that include racemization, cycloisomerization and fJ elimination of either 
water or ammonia using diverse carboxylate anions as substrate. 
There are three subgroups in this superfamily, which is divided according to the basic 
residues involved in the formation of enolic intermediates (23): (i) an Enolase subgroup which 
utilizes a single lysine residue, (ii) a mandelate racemase subgroup (MR) which utilizes one lysine 
and/or a histidine residue(s) and (iii) a muconate lactonizing enzyme (MLE) subgroup which 
utilizes two lysine residues (138). Studies that recognize such a structure-function paradigm have 
provided a rational basis for understanding the chemistry of aIl of the superfamily members (22, 
23). 
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3.2.7. Location diversity 
3.2.7.1. Enolase as a cytosolic enzyme 
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As explained above, enolase was discovered for its participation in one of the steps of the 
glucolysis and gluconeogenesis. As both metabolic pathways take place within the cytosol of the 
ceIl (272), it was commonly believed that the localisation ofthis enzyme was only the cytoplasm of 
ceIls. However, through the years, it has been demonstrated that the localisation of this metabolic . 
enzyme is not restricted to cytoplasm but it can also been found in the other cell compartments. 
3.2.7.2. Enolase as a surface protein 
Enolase was first described on the surface of a great variety of eukaryotic cells as a strong 
plasminogen-binding receptor (245, 256, 303). Later, the presence of enolase on the surface of 
prokaryotes a~ a plasminogen receptor was also reported in many pathogens and commensal 
bacteria (273). The expression of a glycolytic enzyme on the surface of cells is not unprecedented. 
Other enzymes such as GAPDH and phosphoglycerate kinase have also been reported on the 
surface of different ceU types including prokaryotes (274). However, a chaUenging question 
remains about how these glycolytic enzymes, including enolase, are expressed on the surface of 
eukaryotic ceUs such as haematopoetic ce Us, epithelial cells, neuronal ceUs and also on Gram-
positive cocci, Candida and parasites (272). The mechanism used for its translocation to the surface 
of cells is still unknown; however, it is important to remark that in almost ail cases, the surface 
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localisation of these proteins belongs to organisms which possess only plasma membrane or a 
membrane and a cell wall, but not organisms which possess two membranes, such as in Gram-
negative bacteria. 
The amino acid sequence of bacterial enolases shows that this enzyme lacks the N-terminal 
signal sequence and also the anchor carboxyl terminus LPXTG motif. These domains have been 
shown to be crucial for translocation through the cell wall and for anchoring surface proteins to the 
Gram-positive bacterial cell wall (104). Furthermore, repeats that might anchor the protein non-
covalently to the surface, as shown for choline-binding proteins of S. pneumoniae (405) are neither 
present on bacterial enolases. The precise mechanisms of how enolases or other anchorless prote in 
(273, 274) are transported through the cell wall and how these proteins are anchored to the bacterial 
cell surface need further investigation. One study suggested that the secretion of the L. 
monocytogenes enolase is SecA2-dependent (213). Another study speculated that surface GADPH 
and enolase are rather 'scavenged' from other cells that have undergone programmed cell death 
through allolysis (137). However, it remains unknown why these enzymes and, in particular, 
enolase appear on the surface of cells. 
3.2.7.3. Enolase as a nuclear protein 
In addition to the cytoplasmic and surface localisation of this enzyme, it has been recently 
demonstrated that enolase is also found in the nucleus in several cell types. Western blotting shows 
that this prote in is present in both nucleus and cytoplasm of endothelial cells (1) and HeLa cells 
(357). Immuno-histochemistry alsoshows a nuclear location for a-enolase in astrocytes (201), type 
II neurons of the spiral gang lia (81), bronchial epithelial ce Ils, type 1 and type II alveolar ce Ils and 
endothelial cells (58). 
It has also been demonstrated that during muscle regeneration a-enolase changes from a 
cytoplasmic to a perinuclear location suggesting a role of nuclear ,enolase during this regeneration 
(240). This hypothesis was also proposed when a recent study showed that in the parasite 
Plasmodium yoelii, a small fraction of enolase undergoes several posttranslational modifications, 
permitting this protein to switch from cytoplasm to nuclear localization (270). The variable amounts 
of enolase detected in nucleus at different life cycle stages of the parasite, also suggests that enolase 
could have sorne type of nuclear function depending on the stage of development of the parasite. 
3.2.8. Multifunctional nature of enolase 
Since enolase is abundantly expressed in most cells, it has been proved useful as a model 
for studying basic mechanisms of enzyme action as weil as structural analysis. However, unlike the 
gene that expresses GAPDH, the gene that expresses enolase is not a housekeeping gene since its 
expression varies according to the pathophysiological, metabolic or developmental conditions of 
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cells (272). Several studies have reported different unrelated functions for enolase. The 
accumulating evidence makes clear that enolase is a multifunctional protein. 
3.2.8.1. Enolase as a plasminogen-binding protein 
[n both eukaryotic and prokaryotic cells, cell-surface a-enolase serves as a strong receptor 
and activator of plasminogen, a key component of the intravascular and pericelIular fibrinolytic 
systems (21, 272). In S. pyogenes infections, the binding of a-enolase to the cell-surface is 
associated with the 10ss of its glycolytic activity and the acquisition of a high affinity for 
plasminogen (Ill, 272). The surface-exposed epitope involved in this function is located in the 
central loop of human a-enolase (amino-acids 257-272) (21). The crystal structure study of a-
enolase from S. pneumoniae reveals in fact the presence of two plasminogen binding sites. The first 
one matches the C-terminal lysyl residues but may not be as important as the second one since sorne 
a-enolases, including C. albicans a-enolase, entirely lack the first plasminogen binding site. In S. 
pneumoniae, the a-enolase binding to plasminogen induces plasminogen transformation into 
plasmin and is thought to be a virulence factor by preventing the generation of fibrin clots and thus 
enables tissue invasion, as described for S. pyogenes and S. pneumoniae (111). 
3.2.8.2. Enolase as a laminin-binding protein 
In addition of its plasminogen-binding activity, it has been demonstrated that enolase from 
S. aureus is also able to adhere to laminin, the major protein constituting the basement membrane of 
cells (54). This laminin-binding activity might function as a guidance mechanism, allowing S. 
aureus adherence to the basement membrane and initiating tissue colonization. Recently, it has been 
demonstrated that the enolase of the commensal bacteria Lactobacillus crispatus also adheres to 
laminin indicating that this is not an isolated feature of S. aureus and that this function could be 
biologically important for the se bacteria (15). 
3.2.8.3. Enolase as an eye 'V-crystallin protein 
The principal components of eye lens, contributing about 20-60% of total wet weight are 
the crystallins (286). The vertebral lenses are composed of a-,~, r, ~, e- and t-crystallins 
(401). 'V-crystallin is present in as much as 23 % of the total protein of the lens. Purified 'V-crystallin 
sequence shows strong similarity to the sequences of human and yeast enolases indicating a 
commun origin for both proteins. However, in contrast with the glycolitic enolase, this protein 
shows significantly low enzymatic activity (399). Three different reasons seem to be the cause for 
this discrepancy in activity: i) it seems that during development and differentiation, the fiber cells of 
the lens lose ail their organelles, and hence they must rely on cytoplasmic glycolysis as a source of 
energy (400), ii) as described above, enzymatically active enolase is found in dimeric form (402), 
however, r-crystallin is redominantly found in monomeric losing its activity and finally iii) it is 
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also believed that the loss of enzyme activity may be due to aging in the lens or the presence of 
sorne inhibitor substance(s) in the lens (399). 
3.2.8.4. Enolase as a Myc-binding protein (MBP-l) 
C-myc is a DNA-binding phosphoprotein protooncogene that plays a crucial role in the 
regulation of cell growth and differentiation (231). The human c-myc protooncogene contains two 
TATA boxes separated by 165 bp located at the 5' end of the first axon (287). MBP-1 is a 37 -kDA 
protein that is able to bind in a region + 123 to + 153 relative to the c-myc P2 promoter (301). MBP-
1 is a negative regulator of c-myc expression because it binds in the minor groove of the c-myc P2 
protein simultaneously with TA TA-binding prote in impeding the transcription of the gene (101, 
231). It has been proved that binding of MBP-1 to c-myc leads to tumor suppression. 
The sequence analysis of MBP-1 has shown that there is extensive homology between this 
gene and the gene coding for a-enolase (357). Insterestingly, the start codon MBP-1 A TG 
corresponds to the 400 bp downstream of the a-enolase ATG, and hence MBP-1 is considered to be 
an alternative translation initiation product of the a-enolase RNA (357). Since MBP-1 lacks the first 
96 residues of a-enolase, it does not show enolase activity, suggesting that the N-terminal portion is 
essential for glyco1ytic activity, and is not essential for c-myc binding. However, studies using a 
mutant enolase prote in lacking amino acid residues 96-236, showed that this mutant no longer 
binds to DNA, suggesting that the N-terminal portion of MBP-1 is involved in c-myc binding for 
the downregulation of its expression and tumor suppression (101). 
3.2.8.5. Enolase as an endothelial hypoxic stress protein 
In adapting to extreme environments such as high temperature or glucose deprivation, cells 
often secrete or express specific proteins known as heat-shock proteins (HSPs) (406). Vascular 
endothelial cells in a similarly stressful situation such as chronic hypoxia respond by upregulating 
the expression of a unique set of five cell-associated stress proteins (HAPs) (Mr 34, 36, 39, 47 and 
57) in a time- and oxygen concentration-dependent manner (133). One ofthese proteins, the 47-kDa 
prote in, has been identified as a-enolase. These results proposed that, in a hypoxic situation, 
upregulation of enolase may provide protection to cells by increasing anaerobic metabblism (1). 
3.2.8.6. Enolase as a heat shock protein (HSP) 
In Saccharomyces cervesiae several HSPs are induced at elevated temperatures. One of 
these, HSP48; has been identified as a-enolase (164). HSP48 is the product of the enD gene and is 
thought to be involved in both thermal tolerance and growth control in this organism. The 
expression of the enD gene is negatively regulated by the HSRl (heat shock resistant) gene since the 
HSRl mutant renders the organism extremely resistant (1000-fold more resistant th en the parental 
strain) to heat shock (164). 
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3.2.8.7. Enolase as microtubule organizer 
Recently, several studies have indicated that glycolytic enzymes are anchored to specific 
substructures(188). In fact, adhesion of enolase to microtubules has been reported by several 
groups. Such mechanism appears to occur, for example, in sperm tlagellae, where the association of 
glycolytic a-enolase to microtubules is likely necessary for human sperm motility (119). In a 
similar way, the high A TP turnover rates, needed in Chlamydomonas for tlagellae motility, are 
supported by the presence of enolase in the flagellar microtubular compartment (248). The 
conservation during evolution of this enolase/microtubule interaction most probably retlects a 
fundamental, indispensable function ofthese molecular associations. 
Moreover, it has also been proposed that enolase cou Id play a role in the dynamic 
cytoskeletal re-organization accompanying myogenesis both via its direct binding to 
tubulinlmicrotubule system and via glycolytic energy production (183). The co-localisation of 
enolase with the microtubular system was demonstrated in undifferentiated myoblasts. It seems that 
under this condition, the tubulin formed by depolymerisation of microtubules, could be complexed 
with the enolase. One can, therefore, speculate that the multiple associations of enolase with 
tubulinlmicrotubules cou Id intluence effectively the dynamics of the microtubular network and 
could contribute to regulate the reorganisation of cytoskeleton known to occur du ring myogenesis 
(183). 
3.2.9. Enolase and disease 
Antibodies against a-enolase have been detected in a large variety of infectious and 
autoimmune diseases. These antibodies might arise as a consequence of a microbial infection or 
uncontrolled growth or proliferation of cells in specific organs under pathophysiological conditions. 
3.2.9.1. Anti-<l-enolase antibodies in infectious diseases 
A major contributing factor in the development of antibodies against bacterial antigens is 
the fact that several antigens may share common epitopes with the antigens present on the surface 
of other bacteria. This is especially true for enolase which has epitopes that are able to ross-react 
with different species of streptococci and the human enzyme (313). Despite the differences found in 
species, a-enolase is highly conserved, with a 40 to 90% identity between enolases from two 
different species (272). For example, Group A Streptococcus and Saccharomyces cerevisiae 
enolases share 43% and 62% homology with human a-enolase, respectively. 
Antibodies against S. pneumoniae a-enolase develop early in Iife. Adrian et al., in a cohort 
study of children presenting with otitis media during their first two years of Iife, detected antibodies 
against S. pneumoniae a-enolase in 99% of the sera (6). The authors suggest that the high 
prevalence of anti-a-enolase antibodies in children may be due to cross-reactive epitopes of a-
enolase from colonizing bacterial species because of the high degree of homology of a-enolase 
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among these species (6). Anti- a-enolase antibodies, along with other anti-neuronal glycolytic 
enzymes, have also been detected more frequently in patients with post-streptococcal 
neuropsychiatric sequelae as compared to controls (75). Anti-a-enolase antibodies cou Id also play a 
role in limiting tissue invasion in streptococcal infections as shown by partial inhibition of 
plasminogen binding to pharyngeal cells in the presence of polyclonal anti-S. pyogenes-a-enolase 
antibodies (272). Finally, anti-streptococcal enolase monoclonal antibodies inhibit phagocytosis of 
the bacteria by human neutrophils (111). Antibodies against C. albicans a-enolase are also present 
in the sera of immunocompetent subjects in case of colonization with C. albicans. For 
immunodeficient patients, the rates of antibodies against C. albicans a-enolase are significantly 
higher in the sera of patients with invasive candidiasis than in the sera of patients colonized with C. 
albicans and anti-a-enolase antibodies can thus be used as a diagnostic test for systemic candidiasis 
(377). 
3.2.9.2. Anti-a-enolase antibodies in systemic autoimmune disorders 
Anti-a-enolase antibodies have been found in a large variety of autoimmune and 
inflammatory diseases. Anti-a-enolase antibodies have been initially reported in sera from patients 
that reacted with centrosomes in systemic rheumatic diseases (300). Then, anti-a-enolase antibodies 
have been shown to be a minor target antigen of anti-neutrophil cytoplasm antibodies (ANCA) in 
systemic vasculitides (250), u1cerative colitis and Crohn's disease (310) and primary sclerosing 
cholangitis (266). Since then, ànti-a-enolase antibodies have also been found in a large variety of 
autoimmune and inflammatory disorders such as systemic lupus erythematosus (SLE) (288), mixed 
cryogiobuinemia (MC) (288), systemic sclerosis (SSc) (288), rheumatoid arthritis (RA) (323), 
Behçet's disease (211), multiple sclerosis (212), Hashimoto's encephalopathy (HE) (114) and 
paraneoplastic retinopathy such as cancer-associated retinopathy (CAR) (5). In heaithy controIs, 
antibodies against a-enolase have been found in 0 to 6% (266)(288) (5). The production of anti-a-
enolase antibodies is not isotype restricted (288). 
Taking into account the wide spectrum of diseases associated with anti-a-enolase 
antibodies, these antibodies cannot help in the diagnosis of a specific autoimmune disease. 
\ . 
However, anti-a-enolase antibodies could be used as prognostic markers. In SLE and MC, the 
presence of anti-a-enolase antibodies was associated with renai invoivement (250, 288, 313) 
although this remains controversial. In SSc, the number of patients tested was small and no 
correlation was clearly made between the detection of anti-a-enolase antibodies and clinical 
manifestations, except for severe organ involvement (288). In RA, the presence of anti-a-enolase 
antibodies was associated with radiological progression (323). In HE, high titers of anti-a-enolase 
antibodies were associated with an excellent corticosteroid sensitivity (114). In primary biliary 
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cirrhosis, no correlation was found between the presence of anti-a-enolase antibodies and clinical 
presentation, but the mortality rate associated with hepatic failure was significantly higher in 
patients with anti-a-enolase antibodies (8). 
The titer of anti-a-enolase antibodies is high in systemic diseases, and relatively low in 
liver diseases, suggesting that the level of Ab affinity cou Id play an important role, as weil as 
differences in terrns of Ab specificity. Indeed, the identification of reactivities with the different 
enolase isoforrns (a, ~, y) in various autoimmune diseases suggest the recognition of different 
epitopes of enolase (288). Moreover, reactivities between purified and recombinant a-enolase 
differ, suggesting the predominant recognition of post-translationally or post-traductionally 
modified forrns of a-enolase, such as citrullination (186). For example, the majority of sera tested 
in SLE, MC or HE expressed Ab reactivity toward a-enolase, whereas more than ha If of sera from 
patients with CAR (5) and lymphocytic hypophysitis (262) reacted either with a- or y-enolase. 
Epitope-mapping was perforrned in CAR and in endometriosis. Four -major epitopes of a-
enolase (amino-acids 31-38, 176--183,421-428 and 56--63) were found to be recognized by aIl 
anti-a-enolase antibodies of CAR patients, the epitope 56--63 being specifically associated with 
pathogenic sera (4). Interestingly, sera from healthy subjects recognized the epitopes 30-37, 176-
183 and 421-428 of a-enolase but not the epitope 56--63 (4). In endometriosis, anti-a-enolase 
antibodies bound preferentially to two epitopes (53-87 and 207-238) (387), and shared the 
reactivity against the epitope 5~63 with CAR patients. 
3.2.9.3. Pathogenic role of anti-a-enolase antibodies 
Anti-a-enolase aritibodies might be produced after a contact with bacteria or yeast and 
cross react with human-a-enolase (288) Indeed, Fontan et al. suggested that antibodies raised 
against streptococcal a-enolase during S. pyogenes infections might recognize common epitopes of 
human a-enolase expressed at the membrane of eukaryotic ce Ils and could be involved in post 
streptococcal sequelae (111). Interestingly, higher titers of anti-streptococcal a-enolase antibodies 
are found in serum samples from patients with acute rheumatic fever as compared with healthy 
controls or patients with minor pharyngitis. The potential role of an immune response directed 
against yeast was supported by the binding of anti-a-enolase antibodies from patients with 
autoimmune hepatitis and primary sclerosing cholangitis to Saccharomyces cerevisiae enolase. 
AIso, in patients with a C. albicans infection, yeast enolase is released (358) and may generate an 
immune response. Finally, particular immune background may play a role since it was shown that 
human a-enolase-derived peptides bound to HLA-DR8, suggesting the occurrence of autoimmune 
diseases iil patients with HLA-DR8 aIle le (66). 
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The role of anti-a-enolase antibodies has been extensively studied in patients with SLE 
related-nephritis and CAR. In patients with SLE related-nephritis, a-enolase was found to be 
overexpressed in glomeruli and inflammatory les ions such as crescents, whereas in normal kidney, 
a-enolase was almost undetectable in glomeruli and expressed only in tubuli (244). Since the 
upregulation of a-enolase can increase the tolerance to hypoxia (272), anti-a-enolase antibodies 
might be involved in the pathogenesis of SLE related-nephritis and act as a nephrogenic 
autoantigen. BALB/c mice were injected intraperitoneally with hybridoma-producing anti-a-
enolase antibodies, and sorne of the glomeruli showed focal infiltrates or diffuse proliferative 
lesions. Thus, since a-enolase is expressed on the membrane of various cells, anti-a-enolase 
antibodies could play a role in renal and endothelial injury through the generation of immune 
complexes and activation of the complement classical pathway (288) 
Anti-a-enolase antibodies can inhibit the binding of plasminogen to a-enolase (251), and 
thus plasminogen activation to plasmin. As reported in SLE, in MC and SSc, anti-a-enolase 
antibodies react with endothelial ce Ils expressing large amounts of a-enolase, and induce in jury to 
those cells. Moreover, anti-a-enolase antibodies isolated from the serum of patients with SLE, MC 
or SSc bound to the membrane-associated form of the enzyme iilterfering with the plasminogen 
receptor function (251). In addition, although hematopoietic cells display several molecules that 
bind plasminogen, a-enolase is responsible for the majority of the promotion of plasminogen 
activation on their surface, and a monoclonal anti-a-enolase Ab inhibits the cell-surface mediated 
plasminogen activation (220). 
In CAR patients, anti-a-enolase antibodies are capable of penetrating retinal tissue to target 
ganglion cell layer and inner nuclear layers and, consequently, induce death of retinal cells through 
an apoptotic process (304). Cytotoxicity of CAR antibodies occurs independently of complement 
activation and is dependent on the amount of antibodies added and the duration of exposure of 
retinal cells to these antibodies. Moreover, when anti-a-enolase antibodies were injected 
intravitreously into rat eyes, these antibodies also targeted retinal cells in the inner nuclear layer and 
ganglion cell layer, and consequently caused apoptotic cell death (304). Interestingly, it was 
reported that anti-a-enolase antibodies from patients with CAR, patients with endometriosis or 
healthy individuals did not bind to the epitope 257-272, involved in the plasminogen-binding of a-
enolase, suggesting that these conditions are not associated with perturbations of the intravascular 
and pericellular fibrinolytic system (304). 
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ABSTRACT 
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Streptococcus suis serotype 2 is a major swine and human pathogen that causes septicemia 
and meningitis. The ability of S. suis serotype 2 to bind to different extracellular matrix (ECM) 
proteins was evaluated by ELISA. Ali 23 strains tested bound to plasma and cellular fibronectin and 
collagen types I, III, and V, sorne to fibrin, vitronectin, and laminin, and none to the other ECM 
proteins tested. An unencapsulated isogenic mutant bound to ECM proteins better than its parental 
encapsulated strain, suggesting that the polysaccharide capsule interfered with binding. Cross-
inhibition was observed between soluble plasma fibronectin and collagens in the ECM adherence 
assay, indicating that binding domains for both proteins exist on the same or nearby bacterial 
surface molecules. On the other hand, pre incubation with plasma fibronectin increased binding to 
collagen IV, suggesting that S. suis might use fibronectin as a bridging molecule. The results ofheat 
trea~ment and proteolytic digestion suggest that adhesins for these ECM proteins are proteinaceous 
in nature. 
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INTRODUCTION 
Streptococcus suis is a major swine pathogen that causes septicemia, meningitis, 
endocarditis, and arthritis (17). Of the 35 known serotypes, serotype 2 is most frequently isolated 
and associated with diseases (17). This pathogen is also a zoonotic agent that causes similar 
diseases in humans (2, 20, 35). 
Little is known about S. suis virulence factors. The capsule polysaccharide (CPS) is the 
only proven virulence factor since unencapsulated isogenic mutants are completely avirulent and 
are rapidly cleared from circulation in pig and mouse infection models (9, 33). Other putative 
virulence factors include a hemolysin (suilysin), a 136-kDa muramidase-released protein (MRP), a 
110-kDa extracellular factor (EF) protein, a hyaluronidase, a superoxide dismutase, various 
proteases, and bacteriocins (29). 
The extracellular matrix (ECM) is a stable macromolecular structure underlying epithelial 
and endothelial cells and surrounding connective tissue cells (41) that becomes exposed when tissue 
integrity is disturbed by les ions or traumas. The ECM is composed of glycoproteins and 
glycosaminoglycans (GAG). Its composition differs in various organs, but the main components are 
fibronectin, collagen, elastin, laminin and GAG, like heparin, and heparan sulfate (21). Many of 
these proteins can serve as potential cell receptors for bacteria and participate in the infectious 
process (13, 19, 24, 28, 41). In addition, bacterial binding to plasma proteins such as fibronectin 
and fibrinogen can prevent recognition of bacteria by the host immune system by masking 
immunogenic epitopes (12). 
Binding of virulent bacteria to host ce Ils is the first step in the colonization of mucosal 
surfaces. Binding may also be a first step in the invasion of host cells, a process that may lead to 
bacteremia and sepsis (36). The pathogenesis of infections caused by S. suis is not fully understood 
and many steps are probably involved (15). S. suis is able to bind to and, in sorne cases, invade 
endothelial and epithelial cells of human and porcine origin (4, 15, 22, 26, 39). However, the 
mechanisms involved in these interactions are unknown. 
While various streptococci specifically bind to host ECM and while these interactions play 
a role in disease pathogenesis, little is known about the ability of S. suis to bind to ECM proteins. 
Recently, a fibronectin-fibrinogen-binding (FBPS) protein has been proposed as a contributing 
factor in the colonization of organs due to its binding to ECM proteins of host cells (11). However, 
interactions between S. suis and various ECM proteins have never been studied. The purpose ofthis 
study was to evaluate the ability of S. suis serotype 2 field strains to specifically bind to various 
ECM proteins. 
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MATERIALS AND METHODS 
Bacterial strains and growth conditions 
S. suis serotype 2 strain S735 (ATCC 43765) was used as the reference strain. An 
unencapsulated mutant strain (B218) obtained in our laboratory by allelic exchange [22] and 
corresponding to a transposon-derived mutant described previously (14) and its virulent parental 
strain (31533) were also included. Strain B218 was shown to possess the same characteristics that 
mutant 2A, with a complete absence of capsular material at the bacterial surface. In selected 
experiments, 23 field strains of S. suis serotype 2 were used. These strains originated from different 
species (human or swine), different pathologies and different geographical origins. A complete list 
is presented in Table 1. Strains were grown as previously described (1). Late exponential-phase 
bacteria were washed three times in phosphate-buffered saline (PBS) (pH 7.3) and killed by 
suspending them in 0.2% (v/v) formaldehyde overnight at 4°C. 
Chemicals 
Commercially available human ECM proteins were used. Cellular fibronectin, collagen 
types III and V, laminin, plasma vitronectin, plasma fibrin, and fibrinogen were from Sigma· 
Chemical Co. (St. Louis, MO, USA); plasma fibronectin was from Roche Diagnostics Corporation 
(Indianapolis, IN, USA); collagen types 1 and IV were from BD Biosciences (Bedford, MA, USA); 
and elastin was from EMD Biosciences Inc. (La Jolla, CA, USA). Porcine fibrinogen was from 
Sigma, pro nase and proteinase K were from Roche, and trypsin was from Gibco (Burlington, ON, 
Canada). 
Microtiter plate binding assay 
Maxisorp® flat-bottom microtiter 96-well plates (Nunc, VWR, Mississauga, ON, Canada) 
were coated with 100 III (0 to 50 Ilg mr1, depending on the experiment) of ECM protein (plasma 
fibronectin; cellular fibronectin; collagen types l, III, IV, and V; laminin, elastin, vitronectin, fibrin, 
human fibrinogen; and porcine fibrinogen) in 0.1 M carbonate coating buffer (pH 9.6) and were 
incubated overnight at 4°C. The plates were washed three times with PBS containing 0.05% (v/v) 
Tween 20 (PB ST, pH 7.3), and 200 Il,! of 3% (w/v) non-fat dry milk in PBST was added to each 
weil to prevent non-specific bacterial binding. After 1 h at 3ic, the wells were washed three times 
with PBST. Formaldehyde-killed bacteriaJ suspensions (100 Ill) of individual strains were added 
and the plates were incubated for 2 h at 3ic. Different bacterial concentrations, incubation times, 
and temperatures were also tested. Ali unbound bacteria were subsequently removed by washing 
the wells three times with PBST. A 100 III volume S. suis serotype 2-specific rabbit antiserum 
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(diluted 1/3,000 in PB ST) prepared as previously described (16) was then added to each weil. The 
plates were incubated for 1 h at 3ic. The wells were washed three times with PBST and 100 ~I of 
horseradish peroxidase-Iabelled anti-rabbit IgG (Jackson Immunoresearch Laboratories Inc., West 
Grove, PA, USA) (diluted 1/8,000 in PB ST) was added. The plates were incubated for 1 h at 3ic 
with the secondary antibody. After washing three times with PB ST, 3,3',5,5'-tetramethylbenzidine 
(Zymed, San Francisco, CA, USA) was used as the enzyme substrate according to the 
manufacturer's instructions. The reactions were stopped by adding 25 J.lI of H2S04 (1 N) and were 
read at 450 nm using a microplate reader (Uvmax; Molecular Deviees, Menlo Park, CA, USA). 
Uncoated wells served as background controls. Casein-coated wells served as a control for non-
specific adhesion of S. suis to protein-coated wells. 
Proteolytic, formaldehyde, and heat treatments 
For the proteolytic treatment, 1 ml of live bacterial suspension (108 bacteria mt l ) was 
centrifuged and resuspended in the same volume of PBS containing one of following enzymes: 
trypsin, pronase, or proteinase K. All proteolytic enzymes were used at a concentration of 1 mg mt 
1. The suspensions were'ïncubated for 1 h at 3 i C for trypsin and proteinase K and 40 minutes for 
pronase. Controls with either an untreated suspension of live bacteria or 0.2% formaldehyde-treated 
bacteria were also incubated for 1 h at 3ic. The suspensions were then washed three times in PBS 
and resuspended in 1 ml of PBS for use in microtiter plate binding assay. The heat sensitivity of the 
components involved in the adhesion of bacteria to the ECM proteins was evaluated by heating 
bacterial suspensions for 30 min at 60°C or 100°C. 
Inhibition assays 
For the inhibition assays, bacterial suspensions were preincubated for 120 min with 150 J.lg 
mr l of various ECM proteins (plasma fibronectin, cellular fibronectin, collagen type I, collagen 
type III, or collagen type V) before being incubated with immobilized fibronectin, collagen, or 
fibrin. After the preincubation period, the suspensions were centrifuged to remove unbound prote in, 
the bacteria were added to the wells, and the ELISA was performed as described above. 
Statistical analysis 
ELISA tests were performed at least three times for each binding assay. Differences 
between strains (31533 vs. B218), different treatments (proteolytic, formaldehyde, and heat 
treatments), and fibronectin-mediated binding (pre-incubation wit11 fibronectin vs. pre-incubation 
with PBS) were analyzed for significance using general linear models followed by the Tukey-
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Kramer post-hoc test for differences between the various incubation temperatures (4°C, 20°C, and 
3iC). 
Strain Source Geographical Origin 
S735 Pig: meningitis Europe 
98-B575 Pig: endocarditis Canada 
99-1539B Pig: endocarditis Canada 
98-C462B Pig: endocarditis Canada 
98-8993 Pig: endocarditis Canada 
98-B099 Pig: meningitis Canada 
98-B719 Pig: meningitis Canada 
SS166 Pig: meningitis Europe 
0-282 Pig: meningitis Europe 
89-1591 Pig: meningitis Canada 
90-1330 Healthy pig Canada 
94-623 Healthy pig Europe 
24 Pig: septicemia Europe 
T15 Healthy pig Europe 
91-1804 Human: endocarditis Canada 
98-3634 Human: endocarditis Canada 
B iotype2/hemo Human: endocarditis Europe 
Reims Human: Europe 
spondylodiscitis 
94-3037 Human: meningitis Europe 
FRU95 Human: meningitis Europe 
LEF95 Human: meningitis Europe 
31533 Pig: meningitis Europe 
B218 Unencapsulated 
mutant derived 
from strain 31533 
Table 1. Characteristics of the Streptococcus suis strains used in this study 
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RESULTS 
Binding of S. suis serotype 2 reference strain S735 to ECM proteins 
As shown in Figure 1, strain S735 bound to both fibronectins (plasma and cellular) and to 
collagen types l, III, and V. This strain did not bind to the other proteins tested (data not shown). 
No binding was observed in the casein-coated control wells, indicating that ~.inding to the five 
ECM proteins was specifie. 
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Fig. 1. (A) Effect of 
ECM protein 
concentrations on S. 
suis serotype 2 strain 
S735 binding. Plates 
were coated with 
different ECM protein 
concentrations (open 
symbols), bacteria 
were added at 108 
bacteria mr\ and 
binding was evaluated 
after 2 h. (B) Plates 
were coated with fixed 
protein concentrations 
(10 Ilg/ml for plasma 
fibronectin, 25 Ilg/ml 
for cellular 
fibronectin, and 12.5 
Ilg/ml for collagen 
types l, III, and V) 
(open symbols) and 
different bacterial 
concentrations (from 
106 to 108 C.F.U mr1) 
were added. The plates 
were then incubated 
for 2 h. Casein (10 
Ilg/ml; closed 
symbols) was used as 
a negative control. 
Data are expressed as 
means ± standard 
deviations of at least 
three experiments 
performed in triplicate. 
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Binding of S. suis serotype 2 reference strain S735 as a function of protein and bacterial 
concentration, time, and temperature of incubatÎon 
Adherence positively correlated with bacterial and protein concentrations. The binding of 
strain S735 increased with increasing prote in concentration and reached a plateau at 10 Jlg mr l for 
plasma fibronectin, 25 I-lg mr l for cellular fibronectin, and 12.5 Jlgmr l for collagen types l, III, and 
V (Fig. lA). However, even with these proteins, no binding was detected with bacterial 
concentrations under 107 bacteria mrl (Fig. lB). 
Strain S735-binding to both fibronectins and collagen types r and V reached half-maximum 
between 30 and 60 min and maximum binding at 120 min, while binding to collagen type III reach 
half-maximum between 60 and 90 min and maximum at 120 min. (Fig. 2). Similar results were 
obtained with the non-encapsulated strain B218 (result not shown). 
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Fig. 2. Time course of S. suis serotype 2 strain S735-binding to different ECM proteins (open 
symbols). Wells were coated either with 10 Ilglm1 of plasma fibronectin, 25 Ilg/ml of cellular fibronectin, 
or 12.5 Ilg/ml of collagen types l, III, or V and incubated with bacteria (l08 C.F.U m!"I). Data are 
expressed as means ± standard deviations of at least three experiments perf!-lrmed in trip licate. Casein (10 
Ilg/ml; closed symbols) was used as a negative control. 
Strain S735-binding to both fibronectins and collagen types l, III, and V was also measured 
at different temperatures (4°C, 20°C, and 3iC). As shown in Figure 3, the optimum incubation 
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temperature was 3ic for ail five ECM proteins. In general, S735-binding to the collagens was 
significantly (p<O.OOOI) more temperature-dependent than for the two fibronectins. Similar results 
were obtained with the non-encapsulated strain B218 (result not shown). 
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Fig. 3. Effect of incubation temperature on S. suis serotype 2 strain S735-binding to different ECM 
proteins. Wells were coated with either 10 Ilg/ml of plasma fibronectin (pFn), 25 Ilglml of cellular 
fibronectin (cFn), or 12.5 Ilg/ml of collagen type 1 (Cn 1), type III (Cn III), or type V (Cn V) and were 
incubated with bacteria (108 C.F.U mr l ) at different temperatures for 2 h. [4°C (white bars), 20°C (grey 
bars), and 3ic (black bars)]. Data are expressed as means ± standard deviations from at least three 
experiments performed in triplicate. 
Binding capacity ofvarious S. suis serotype 2 field strains to immobilized ECM proteins 
Ali the strains tested (Table 2), bound to both fibronectins and collagen types I, III, and V. 
However, individual differences in the degree of binding of the various strains were observed (data 
not shown). Unlike strain S735, sorne field strains were able to bind to fibrin, and laminin. None of 
the strains bound to collagen type IV, elastin, human fibrinogen, or porcine fibrinogen. No 
correlation was noted between the ability of the various strains to bind to the ECM proteins and 
their source (diseased or healthy animais), the host from which they had been recovered (swine or 
human) (Table 2A), or their geographical origin (European or North American) (data not shown). 
The unencapsulated mutant strain B218 bound significantly (p<O.OOOI) more to both 
fibronectins, collagen type III, and collagen type V than the parental strain 31533. In addition, 
unlike 31533, B218 bound to vitronectin and laminin (Table 2B). 
) 
103 
Diseased Healthy 
Humans 31533 B218 
Pigs Pigs 
pFn 12/12 3/3 7/7 2.48±0.21 * 3.16±0.07* 
cFn 12/12 3/3 7/7 2.06±0.09* 2.34±0.12* 
CnI 12/12 3/3 7/7 1.83±0.10 1.81± 0.07 
Cn III 12/12 3/3 7/7 2.34±0.12* 3.79±O.l9* 
CnIV 0112 0/3 0/7 0.07±0.04 0.25±0.02 
CnV 12112 3/3 7/7 1. 72±O.l8* 3.89±0.07* 
Fibrin 5112 2/3 1/7 0.15±0.05 0.29±0.01 
pFg 0/12 0/3 0/7 0.14±0.01 0.32±0.01 
hFg 0/12 0/3 0/7 0.12±0.03 0.32±0.04 
Lam 3/12 1/3 1/7 0.07±0.01 * 1.32±0.19* 
Vitro 0112 0/3 0/7 0.10±0.01 * 0.58±0.01 * 
Elast 0/12 0/3 0/7 0.13±0.06 0.28±0.03 
Casein 0/12 0/3 0/7 0.19±0.02 0.25±0.09 
Table 2. Adherence to ECM proteins of different S. suis serotype 2 field strains according to species 
of isolation or presence of disease (A). Effect of the capsule on adhesion between S. suis serotype 2 
and ECM proteins (8) 
B218: unencapsulated mutant derived from S. suis serotype 2 strain 31533. pFn, plasma fibronectin; cFn, 
cellular fibronectin; Cn l, collagen type 1; Cn Ill, collagen type III; Cn IV, collagen type IV; Cn V, collagen 
type V; pFg, porcine fibrinogen; hFg, human fibrinogen; Lam, laminin; Vitro, vitronectin; Elast, elastin. 
Casein was used as negative control. Table 2B data are represented as means (O.D.4S0) ± standard 
deviations. *Generallinear model, (p<O.OOO 1). 
Proteolytic, formaldebyde, and beat treatments 
Strain S735-binding to ECM proteins was affected by both proteolytic and heat treatments, 
decreasing by almost 90% of adhesion for ail five ECM proteins tested (plasma and cellular 
fibronectin, and collagen types l, 111 and V). The 0.2% formaldehyde treatment did not affect 
binding to ECM proteins (p<O.OOOI) (results not shown). Similar results were obtained with the 
non-encapsulated strain B2IS as well as with three different field strains randomly tested (results 
not shown). 
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Inhibition assays 
Plasma fibronectin and collagen types I, III, and V, but not cellular fibronectin (even at 
high concentrations), competed with the homologous protein used in the ELISA as say, confirming 
the specificity of the binding (data not shown). Collagen at a concentration of 150 !-tg mr1 inhi~ited 
binding not only to the homologous collagen but also to thé two other collagens (data not shown). 
Preincubation of the bacteria with 150 ilg mr1 of plasma fibronectin significantly (p<O.OOOl) 
reduced binding to immobilized cellular fibronectin and collagen types l, III, and V (Fig 4). Since 
fibronectin is a multifunctional prote in that also carries recruitment domains for host factors such as 
collagen and fibrin, strain S735-binding to collagen type IV and fibrin after preincubation with 
plasma fibronectin was evaluated. The addition of soluble plasma .fibronectin promoted binding of 
this strain to collagen type IV (p<O.OOOl) (Fig. 4) but not to fibrin (data not shown). 
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pFn cFn en 1 en III en V en IV 
Fig. 4. Effect of pre-incubating bacteria for 90 min with 150 lJ.g/ml of soluble plasma fibronectin on 
S. suis serotype 2 strain S735-binding to plasma fibronectin (pFn), cellular fibronectin (cFn), 
collagen type 1 (Cn 1), collagen type III (Cn III), collagen type V (Cn V), and collagen type IV (Cn 
IV). Data represent the binding of S. suis preincubated with plasma fibronectin (white bars) or PBS (black 
bars). Bars represent means ± standard deviations of at least three experiments performed in triplicate. 
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DISCUSSION 
Many adhesins have been described for S. suis serotype 2 in the last decade, including an 
18-kDa galactosyl-alpha 1-4 galactose binding adhesin, which is present on different S. suis 
serotypes; a 60-kDa IgG-binding protein, which reacts with a large number of IgGs; and a 39-kDa 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which binds to various host proteins, 
including plasminogen and albumin (18, 27, 32, 38). GAPDH is known to be involved in the 
binding of S. suis to host tissues because mutants defective in the surface expression of this protein 
bind to a lesser degree to tracheal cens and porcine tracheal rings (6, 7). Lastly, a 64-kDa 
fibronectin-fibrinogen-binding prote in (FBPS) with a high binding capacity for fibronectin and 
fibrinogen has recently been described (11). While the jbps gene is present in most S suis serotypes 
and pathotypes and while FBPS has been cloned and its' binding activity verified (11), the 
expression of FBPS in the different serotypes and phenotypes was not studied, and no direct studies 
of who le S. suis bacteria or constructed jbps knockout mutant binding to fibronectinlfibrinogen 
have been carried out. The role of FBPS in bacterial pathogenesis is not weil understood. However, 
studies with the jbps mutant suggest that this prote in plays a role in S. suis colonization of various 
organs (11). We report here for the first time that whole S. suis cens are able to bind to fibronectin, 
confirming published data using purified proteins (11, 32). However, we could not confirm that S. 
suis binds to fibrinogen, probably because we used whole bacteria rather than purified protein. 
Fibronectin exists in two main forms. Cellular fibronectin,which is an insoluble 
glycoprotein dimer that serves as a linker in the ECM, is produced by fibroblasts, chondrocytes, 
endothelial cens, macrophages, and certain epithelial cells. Plasma fibronectin, which is a soluble 
disulfide-linked dimer, is produced by hepatocytes and released in an unbound form into the 
plasma. Our study shows that all the S. suis serotype 2 strains tested are able to bind to both plasma 
and cellular fibronectin. In addition, S. suis serotype 2 binds to immobilized cellular fibronectin but 
not to soluble cellular fibronectin. Similar results have been obtained with Group B streptococci 
(GBS) and plasma fibronectin. In fact, GBS are able to bind to immobilized but not soluble plasma 
fibronectin (36). These results might be due to structural changes resulting in the exposure of 
determinarits required for bacterial binding when fibronectin is attached to a so\id surface. On the 
other hand, S. suis binds to both immobilized and soluble plasma fibronectin, probably due to the 
soluble disulphide-linked dimer conformation of plasma fibronectin, which allows a monomer 
conformation that exposes the determinants required for S. suis binding. Fibronectin appears to be 
one of the components mediating binding to and, in sorne cases, invasion of various host cell types 
by streptococci and staphylococci (3, 34, 40), but its role in S. suis binding to and/or invasion of 
epithelial, endothelial, and phagocytic cells (4,9,22,30,31,39) remains to be elucidated. 
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Collagen is a major constituent of the ECM and, as such, may be a major target for 
pathogenic bacteria. Collagen is found in basement membranes (type IV), bone, skin, cartilage, 
tendons, and joints (12). This study demonstrated that S. suis serotype 2 is able to directly bind to 
collagen types l, III, and V, but not to type IV, probably due to structural differences (8) that might 
hide receptors required for S. suis binding. Interestingly, white S. suis is not able to bind directly to 
collagen type IV, it has the potential to adhere to this protein via a surface-bound fibronectin 
mechanism. Fibronectin-mediated collagen recruitment might represent a novel mechanism of 
colonization and immune evasion for Streptococcus pyogenes (12). 
S. suis serotype 2 binds to both fibronectin and collagen in a bacterial and protein 
concentration-dependent manner. No binding was detected at bacterial concentrations under 107 
bacteria mr l . Interestingly, it has been previously demonstrated in vivo that the presence of clinical 
signs and symptoms in diseased animais infected with S. suis correlates with high levels of bacteria 
in the bloodstream (5) .. 
Cross-inhibition was observed with soluble fibronectin and collagen in the ECMbinding 
assay, indicating that fibronectin and collagen binding domains exist on the same or nearby 
bacterial surface adhesins. Similar results were obtained with GBS by Tamura and Rubens (37). 
The bacterial Iigand(s) that allows binding to ECM proteins cou Id be either a protein (10) 
or a cel! wall component (25). The dramatic reduction in binding by trypsin-, pronase-, and 
proteinase K-treated bacteria indicates, in the case of S. suis, a protein-mediated binding 
mechanism. This conclusion is supported by the fact that heat treatments (60°C and 100°C) also 
decreased binding to ECM proteins. 
Most of the S. suis serotype 2 field strains tested behaved in a fashion similar to that of the 
reference strain. However, sorne were also able to bind to laminin, vitronectin, and fibrin, 
suggesting that they,possessed other adhesins. On the other hand, interference by the CPS of sorne 
strains cannot be ruled out. In fact, our study showed that unencapsulated mutant B218 not only 
bound better to both fibronectins and collagen types III and type V than the encapsulated parental 
strain 31533, but it also bound to vitronectin and laminin, unlike strain 31533. In addition, 
Tikkanen et al. (1996) (38) reported an inverse relationship between the binding activity of the 
galactosyl-alpha 1-4 galactose binding adhesin and the expression of capsular polysaccharide. It has 
already been reported that CPS also influences the binding of S. pyogenes, Staphylococcus aureus 
(40), and Lactobaci/lus acidophilus (23) to sorne ECM proteins. 
In summary, this study shows that S. suis serotype 2 is able to specifically bind to major 
constituents of ECM such as fibronectin and collagens, and that the adhesin(s) responsible for these 
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interactions are proteinaceous in nature. The identification of the S. suis surface proteines) 
responsible for this binding phenotype and the creation of isogenic knock-outrnutants of the 
associated gene(s) rnay give sorne insights about the role of the se adhesins in the pathogenesis of 
the infection caused by S. suis. These efforts are ongoing in our laboratory. 
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SUMMARY 
Streptococcus suis is an important swme and human pathogen that causes meningitis, 
endocarditis, arthritis and septicaemia. As a zoonotic agent, S. suis also causes similar diseases in 
humans. Binding of pathogenic bacteria to extracellular matrix components enhances their adhesion 
to and invasion of host cells. In the present study we isolated and identified a novel fibronectin-
binding prote in from S. suis. The native protein (designated SsEno) possessed not only high 
homology with other bacterial enolases but also enolase activity. We cloned, expressed and purified 
the SsEno and showed that it is ubiquitously expressed by ail S. suis serotypes and we identified its 
surface localisation using immunoelectron microscopy. ELISA assay demonstrated that SsEno 
specifically binds to fibronectin and plasminogen in a Iysine-dependent manner. Additional Surface 
Plasmon Resonance assays demonstrated that SsEno binds to fibronectin or plasminogen with low 
nanomolar affinity. Inhibition experiments with anti-SsEno antibodies also showed that bacterial 
SsEno is important for the adhesion to and invasion of brain microvascular endothelial cells by S. 
suis. Ove raIl, the present work is the first study to demonstrate a fibronectin-binding activity of a 
bacterial enolase and that, similar to other bacterial fibronectin-binding proteins, SsEno may 
contribute to the virulence of S. suis. 
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INTRODUCTION 
. Streptococcus suis is a major swine pathogen that causes septicaemia, meningitis, endocarditis, 
and arthritis (19). Of the 35 known serotypes, serotype 2 is most frequently isolated and associated 
with disease (19).lt has been proposed that two serotypes (serotypes 32 and 34) be excluded from 
S. suis species and re-designated as Streptococcus orisratti (20). S. suis, especially serotype 2, has 
also been described as an important zoonotic agent that affects people in close contact with infected 
. pigs or pork-derived products (37). Indeed, an important number of cases of human disease with a 
high rate of mortality in China were directly linked to a concurrent outbreak of S. suis infection in 
pigs (71). 
Little is known about S. suis virulence factors. The capsule polysaccharide (CPS) is a 
critical virulence factor given that unencapsulated isogenic mutants are completely avirulent and 
rapidly cleared from the circulation in pig and mouse infection models (13, 58). However, non-
virulent strains are also encapsulated, indicating that virulence of this pathogen is a multifactorial 
process (18). Other potential virulence factor have also been described in S. suis, including a 
haemolysin (suilysin), a 136-kOa muramidase-released prote in (MRP), a 110-kOa extracellular 
factor (EF) prote in, a hyaluronidase, a superoxide dismutase, various proteases, a serum opacity 
factor and different adhesins (3, 55). 
The pathogenesis of S. suis infection is not fully understood and likely involves many steps 
(18). The binding between bacterial adhesins and host proteins is an essential step in the 
colonization of mucosal surfaces and it has also been implicated in bacterial invasion of host cells 
(60). Indeed, S. suis is able to bind to and, in sorne cases, invade endothelial and epithelial ce Ils of 
human and porcine origin (4, 18, 33, 45, 66). However, the specific mechanisms involved in these 
interactions are unknown. 
SOIpe pathogens use ho st extracellular matrix proteins to potentiate their virulence. The 
extracellular matrix (ECM) is a stable macromolecular structure underlying epithelial and 
endothelial cells and surrounding connective tissue ce Ils (69). Its composition varies among 
different organs, but the main components are fibronectin, collagen, elastin, laminin and 
glycosaminoglycans (32). Many of these proteins can potentially serve as surface receptors for 
bacterial binding to host cells via their adhesins (25, 54, 69). S. suis is able to adhere to fibronectin 
and different types of collagens (17). In fact, a 64-kOa fibronectin-and fibrinogen-binding prote in 
(FBPS) with binding capacity for these two host proteins has been described for S. suis (14). The 
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role of FBPS in bacterial pathogenesis is not weil understood. However, studies with the jbps 
mutant suggest that this protein cou Id play a role in S. suis colonization ofvarious organs (14). 
Another S. suis adhesin that is able to bind to different host proteins such as plasminogen 
and albumin is the 39-kDa glyceraldehyde-3-phosphàte dehydrogenase (GAPDH) (23, 51). 
Evidence that this protein is involved in the binding of S. suis to host tissues is provided by findings 
that mutants deficient in the surface expression of GAPDH have decreased binding to tracheal ce Ils 
and porcine tracheal rings (9, 10). GAPDH is also a cytosolic erizyme that participates in the 
degradation of carbohydrates via glycolysis and other catabolic pathways as weil as in glucose 
synthesis via gluconeogenesis. Another enzyme essential for glycolysis and gluconeogenesis is 
enolase (39). This cytosolic enzyme catalyses the conversion of 2-phosphoglycerate (2-PG) into 
phosphoenolpyruvate (PEP) via the elimination of a water molecule (70). Enolase has also been 
identified as a novel plasminogen receptor on the surface of many eukaryotic cells (40, 43). This 
unexpected feature has also been described in several bacteria (such as Staphylococcus aureus and 
many streptococci), fungi and nematodes (5, 26, 27, 41, 48, 57). While the role of plasminogen as 
an important component in streptoccoci adhesion is weIl established (49), the role of enolase in 
bacterial adherence and host cell invasion has not been previously investigated. 
In addition to identifying and inducing the expression of S. suis a-enolase (SsEno), we now 
demonstrate for the first time that this protein not only has plasminogen-binding activity but also 
has important fibronectin-binding properties. Finally, we also demonstrate that surface SsEno, 
which is present in aIl the described serotypes of S. suis, may play an important role in the adhesion 
and invasion process of host endothelial cells. 
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METHODS 
Bacterial strains and growth conditions 
Reference strains from the 35 different S. suis serotypes came from our collection. Highly 
virulent strain 166' of S. suis serotype 2 (8) was kindly provided by Dr. M. Kobisch, AFSSA, 
Ploufragan, France. S. suis strains were grown in Todd Hewitt broth (THB) (BD, Sparks, MD) as 
previously described (l). Late exponential-phase bacteria were washed in phosphate-buffered saline 
(PBS) (pH 7.3). Escherichia colistrain BL210E3 was used for expression experiments. E. coli was 
grown in Luria-Bertani broth or agar plates. Ampicillin (100 /lg mr') (Roche, Indianapolis, IN) was 
used in growth media when required. 
Isolation of 52-kDa protein by fibronectin-affinity chromatography 
Strain 166' was harvested from THB by centrifugation at 5500 x g for 15 min, washed 
twiee in phosphate buffered saline (PBS, 0.01 M, pH 7.4), and re-suspended in HEPES 10 mM, pH 
7.4. Bacteria were disrupted by sonicating the bacterial suspension with an ultrasonic probe on ice 
for 30 minutes with 15-second intervals of cooling on ice at 80% duty cycle (Sonics & Materials, 
New Town, Connecticut, USA). Cell debris and non-Iysed bacteria were removed by centrifugation. 
Supematant proteins were concentrated to a volume of <1:0 ml using Amieon Ultra-15 
concentrators (Millipore, Carringtwohill, Cork, Ireland) and applied to a 5 ml fibronectin-coupled 
CNBr-activated Sepharose 4B column (Amersham Biosciences AB, Uppsala, Sweden) pre-
equilibrated with 0.1 M Tris/HCl buffer, pH 8.0. After washing with 5-column volumes of this 
buffer, bound proteins were eluted with 30 ml of 8 M urea. Starting Iysates and fractionated samples 
were analyzed by SOS-PAGE (12.5% polyacrylamide) under reducing conditions, followèd by 
Coomassie Blue staining. Protein concentrations were determined by the Lowry method (36). 
Samples were maintained at -70°C until analysis. 
N-terminal sequencing was carried out with chromatographie fractions containing 
fibronectin-binding proteins after being electroblotted onto polyvinylidene difluoride (PVOF) 
membranes (lmmobilon-P; Millipore) and visualised by staining with 0.1 % Ponceau S (Sigma-
Aldrieh, St. Louis, Mo) in 1 % acetic acid. Bands of interest were excised, destained with distilled 
water, and subjected to peptide sequencing at the Biotechnology Research Institute (Montreal, 
Canada). 
Cloning, expression and purification of recombinant SsEno (rSsEno) 
The peptide sequence identified by N-terminal sequencing of the predominant fibronectin-
binding protein was subjected to a homology search using the BLAST program againstthe strain P 
1/7 genome sequence of S. suis (http://www.sanger.ac.uk/Projects/S_suis/). Oatabase search 
revealed 100% homology to the N-terminal region of a 1308 bp open reading frame (ORF) that 
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corresponds to the S. suis enolase (SsEno). The sequence was used to design primers for PCR 
amplification of the SsEno gene. The primers used were the Eno1-forward primer 5'-
TA TAAGGATCCTTGTCAA TT A TTACTGA TGTTT ACGC-3', introducing a BamHI site 
(boldface and underline letters) and the En02-reverse primer 5'-
TATAAAGCTTTTATTTTTTCAAGTTGTAGAATGAGTTCAAGCC-3', introducing a HindIII 
site (boldface and underline letters). Automated sequencing was then used to check the amplified 
enolase gene. The verified complete gene was cloned into pET-32a (Novagen, Madison, WT,) using 
the created BamHI and HindIII sites. This plasmid contains a His-tag-encoding sequence of about 
25 kDa. The plasmid pET -32a-SsEno was introduced into E. coli BI210E3 for IPTG-inducible 
expression of recombinant SsEno. Under native conditions, the His-tagged fusion protein was 
purified by HisTrap chromatography according to the manufacturer's protocols (Amersham 
Biosciences). Protein-containing fractions were determined by SOS-PAGE (12.5%) followed by 
Coomasie blue staining. Purified rSsEno was used to produce polyclonal antibodies to SsEno in 
rabbits as previously described (34). To prepare affinity purified anti-SsEno TgG, the polyclonal 
serum was subjected to purification on protein-A Sepharose CL-4B (Amersham Pharmacia) (48). 
Enolase Activity 
a-Enolase activity was determined by measuring the transformation ofNAOH'W to NAO+ 
as described previously (48) with sorne modifications. Briefly, the enzymatic reactions were 
performed at 37°C in 100 mM HEPES buffer, pH 7.0, containing 5.0 mM MgS04, 0.2 mM NAOH 
(Roche), 0.25 mM 2-phosphoglycerate (2-PGE) (Sigma), 1.2 mM AOP (Roche), 10.7 lU lactate 
dehydrogenase (Roche) and 2.5 TU pyruvate kinase (Roche) in a final volume of 1 ml. The reaction 
was started by adding 100 III of the test solution containing rSsEno (from 0 to 20 ~g). The a-
enolase activity was measured in terms of the rate of reduction in the absorbance at 340 nm (i.e. 
increase in the production ofNAO from NAOH-W). Rabbit muscle Enolase (Sigma) was used as a 
positive control and buffer without enolase was used as a negative control. 
Localisation of SsEno in S. suis 
To evaluate the presence of SsEno in different bacterial compartments, S. suis strain 166' 
was grown overnight at 37°C with agitation in 30 ml of THB. The subcellular components 
(supernatant, cell wall, cytoplasmic and membrane fractions) were fractionated with mutanolysin by 
using the method of Yother and White (72). Equivalent amounts of ail fractions were analysed by 
SOS-PAGE (12.5 % polyacrylamide) and Western blot using optimally diluted rabbit anti-SsEno 
IgG. 
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The surface exposure of SsEno was examined by using immunelectron microscopy. Brietly, 
S. suis 166' was grown in 5 ml of THB untillate exponential phase, centrifuged, and resuspended in 
PBS (pH 8.0). A 20 )..LI, aliquot of the bacterial suspension was placed on nickel-Formvar grids 
(INRS, Institut Armand Frappier, Laval, Canada) and allowed to partially air dry. After bloc king for 
30 min with 10% normal donkey serum in dilution buffer (PBS-I % bovine serum albumin-I % 
Tween 20, pH 8.0), the grids were incubated with optimally diluted rabbit anti-SsEno IgG for 2 h at 
room temperature. The grids were washed three times with PBS, pH 8.0, 1 % Tween 20 and 
incubated for 1 h at room temperature with 12-nm colloidal gold-Affinipure donkey anti-rabbit IgG 
(Jackson ImmunoResearch Laboratories, West Grove, PA). After several washes with PBS-I % 
Tween 20, bacteria were stained with 1 % phosphotungstic acid and examined with an electron 
microscope (Philips 201) at an accelerating voltage of 60 kV. Bacteria coated with normal rabbit 
antibodies served as a negative control. 
rSsEno Binding Assays for Plasminogen and Fibronectin 
Purified rSsEno binding to immobilized fibronectin (Roche) and plasminogen (Sigma) was first 
determined by ELISA. Maxisorp® flat-bottom microtiter 96-well plates (Nunc, VWR, Mississauga, 
ON, Canada) were coated with 100)l1 of seriai dilutions of fibronectin or plasminogen, depending 
on the experiment, in 0.1 M carbonate coating buffer (0.15% [wtlvol] Na2C03, 0.1% [wtlvol] 
MgCh - 6H20, 0.3% [wtJvol] NaHC03 [pH 9.6]) and incubated ovemight at 4°C. Casein-coated 
wells served as a control for non-specific adhesion of rSsEno. The plates were washed three times 
with PBS containing 0.05% (v/v) Tween 20 (PBST, pH 7.3), and 200 )lI of 3% (w/v) non-fat dry 
milk in PBST was added to each weil to prevent non-specific binding. After 1 h at 37°C, the wells 
were washed three times with PBST. Next, 100 )lI of 5 )lg mr1 of rSsEno was added and the plates 
were incubated for 2 h at 37°C. After several washes with PBST, optimally diluted rabbit anti-
SsEno IgG were added to each weil and the plates were incubated for Ih at 37°C. The wells were 
washed three times with PBST and specific horseradish peroxidase-Iabelled IgG (Jackson 
Immunoresearch Laboratories) was added. Plates were then incubated for 1 h at 37°C with the 
secondary antibody and 3,3',5,5'-tetramethylbenzidine (Zymed, San Francisco, CA, USA) was used 
as the enzyme substrate according to the manufacturer's instructions. The reactions were stopped by 
adding 25 )lI of H2S04 (1 N) and were read at 450 nm using a microplate reader (Uvmax; Molecular 
Devic,es, Menlo Park, CA, USA). 
Binding interactions between rSsEno (75 kDa) and fibronectin (440 kDa) or plasminogen 
(92 kDa) were also analyzed in real-time using Biacore 2000/3000 instrumentation (BiacoreAB, 
Uppsala, Sweden). Surface Plasmon Resonance (SPR) assays were performed on research-grade 
CM4 sensor chips at 25°C using filtered (0.2 )lm) and degassed HBS-EP running buffer (lOmM 
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HEPES pH 7.4, 150 mM NaCI, 3 mM EOTA, 0.005% (v/v) Tween 20). Prior to ail experiments, the 
purity of protein preparations (>95%) was assessed by SOS-PAGE (12.5% polyacrylamide) under 
non-reducing and reducing (5% (v/v) 2-mercaptoethanol) conditions, followed by Coomassie Blue 
and silver staining. Prote in concentrations were determined using the Lowry method (36). The 
zwitterionic detergent Empigen was from Calbiochem; ail other chemicals were of reagent-grade 
quality. 
Fibronectin or plasminogen (10 flg mr' in 10 mM sodium acetate pH 4.5) was immobilized 
to sensor chip surfaces using the Amine Coupling Kit (BiacoreAB) according to the manufacturer's 
recommendations. Similarly, corresponding reference surfaces were prepared in the absence of 
ligand addition. rSsEno (0 -250 nM diluted in HBS-EP) was injected in-tandem over reference (no 
ligand) and active (290 relative units (RU) fibronectin or 140 RU plasminogen-immobilized) 
surfaces at 25 J..lL min-' (600 sec association + 600 sec dissociation). Surfaces were regenerated at 
50 J..lL min-' using two 30-second pulses of solution 1 (HBS-EP containing 1 M NaCI, 5 mM NaOH, 
and 0.03% (v/v) Empigen) and solution II (HBS-EP), followed by EXTRACLEAN and RINSE 
procedures. Additional assay controls to test for binding specificity (BSA negative control), surface 
performance (consistent replicate injections), and lack of mass transport were performed as 
recommended by the manufacturer. 
Ali binding data were doubled-referenced (42) and representative of triplicate injections 
acquired from three independent trials. Due to the slow off-rates observed (Jess than 10% 
dissociation over 10 minutes), it was not possible to evaluate the data using standard kinetic (ka, kd) 
analysis in the BIAevaluation 4.1 software (BiacoreAB). A lternatively, steady-state binding 
responses were averaged (540-580 sec plateau) and then analyzed globally as a function of rSsEno 
concentration. For non-linear regression analysis (Req vs. C), overall affinity constants were derived 
by fitting the data to a steady-state binding model: Req = (Rmar: • C) / (KD + C) where Reg is the 
binding response at equilibrium, Rmar: is the maximal specific binding to the ligand surface, C is the 
concentration of analyte in solution, and KD is the equilibrium dissociation constant. For linear 
regression analysis, KD values were derived as the negative inverse of the slope generated by 
Scatchard transformations (Re/C vs. Reg). 
Lysine-dependent rSsEno binding to fibronectin and plasminogen 
To address the importance of lysine residues in the binding of rSsEno with fibronectin, 
competition binding assays were performed using the lysine analog E-amino-n-caproic acid 
(EACA). Briefly, fibronectin and the positive control plasminogen (10 and 1 J.:lg mr l respectively) 
were incubated overnight at 4°C in Maxisorp® flat-bottom microtiter 96-well plates and an ELISA 
was performed as described above using 20 J..lg mr' of rSsEno mixed with different concentrations 
119 
ofEACA (1, 5, 10 and 50 mM, Sigma) and rabbit anti-SsEno IgG as a primary antibody. Binding of 
SsEno to fibronectin and plasminogen in the absence ofEACA competitor was considered as 100%. 
Role of SsEno in adhesion and invasion of S. suis to PBMEC 
The porcine brain microvascular endothelial cell (PBMEC) line PBMEC/CI-2 (62), already 
tested with S. suis in our laboratory (66) was used. The adhesion assay to quantify total cell-
associated (intracellular plus surface-adhered) bacteria was performed as previously described (44, 
66), with sorne modifications. Briefly, S. suis strain 166' (107 CFU m!"') was incubated with eq4al 
concentrations of either normal rabbit IgG or purifed rabbit anti-SsEno IgG for 1 h at 37°C in fresh 
cell culture medium without antibiotics. Confluent cell monolayers were inoculated with 1 ml 
aliquots of either bacterial suspension. The plates were centrifuged at 800 x g for 10 minutes and 
incubated for 2 h at 37°C with 5% CO2• The monolayers were th en vigorously washed 5 times to 
eliminate non-specific bacterial attachment, incubated for 10 min at 37°C in the presence of 200 ~I 
of 0.05% trypsin-0.03% EDT A, and disrupted by scraping the bottom of the weil and by repeated 
pipetting to liberate cell-associated bacteria in the presence of ice-cold deionized water. Seriai 
dilutions of this cell Iysate were plated onto THB agar and incubated ovemight at 37°C, after which 
the bacteria were counted. The invasion assay to quantify intracellular bacteria was performed in a 
similar manner. However, to kill extracellular and surface-adhered bacteria after the initial infection 
period, cells were washed twice with PBS, and 1 ml of ce Il culture medium containing 1 00 ~g mr' 
of gentamicin and 5 ~g mr' of penicillin G (Sigma) was added to each weil. After incubation for 1 
h at 37°C with 5% CO2, monolayers were washed 3 times with PBS and processed as described 
above. Results obtained with bacteria incubated with normal rab bit IgG were considered as 100% of 
adhesion or invasion. 
Statistical analysis 
Ali experiments were performed at least three times with samples in triplicate. Ail 
numerical data presented here are expressed as means ± standard deviation.Statistical significance 
was determined using Student's t test. Differences were considered significant at P :s 0.05 (*). 
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RESULTS 
Identification of a major S. suis fibronectin-binding protein of 52-kDa as an a-enolase 
Loading of S. suis lysates onto a fibronectin-affinity colurnn resulted in the specific 
retention and elution of a predominant native 52-kDa protein along with very few faint bands of 
addition al proteins (Fig. 1). N-terminal amino acid sequencing of the 52 kDa protein revealed the 
following 14 residues: MIITDVY AREVLDS. Comparison of this 14-amino acid N-terminal 
sequence with the genomic sequence database of S. suis (http://www.sanger.ac.ukIProjects/S_suisl) 
revealed 100% homology to the N-termÏnal region of a 1308 bp ORF, which encodes a putative 
435-amino acid protein with a deduced molecular weight of 47.09 kDa. A protein BLAST search 
with the putative protein sequence in the NCBI sequence database 
(http://www.ncbi.nlm.nih.govIBLASTD revealed significant homology to bacterial a-enolases, a 
family of proteins involved in carbohydrate transport and metabolism. The identity between the 
putative S. suis protein and the a-enolase from the closely related streptococci is more than 93% 
(data not shown). These results indicated that this S. suis 52 kDa protein is most likely an a-enolase 
(SsEno). Sequence analysis showed that the SsEno contains neither a signal peptide nor an LPXTG 
motif. This protein also does not contain choline-binding repeats. Immunoblot analysis confirmed 
the cross-reactivity of SsEno with polyclonal antibodies against Streptococcus pyogenes enolase 
(SEN) (data not shown). 
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Fig. 1. Isolation of a 52-kDa 
protein by fibronectin-affinity 
chromatography. S. suis Iysate was 
applied to a fibronectin coupled 
CNBr-activated Sepharose 4B 
column pre-equilibrated with 0.1 M 
TrislHCl buffer, pH 8.0. After 
washing, bound protein was eluted 
with 30 ml of 8 M urea elution 
buffer. Elution profiles were 
analyzed by SDS-PAGE (12,5 % 
polyacrylamide) with Coomassie 
Blue staining. Lane 1: Molecular 
markers, lane 2: S. suis total 
proteins, lane 3: S. suis Fibronectin-
binding proteins. Large arrow 
: 52 kDa enolase; small arrows: 
other fibronectin-binding proteins. 
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rSsEno has enolase activity 
rSsEno was successfully cloned and expressed as a His-tagged fusion protein of -75 kDa in 
E. coli. The higher molecular weight of the c10ned protein compared to the native protein (52 kDa) 
is due to the N-tenninal sequence of about 25 kDa containing the His-tag added by the plasmid. The 
recombinant protein was purified to homogeneity (>95%) using HisTrap affinity chromatography 
(Fig. 2) and it presents identical cross-reactivity to the native protein as shown by immunoblot with 
antibodies against SEN (results not shown). 
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Fig. 2. Expression and purification of recombinant SsEno. SsEno gene was cloned into pET-32a which 
was introduced into E. coli BI2l DE3 for an IPTG-inducible expression of rSsEno (recombinant S. suis 
enolase). The His-tagged fusion protein was purified by chromatography on HisTrap column according to 
the manufacturer's protocols. Lane 1 represents molecular weight markers, lane 2: non induced E. coli, 
Jane 3: induced E. coli, Jane 4: French press control, Jane 5: His-trap non adhered proteins, lane 6: His-
Trap purified SsEno. 
To confirm that the fibronectin-binding protein candidate is an a-enolase, its activity was 
assayed in a coupled enzyme assay for enolase. Similarly to the positive control used, we 
demonstrated that the recombinant protein was able to convert NADH to NAD resulting in a change 
in absorbance at 340 nm (Fig. 3). This indicated that pyruvate was converted to lactate and NADH 
by lactate dehydrogenase, confirming the conversion of phosphoglycerate to phosphoenolpyruvate 
by a-enolase and finally to pyruvate in the presence of extemally provided pyruvate kinase and 
ADP in a sequential manner. 
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Fig. 3. Enolase activity assay for recombinant SsEno. Alpha-Enolase activity of the purified rSsEno 
was measured usin·g a coupled enzyme assay catalyzing 2- phosphoglycerate to phosphoenolpyruvate as 
described under "Experimental Procedures" (a) Enzyme kinetics of the purified rSsEno was determined, 
using 1 Ilg of the purified rSsEno ("') or 1 Ilg of muscle rabbit enolase as positive control (.) as the 
enzyme source. As negative control, enolase was omited (+). Alpha-enolase activity of SsEno was also 
measured as described in A. (b) complementary assay in which different SsEno concentrations were used 
as enzyme source and the enzyme activity in the reaction mixture was measured at the end of 1 min 
incubation. Data represent results of one individual experiment. The enolase assay was done at least in 
trip licate. 
SsEno bas fibronectin- and plasminogen-binding activities 
Prior to ail ELISA and· SPR analyses, the purity (>95%) of commercially-available 
fibronectin and plasminogen (data not shown) and rSsEno preparations was detennined by scanning 
densitometry of the prote in on an SDS-PAGE gel stained with Coomassie blue (data not shown) 
and with a silver-stained SDS-PAGE gel (Fig. 4a). Qualitatively, ELISA assays provided the initial 
demonstration that rSsEno specifically interacts with immobilized fibronectin and plasminogen 
(positive control) in a saturable, dose-dependent manner (Fig. 4b-c). Under similar assay conditions, 
rSsEno failed to interact with immobilized casein as a negative control (Fig. 4d). Competition 
experiments with the lysine analogue EACA showed lysine-dependent interactions between rSsEno 
and fibronectin or plasminogen (Fig. Sc). Notably, the inhibition of rSsEno binding by EACA was 
more pronounced with plasminogen as compared to fibronectin. 
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Fig. 4. Qualitative binding of SsEno to fibronectin and plasminogen. Silver nitrate staining (a) of SsEno 
used for ELISA and SPR tests. Representative ELISA analysis for the binding of SsEno (5 J.l.g mrl) ta 
immobilized plasminogen (b), fibronectin (c) and casein (d, negative control). Binding was evaluated after 2 
h. Data are expressed as means ± standard deviation of at least three experiments with samples in triplicate. 
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Fig. 5. Lysine-dependent binding of SsEno to fibronectin and plasminogen. Different EACA 
concentrations were used to evaluate the role of the lysines residues in the binding of SsEno to plasminogen 
(black bars) and fibronectin (grey bars) by ELISA as described in "Experimental procedures". An asterisk 
indicates that the P value is <0.05 for a comparison with the level of adhesion without competitor 
(considered as 100% of adhesion). Data are expressed as means ± standard deviation of at least three 
experiments with sampi es in triplicate. 
124 
To complement the ELISA data sets with more detailed quantitative kinetic analysis, 
rSsEno binding interactions were also examined in real-time by SPR. Specifie, dose-dependent 
binding of rSsEno to immobilized fibronectin or plasminogen (positive control) was characterized 
by slow association (ka) and slow dissociation (kd) rates in both cases (Fig. 6a,c). Under similar 
assay conditions, bovine serum albumin failed to interact with the immobilized surfaces as a 
negative control (data not shown). Due to the slow off-rates observed for rSsEno binding to 
fibronectin or plasminogen (Jess than 10% dissociation over 10 minutes), it was not possible toI 
evaluate the data using standard kinetic (ka, kd) analysis in the BIAevaluation 4.1 software 
(BiacoreAB). A ItemativeIy, steady-state binding responses were averaged at the end of the 
association phase (540-580 sec plateau) and then analyzed globally as a function of rSsEno 
concentration. Linear and non-linear regression analyses (Fig. 6b,d) indicated similarly high-
affinity interactions between SsEno-fibronectin (KD ~21 nM) and SsEno-plasminogen (KD ~14 nM). 
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Fig. 6. Quantitative binding of SsEno to fibronectin and plasminogen. Representative SPR analysis of 
rSsEno (0, 3.9, 7.8, 15.6,31.3,62.5, 125,250 nM) i'njected (600 sec association + 600 sec dissociation) 
over amine-coupled fibronectin (290 RU; (a)) or plasminogen (140 RU; (c)) at 25 ilL/min. Equilibrium 
binding responses (R.,q) were averaged (540-580 sec) and then evaluated according to the steady-state 
affinity model (R.,q vs C; fibronectin (b); plasminogen (d)). Subsequent scatchard transformations (R.,qlC 
vs R.,q; insets) indicate similar high-affinity interactions between SsEno-fibronectin (KD ~21 nM) and 
SsEno-plasminogen (KD ~ 14 nM). 
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SsEno is present both iotracellularly and at the bacterial surface 
Western blot results showed that SsEno is present in S. suis supernatant, cel! wall, and 
cytoplasmic fractions, with negligible amounts in the membrane fraction (data not shown). 
Immunoelectron microscopy using the same antibody confinned the surface location of SsEno on S. 
suis (strain 166') cells (Fig. 7a). In contrast, no labeling was observed for the negative control (Fig. 
7b). 
Fig. 7. Surface localization of SsEno on S. suis. (a) Immunogold electron microscopic detection of the 
location of SsEno (magnification x 45,000) on S. suis pretreated with rabbit anti-SsEno IgO, followed by 
colloidal gold-Iabeled anti-rabbit IgO (gold partic\e sizes are 12 nm; indicated by the arrow). (b) Normal 
rabbit IgO was used as a negative control. Bars, 250 nm. 
SsEno participates in S. suis adhesion to and invasion ofPBMEC 
To evaluate the potential role of SsEno in S. suis adhesion to and invasion of PBMEC, 
bacterial SsEno was blocked with affinity purified rabbit anti-SsEno IgG. As shown in Fig. 8, anti-
SsEno IgG treatment decreas~d to ~46% the adhesion of S. suis serotype 2 strain 166' to PBMEC 
compared with the control. The invasion of S. suis to PBMEC was also decreased to ~ 79%, 
compared with the control. 
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Fig. 8. Decrease of the adhesion and 
invasion of S. suis strain SS166 to 
PBMEC by antibodies against 
SsEno. S. suis strain 166' was 
preincubated with the appropriate 
concentrations (10 /lg) of antibodies 
at 37°C for 60 min prior to infection. 
Adhesion was determined after 
exposure of PBMEC to S. suis (10 7 
CFU mr1), followed by extensive 
washing of nonadherent bacteria and 
cell lysis to obtain S. suis viable plate 
counts on THB. Invasion was 
determined as described above, 
except that after washing the bacteria 
and cells were exposed to antibiotics 
to kill extracellular bacteria. An 
asterisk indicates that the P value is 
<0.05 for a comparison with the level 
of adhesion/invasion with control 
antibodies (considered as 100% 
adhesion/invasion). 
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DISCUSSION 
Over the past 15 years, S. suis infections have emerged as a major problem for the swine 
industry worldwide, and they are also considered an important zoonotic agent (19, 61, 71). The 
pathogen is able to spread systemically from the nasopharynx, resulting either in general 
septicaemia or infections of specific organs (e.g. endocarditis, meningitis, arthritis), foIiowed 
frequently by death (18, 38). The palatine and pharyngeal tonsils are both potential portais of entry 
for S. suis, although the mechanisms and virulence factors that enable the pathogen to disseminate 
throughout the animal and colonize different tissues are not well understood. 
Adhesion of pathogens to host tissues is a critical early step in the process of infection. The 
ability to bind to fibronectin is a characteristic that has been reported for many pathdgens (25). As 
fibronectin plays an important role in diverse normal physiological processes, its targeting appears 
to be an example of the exploitation of a host cell process in the establishment, maintenance or 
dissemination of infection (29). Although a previously reported fibronectin-and fibrinogen-binding 
prote in (FBPS) has been described for S. suis (14), a jbps mutant was shown to adhere to 
fibronectin at similar levels as those presented by the wild-type parent strain (67), suggesting that 
other major adhesins are also involved. 
In the present study, using fibronectin-coupled affinitychromatography, we have identified 
a predominant S. suis fibronectin-binding native protein of 52 kDa. Subsequently, the prote in was 
identified as an a-enolase based upon to the high similarity of its sequence with other described 
bacterial enolases (93% with other streptococcal a-enolase) and our biochemical tests confirmed 
enolase activity. Furthermore, SsEno is also cross-reactive with anti-SEN antiserum, which has 
previously been shown to react with a-enolase-like molecules on streptococci (48). This is the first 
time that the fibronectin-binding activity of an a-enolase is described. These resuIts were confirmed 
using rSsEno c10ned and expressed in the present study. In fact, Antikainen et al. (2007) have 
recently reported that a-enolases from other gram positive bacteria such as S. pyogenes, 
Streptococcus pneumoniae, Staphylococcus aureus, Lactobacillus crispatus and Lactobacillus 
johnsonii, do not possess the ability to bind to fibronectin. Thus, the interaction of enolase with 
fibronectin may serve different purposes in S. suis than in the pathogenic and commensal bacteria 
studied in that work. Interestingly, Jing et al. (22) has recently proposed, after a complete proteome 
analysis, the enolase as one of two putative virulence-associated factors for S. suis serotype 2. 
However, the hypothetical plasminogen binding of the S. suis enolase (based on previous studies 
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performed. with other streptococci) is proposed in that study as the mechanism used by this 
virulence factor to participate in the pathogenesis of the infection caused by this pathogen. 
To possess fibronectin-binding activity, it was anticipated that SsEno should be exposed at 
the surface of bacteria. Fractionation of S. suis strain 166' showed that SsEno is present in ail the 
subcellular components, including the bacterial. surface, as previously demonstrated for other 
pathogens including S. pyogenes (48). ELISA tests carried out with whole bacteria and anti-SsEno 
also showed aclear recognition of this protein at the bacterial surface (M. Esgleas and M. 
Gottschalk unpublished observations). Electronic microscopy corroborated this surface localization 
and also showed that SsEno is present at the surface in low abundance, a feature that has also been 
described for S. pneumoniae enolase (30). Moreover, such a relatively low amount has proven 
sufficient for contributing to bacterial pathogenesis (7). Interestingly, in addition to serotype 2, al! 
reference strains of other serotypes of S. suis were found to express surface-exposed SsEno (M. 
Esgleas and M. Gottschalk unpublished observations). The mechanisms by which this protein is 
translocated to the bacterial surface are still unknown. In fact, the amino acid sequence of SsEno 
shows the absence of an N-terminal signal sequence and of an anchor carboxyl terminus LPXTG 
motif. It has been demonstrated that this LPXTG motif is necessary for the translocation of proteins 
to the bacterial surface because it is recognized by a transpeptidase (sortase A) that cleaves between 
the Thr and Gly residues (53). Once cleaved, the carboxyl group of the Thr residue is linked to a 
free amino group of a branch peptide within the peptidoglycan cel! wall permitting the anchorage of 
these LPXTG containing proteins to the bacterial cell wall (53). Interestingly, we have recently 
shown that disruption of srtA gene in S. suis results in only a slight decrease in adhesion to 
fibronectin (68), confirming that anchorless (such as the enolase) rather than LPXTG motifproteins 
play a major role in the adhesion to this extracellular matrix protein. 
To date, the major function described for surface enolases is a strong plasminogen-binding 
activity (47, 48). In this study we confirmed that, in addition to a previously described GAPDH 
(23), SsEno is also a S. suis plasminogen-binding protein. Although it has recently been 
demonstrated that enolases of other gram-positive bacteria bind to laminin and/or collagen (2), we 
could not identify any adhesion activity of rSsEno to any of these two proteins (M. Esgleas and M. 
Gottschalk unpublished observations). Interestingly, in addition to the fibronectin and plasminogen-
binding activities of the rSsEno, a heat-shock protein activity (as previously described for other 
enolases (21, 50)) and an IgG-binding properties of this protein have also been observed (M. 
Esgleas and M. Gottschalk unpublished observations). 
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The binding of purified rSsEno to both plasminogen and fibronectin was demonstrated 
qualitatively by ELISA and quantitatively by SPR. Interestingly, a higher amount of fibronectin, 
compared to that used for plasminogen, had to be used in the ELISA test to obtain similar 
absorbances. Although this might be interpreted as a significant higher affinity (which was not 
confirmed by SPR), this is not the case. The ELISA test was used in this study as a qualitative test, 
since plasminogen and fibronectin have different molecular weights and their attachment to plastic 
wells may vary with the conditions used for the ELISA. In particular, SPR analysis c1early indicated 
that rSsEno interactions with plasminogen and fibronectin were of similar high affinity (Ko ~ 14 nM 
and KD ~21 nM, respectively). High-affinity binding between SsEno and fibronectin is consistent 
with other bacterial fibronectin-binding adhesins, inc1uding FI and F2 of S. pyogenes (16, 31). 
These results support our hypothesis that the specific interaction between SsEno and fibronectin 
may be biologically significant. Both ELISA and SPR also demonstrated, as previously described 
for other pathogens, that the interaction between rSsEno and plasminogen is specific, suggesting 
that this interaction is also a biologically significant event. This provides further evidence to support 
the previous finding that bacterial enolases interact with plasminogen with high affinity (2, 28). ln 
fact, the low nanomolar affinity constant between SsEno and plasminogen obtained in this study 
agrees with values obtained for adhesion of S. pyogenes (48) and S. pneumoniae (7) enolases for 
plasminogen. 
Plasminogen-binding interactions were originally described as mediated by recognition of 
the C-terminal lysine residues of eukaryotic and prokaryotic enolases by the lysine binding sites of 
plasminogen (52). Later, Bergmann et al. (7) identified another internai plasminogen-binding site in 
the pneumococcal enolase (FYDKERKVY) that is located on the outer surface of the octameric 
molecule (15) and where the lysines and glutamic acid are important for plasminogen binding (6). 
Importantly, SsEno possesses both plasminogen-binding motif (M. Esgleas and M. Gottschalk 
unpublished observations) which could explain the similar nanomolar affinity constant of both S. 
pneumoniae (7) and S. suis enolase to plasminogen. Binding of plasminogen to S. suis enolase is 
inhibited by the lysine analog EACA, which indicates involvement of the lysine residues in this 
binding activity. Interestingly, SsEno adhesion to fibronectin is also decreased by EACA, indicating 
that lysines are also important for its fibronectin-binding activity. However, further research is 
required to determine the specific domaines) and the individual amino acids that participate in the 
binding of SsEno to fibronectin. 
As mentioned above, the pathogenesis of S. suis infection is poorly understood at present. 
Once in the bloodstream, S. suis resists phagocytosis and killing by neutrophils and monocytes (Il, 
12,56,58). In the event that S. suis fails to cause acute fatal septicaemia, bacteria are able to reach 
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the CNS via different mechanisms that are only partially elucidated, such as adhesion to, with or 
without toxicity, and invasion of brain microvascular endothelial ce lis (BMEC) (4, 13, 66) and/or 
choroid plexus epithelial cells (63, 64). In fact, interactions of S. suis with both fibronectin and 
plasminogen may play a 'role in sorne of these mechanisms. For example, fibronectin-binding 
proteins of streptococci and staphylococci have been reported to mediate bacterial adhesion to and 
invasion of host cells (46, 59, 65). In the case of S. suis, it has been recently demonstrated that S. 
suis adhesion to and intracellular invasion of PBMEC increases more than 500% and 700%, 
respectively, when bacteria are precoated with fibronectin (67). Although the mechanisms by which 
fibronectin-binding proteins trigger the intemalization of bacteria by mammalian cells are not 
completely understood, it has been suggested that binding of fibronectin to a host integrin might 
initiate a complex cascade of ce li signaling that leads to reorganization of cytoskeletal components 
and consequent intemalization of the bacteria (54). Accordingly, S. suis invasion of endothelial cells 
is actin-dependent (66). In the present study, a role of SsEno in the adhesion to and invasion of 
these ce Ils has been shown by blocking the proteinusing affinity purified anti-SsEno IgG. Since 
the se studies have been carried out with cell monolayers, the fibronectin-binding activity of SsEno 
might explain this inhibition. It might be hypothesized that S. suis enolase is an important receptor 
for plasma fibronectin, which may increase bacterial adhesion to host cells. Another mechanism 
consisting in a certain adhesion of S. suis enolase to cellular fibronectin present in endothelial cells 
can not be completely ruled out. However, further studies have to be carried out to demonstrate 
such an interaction. Although no increase of adhesion/invasion to PBMEC were observed when 
increased concentration of plasminogen were added (M. Esgleas and M. Gottschalk unpublished 
observations), a certain role of the plasminogen-binding activity of SsEno (and GAPDH) in vivo, 
cannot be discarded. In fact, it has also been demonstrated that plasminogen adhered to S. suis ·is 
able to acquire plasmin activity when co-incubated with human BMEC (24). As a consequence of 
plasminogen activation on bacterial surfaces, bacteria become armed with the broad substrate 
spectrum proteolytic potential of plasmin that is not susceptible to regulation by host-derived 
inhibitors (35). The capture of plasminogen by adhesins such as SsEno and GAPDH and its 
convertion to plasmin has previously been described for other pathogens (2, 28) and can be used to 
facilitate bacterial penetration through biological membranes such as the BBB and therefore could 
represent an important determinant of virulence. The role of SsEno in studies using endothelial cells 
monolayers in a Trans-well system is currently under investigation in our laboratory. 
In conclusion, we have demonstrated for the first time that S. suis a~enolase has not only a 
high affinity for plasminogen, as demonstrated in other bacterial enolases, but also a similarly high 
affinity for fibronectin. Moreover, we have shown that this protein is a new S. suis adhesin that 
participates in bacterial adhesion to and invasion of endothelial cells. Our results indicate that 
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SsEno of this human and porcine pathogen could be a key molecule in pathogenesis by facilitating 
bacterial interactions with host cells. This is in agreement with two recent studies that describes S. 
suis enolase as an antigenic protein and a putative virulence factor of S. suis serotype 2 (22, 73). 
Mutants with defective export of enolase to the surface of the bacteria may give sorne insights into 
the role ofthis adhesin in the pathogenesis of S. suis infection. 
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SUMMARY 
In our ongoing efforts to develop a vaccine against Streptococcus suis infection, we tested 
the potential of Streptococcus suis enolase (SsEno), a recently described S. suis adhesin with 
fibronectin-binding activity, as a vaccine candidate in a mouse model of S. suis- induced septicemia 
and meningitis. Here, we show that SsEno is highly recognized by sera from convalescent pigs and 
is highly immunogenic in mice. Subcutaneous immunization of mice with SsEno elicited strong 
immunoglobulin G (IgG) antibody responses. Ali four IgG subclasses were induced, with IgG 1, 
IgG2a and IgG2b representing the highest titers followed by IgG3. However, SsEno-vaccinated and 
non-vaccinated control groups showed similar mortality rates after challenge infection with the 
highly virulent S. suis strain 166'. Similar results were obtained upon passive immunization of mice 
with hyperimmunized rabbit IgG anti-SsEno. We also showed that anti-SsEno antibodies did not 
increase the ability of mou se phagocytes to kill S. suis in vitro. In conclusion, these data 
demonstrate that although recombinant SsEno formulated with Quil A triggers a strong antibody 
response, it does not confer effective protection against infection with S. suis serotype 2 in mice. 
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INTRODUCTION 
Despite increasing research in recent years, Streptococcus suis continues to cause a variety 
of diseases in pigs worldwide, including septicemia, meningitis, arthritis and endocarditis (14). 
Among the 35 serotypes described, serotype 2 is considered the most virulent and is most frequently 
isolated from diseased pigs (14). ln addition, S. suis has also been described as ,an important 
zoonotic agent, especially in Europe and Asia (22). Human infections with S. suis are most 
frequently manifested as purulent meningitis, but septie shock with multiple organ failure, 
endocarditis, pneumonia, arthritis, and peritonitis have also been reported (22). 
The pathogenesis of S. suis infection is not fully understood. In swine, the potential portais 
of entry for S. suis are the palatine and pharyngeal tons ils and thereafter bacteria can spread via the 
hematogenous or Iymphogenous route (23). Once in the bloodstream, S. suis has to resist 
phagocytosis and killing by phagocytic cells to cause acute septieemia that may lead to septic 
shock. Bacteria can reach different organs, including the central nervous system (CNS), via 
different mechanisms that are only partially elucidated to date (10). 
Several potential virulence factors qave been implieated in the infection process. The most 
promising virulence factors to date are the capsule polysaccharide (CPS) and serum opacity factor 
(OFS) (1), as isogenic mutants lacking either of these factors are rapidly cleared and eliminated 
from circulation (l, 6, 29). However, sorne non-virulent strains are also encapsulated or have allelic 
variations of OFS (30), indicating that virulence of S. suis likely involves multiple factors (10). 
Other virulence candidates have been proposed, but most of them are not present in ail virulent 
strains or are present in non-virulent strains (Il). So far, whole cell vaccines or bacterins 
(commercial and autogenous) have been used in the field to prevent S. suis disease, however, with 
disappointing results (13, 18). Vaccination with these bacterins does not induce high levels of 
antibodies and causes, at most, serotype-specific responses (14). We recently identified SsEno, a 
new S. suis surface fibronectin-binding protein (9) that might participate in the pathogenesis of S. 
suis infection by mediating bacterial attachment to and internalization into brain microvascular 
endothelial cells (BMEC) (9). SsEno might be an attractive vaccine candidate against S. suis 
infections as it possesses highly conserved epitopes (8) and is expressed at the surface of ail S. suis 
serotypes described to date (9). In addition, a recent study identified S. suis enolase as an important 
antigenic protein that contributes to the virulence of S. suis (16). The objective of this study was to 
determine whether the immune response induced by immunization with purified SsEno can confer 
protection against challenge with the homologous strain of S. suis serotype 2 in a mouse model of 
infection. 
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METHODS 
Bacterial strains 
S. suis serotype 2 highly virulent strain 166' (2) was kindly provided by Dr. M. Kobisch, 
AFSSA, Ploufragan, France. Working log-phase cultures were prepared in Todd Hewitt broth 
(THB) (BD, Sparks, MD) as previously described (7). Growth was allowed until the suspension 
reached approximately 5 x 108 CFU mr!. Final inoculum corresponded to 107 CFU mr! (for pigs) 
and 108 CFU mr! (for mice). Escherichia coli strain BL21 DE3 (Novagen, Madison, WI) was used 
for expression experiments as described elsewhere (9). 
Cloning and expression of the a-enolase gene 
Cloning and purification of SsEno were performed as previously described (9). Briefly, the 
coding sequence of SsEno (S. suis Enolase) was amplified by PCR using chromosomal DNA from 
S. suis SS166 as template and the complete gene was cloned into pET-32a vector (Novagen, 
Madison, WI). The plasmid pET-32a-SsEno was introduced into E. coli BI21DE3 for an IPTG-
inducible expression of recombinant S. suis enolase (rSsEno). The His-tagged fusion prote in was 
purified by chromatography under native conditions on HisTrap according to the manufacturer's 
instructions (Amersham Biosciences AB, Uppsala, Sweden). Prote in concentrations were 
determined by the Lowry method (21). Prior to vaccination as say, the purity (>95%) of recombinant 
SsEno preparations was determined by scanning densitometry of the prote in on an SDS-PAGE gel 
stained with Coomassie blue and with a silver-stained SDS-PAGE gel (data not shown) as 
previously reported (9). 
Presence of anti-SsEno antibodies in convalescent animais 
AIl animal experiments were conducted according to the guidelines and protocols set forth 
by the Canadian Council on Animal Care and approved by the Université de Montréal committee 
on animal care. Seven 4-week-old piglets from a herd free of S. suis serotype 2 disease were 
infected intravenously with 107 CFU from a log-phase culture of S. suis strain 166'. AnimaIs were 
monitored for clinical signs and treated with antibiotics if needed to avoid death. Serum samples 
were taken befor and three weeks post-infection. Antibody titers against rSsEno from these 
convalescent pig sera were measured by direct ELISA. Maxisorp® flat-bottom mÎcrotiter 96-well 
plates (Nunc, VWR, Mississauga, ON, Canada) were coated ovemight at 4°C with 5 Mg mr! of 
purified recombinant SsEno. The plates were further incubated with 1/1000 dilution of pig sera and 
bound antibodies were detected by incubation with peroxydase-conjugated goat anti-swine IgG 
(Jackson Immunoresearch Laboratories West Grove, PA) for 1 h at room temperature. The plates 
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were developed wit~ TMB substrate (Zymed, S. San Francisco, CA, USA) and absorbance was 
measured at 450 nm. 
Active protection assay of mice with rSsEno 
Six-week-old female CD-1 mice (Charles River Laboratories, Wilmington, MA, USA) were 
immunized subcutaneously twice, one week apart, with either 20 IJ,g of purified SsEno mixed wlth 
20 IJ,g of Quil-A adjuvant (Brenntag Biosector, Frederikssund, Denmark) or 20 IJ,g of Quil-A only as 
a control in 100 IJ,I of phosphate-b~ffered saline (PBS) per mouse. Ten days after the second 
vaccination, animais were challenged intraperitoneally with 108 CFU per mouse of log-phase S. 
suis, strain 166' in 1 ml of THB. Sera collected from each mouse before immunization, before the 
second dose and before challenge infection were assayed for anti-SsEno antibody titers by ELISA, 
as described below. Mice were monitored daily for clinical signs such as ab normal behavior 
(hyperexcitation,episthotonus, opisthotonus, bendingofthe head toward one side, walking in circles 
or strong locomotive problems), rough hair coat, ataxia and mortality until day 10 post-infection 
(7). This mouse model of infection was recently used to reproduce septic shock and meningitis that 
might be consider to be similar to those induced by S. suis in pigs (7, 14). 
Passive protection of mice with rabbit antibodies against rSsEno 
Groups of 12 female CD-1 mice (Charles River, 6 week old) were injected intraperitoneally 
with 0.5 ml of rabbit anti~rSsEno serum (9) or 0.5 ml of normal rabbit serum as a control. 
Hyperimmune sera against rSsEno was produced as previously described (20) and the titer «11100 
000) evaluated by ELISA (28). Three hours later, 10 mice per group were injected intraperitoneally 
with 108 CFU per mouse of log-phase S. suis, strain 166' in 1 ml ofTHB. Sera were collected 24 h 
after the serum administration to measure anti-SsEno antibodies by ELISA assay as described 
below. Mice were monitored daily for weight loss, clinical signs and mortality. 
Determination of active and passive antibody titers in mice by ELISA 
Titers of SsEno-specific total IgG in mice sera were determined by ELISA as previously 
described (20). Briefly, Polysorb plates (Nunc-Immunoplates, Rochester, NY, USA) were coated 
ovemight at 4°C with purified recombinant SsEno. Due to an extremely high antibody response (see 
below), a:nd comparing to what was used to measure antibodies in swine, a significant reduced 
concentration of SsEno (0.3 IJ,g mr1) was used to coat the plates. After incubation with seriai 
dilutions of test, bound antibodies were detected by incubation with peroxidase-conjugated goat 
anti-mouse IgG, IgG 1, IgG2a, IgG2b or IgG3 antisera (Serotec, Kidlington, Oxford, UK) for 1 h at 
room temperature. For determination of antibodies titers in the passive protection assay, the same 
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protocol was used but with peroxidase-conjugated ariti-rabbit IgG (Jackson ImmunoResearch 
Laboratories, West Grove, PA) as a secondary antibody. Plates were then developed as described 
above. The antibody titer was considered as the serum dilution that resulted in an OD450 reading of 
0.1 after subtracting background. 
. / 
Killing of S. suis serotype 2 strain 166' by mouse phagocytes in the presence of anti-SsEno 
antibodies 
In vitro killing of S. suis serotype 2 strain 166' by mouse phagocytes in the presence of 
polyclonal anti-SsEno antibodies was measured as described previously (17, 26) \Vith sorne 
modifications. Briefly, 0.3 ml (from 5 different animais) of freshly heparinised blood was mixed 
with 0.5 ml ofappropriately THB diluted bacteria (200-500 CFU mr') in the presence of25 ~g mr' 
of protein G purified rabbit anti-SsEno antibodies (9). Similar concentrations of purified normal 
rab bit antibodies were used as negative control and of purified hyperimmune rab bit anti-S. suis 
(who le cell) antibodies as a positive control, as previously described (4). Mixtures were incubated at 
37°C for 3 h with constant slow rotation (17, 26). At the end of the incubation, an appropriately 
diluted aliquot was plated onto THB agar and incubated overnight at 37°C to count survivirtg 
bacteria. Results are expressed as mean percentage ± standard deviation of bacterial survival, with 
survival of bacteria opsonised with normal rabbit antibodies considered as 100%. Data are 
representative of four independent experiments. An internai control for the growth of S. suis 
serotype 2 strain 166' in the presence of the different conditions was also included. Briefly, the 
same concentration of diluted bacteria (200-500 CFU mr') were grown in THB in the presence of 
25 ~g mr' of the different purified antibodies or no antibodies for 3 h in stationary conditions and 
the number of CFU in each condition were counted. 
Statistics 
Antibody titers and percentage of killed bacteria of experimental groups were compared 
using student's (-test (*** p<0.0005,** p<0.005, * p<0.05). Survival curves were evaluated using 
the Kaplan-Meier method and the significance ofthe difference was tested using the Log-rank test. 
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RESULTS 
Immunogenicity of SsEno in pigs 
None of the seven animais used in this study had SsEno-specific antibodies before the 
experimental infection (Fig. 1), as only background values were detected in these animaIs. In 
contrast, pigs infected with a log-phase culture of S. suis strain 166' showed significant anti-SsEno-
IgG responses at 3 weeks post-infection (Fig. 1). 
1.6 
1.4 
1.2 
E 1.0 c:: 
~ 
'<1' 0.8 
cl 
d 0.6 
0.4 
0.2 
0.0 
+ 
Before 
infection 
** • 
• 
.!. 
• • 
• 
After 
infection 
Fig. 1. ELISA detection of antibodies against SsEno in sera from pigs before and after challenge 
with S. suis serotype 2. Plates were coated with rSsEno and then incubated for 1.5 h with a dilution 
of 1/1000 of swine sera (before and after challenge). Mean values (line) comparing sera from non-
infected (n = 7) and infected pigs (n = 7) are shown. **, P<0.005 
SsEno-specific IgG and IgG subclasses in active protection assay 
There were no SsEno-specific antibodies in sera from any of the animaIs before the first 
vaccination (Fig 2(a)). Immunization of mice with SsEno elicited a strong antigen-specific 
response. At 14 days after the first vaccination, SsEno elicited a significant IgG response that was 
further increased after the second immunization (Fig. 2(a)). Analysis of sera demonstrated that 
although SsEno-immunized animais produced ail IgG subclasses, IgGl, IgG2a and IgG2b responses 
were predominant followed by IgG3 (Fig. 2(b)). In contrast, animaIs vaccinated only with adjuvant 
did not show any antibody responses (Fig. 2(a) and 2(b)). 
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Fig. 2. Serum 
antibody responses 
in mice immunized 
with Quil A (open 
cycles) 
alone or Quil A plus 
recombinant SsEno 
(solid cycles). (a) 
Total SsEno-specific 
serum IgG. (b) IgG 
subclasses in sera at 
14 days after the 
second immunization 
(before challenge). 
Antibody titers of 
individual mice are 
shown, with the 
average titer 
represented as a bar. 
(n=16 for SsEno-
immunized animaIs; 
n= 15 for control 
animaIs). 
P<O.0005. 
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A few ho urs after challenge infection with S. suis serotype 2 strain 166', ail mice (control 
and SsEno immunized group) exhibited clinical signs, such as ruftled hair coat suggesting fever and 
slow response to stimuli. From day 0 to 3 post-infection, 25 % of immunized animais died from 
septicemia (Fig. 3(a)). After day 3 post-infection, 58 % of the immunized animais that survived to 
septicemia developed severe CNS signs such as running in circles and opisthotonos and died or met 
criteria for euthanasia due to the severity of their condition (Fig. 3(a)). Similar results were 
observed in the control group; although ail the animais resisted the septicemic phase, 33 % of 
animais died after day 3 post-infection due to meningitis (Fig. 3(a)). In ail dead animais, S. suis 
serotype 2 was isolated from different organs (data not shown). 
During the septicemic phase, the immunized group lost ~ 15 % of their body weight (Fig. 
3(b)). Similar results were ,seen in the control group (Fig. 3(b)). In both groups, animais that 
survived the septicemic phase were able to recover their initial body weight at the end of the 
experiment (Fig. 3(b)). 
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Fig. 3. Survival (a) and weight lost (b) of mice in the active protection assay. Mice were first 
immunized with Quil A (n=14, white) or Quil A-rSsEno (n=15, black) and then challenged with 108 
CFU mr1 of S. suis 166'. Survival rate (a) and % of initial body weight (b) were monitored for 10 
days. Body weight of each mouse was measured every day. ' 
Clinical signs and mortality in the passive protection assay 
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A few hours after infection, passively immunized animais presented similar c1inical signs as 
those vaccinated in the active protection assay. During the first 12 h, 30% of animais immunized 
with anti-SsEno antibody died from septicemia compared with 70% of the control group. However, 
aIl passively immunized animaIs as weIl as control mice died within the first 6 days post-infection 
from either septicemia or meningitis (Fig. 4). Analysis of sera c1early indicated that there was a high 
titer ofrabbit anti-SsEno only in the passive immunized group (data not shown). 
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Fig. 4. Survival of mice in the passive protection assay. Mice were immunized with rabbit anti-
SsEno antibodies (n=12) or control rabbit antibodies (n=12). Mice were then challenged 
intraperitoneally with 108 CFU mr 1 of S. suis serotype 2 strain 166' and survival was monitored for 
10 days. 
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Killing of S. suis serotype 2 straiD 166' by mouse phagocytes 
To further evaluate the bactericidal/opsonic capacity of anti-rSsEno antibodies, a killing 
assay was performed using mouse whole blood. As shown in Fig. 5, S. suis treated with normal 
rabbit IgGs grew weil in mouse blood (negative control). In contrast, S. suis treated with rabbit anti-
who le S. suis IgGs was rapidly killed as expected (positive control). Incubation of S. suis with 
affinity purified anti-SsEno IgG antibodies did not enhance bacterial killing, confirming results 
obtained in the passive protection assay. 
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Fig. 5. Effect of antibodies on opsonophagocytic killing of S. suis strain 166' by mouse 
phagocytes. Antibodies were purified from sera of a rabbit immunized with SsEno. Antibodies 
from a normal rabbit and from a rabbit hyperimmunized with whole S. suis serotype 2 were used 
as negative and positive controls, respectively. Data are expressed as mean percentage ± standard 
deviation of bacterial survival, with survival of bacteria opsonised with normal rabbit antibodies 
considered as 100%. Data are representative of four independent experiments. ***, P<0.0005. 
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DISCUSSION 
Several approaches have been used to develop vaccines for S. suis. However, little success 
has been achieved thus far because the protection elicited was either serotype or strain dependent, 
and results in most instances have been equivocal (12). For example, killed ~hole ce Ils or live 
avirulent vaccines can provide partial protection but only with repeated immunization (3, 33). 
Subunits protein-based vaccines have also been tested. using virulence markers such the hemolysin 
(15), the muramidase-released prote in and extracellular protein factor (33) that have been shown to 
protect pigs from homologous and heterologous serotype 2 strains. However, their use is hindered 
by the fact that a substantial number of virulent strains in sorne geographical regions do not express 
these proteins (10). More recently, a surface expressed protein (SAO) has been observéd to confer 
protection against experimental infection in mice and pigs (19). However, as this protection is not 
complete, other proteins could be combined with SAO to optimize protection. 
Fibronectin-binding proteins have been suggested as potential vaccine targets for preventing 
bacterial infections because antibodies directed against such adhesins may prevent bacterial 
attachment and also enhance opsonization and killing by leukocytes (27, 34). In this study, we 
tested the potential of the recently described fibronectin-binding protein, SsEno, as a vaccine 
candidate in a mouse model of S. suis-induced septicemia and meningitis (7). SsEno is a good 
vaccine candidate based on the following characteristics: i) it is present at the surface of ail 35 
different S. suis serotypes (9); ii) it contributes to S. suis adhesion to and invasion of host cells (9); 
and iii) it is a highly conserved protein (8). In addition, we further showed that sera from 
convalescent animais strongly recognize this protein, suggesting expression of SsEno in vivo. Very 
recently, another study also suggested an important role of enolase in the virulence of S. suis (16). 
However, the potential of this prote in to confer protection against other pathogens is controversial. 
Mice immunized with antibodies against Plasmodium falciparum enolase are protected from 
challenge infection with a lethal mouse malaria strain (25). In contrast, recombinant enolase from 
Candida albicans induces only modest protection against disseminated candidiasis (24). To our 
knowledge, a protection test against streptococci using enolase as an antigen to elicit an immune 
response has not been reported yet. 
To evaluate SsEno as a vaccine candidate against S. suis infection, we used a highly 
virulent strain for swine in a well standardized mouse model, which presents two different phases: 
a) a septicemic phase, (24-48h post-infection) and, b) a meningitis/encephalitis phase, where 
animais that survive septicemia will subsequently die from a serious infection of the CNS (7). Our 
results indicated that the antibodies actively elicited by SsEno at the concentration used in 
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combination with Quil-A adjuvant was not protective from either phase of challenge infection with 
S. suis. The Th I-type responses and IgG subc1asses induced by the SAO prote in are two main 
components of host immunity against S. suis infection (19). In this study, ail SsEno-specific IgG 
subc1asses (IgG 1, IgG2a, IgG2b and IgG3) were induced, with IgG 1 and the Th I-type antibodies, 
IgG2a and IgG2b, as the predominant subc1asses. Therefore, other components of the host immune 
response besides non-opsonic antibodies may be necessary for effective protection against S. suis 
infection. We attributed the fact that the vaccinated group presented a higher level of mortality than 
the control group to a simple variation in an animal assay. Although it wou Id have been tempting to 
interpret the results as a possible role of antibodies against enolase playing a certain role in 
autoimmunity as described (31), animais from both groups were perfectly healthy at the moment of 
challenge. 
To confirm these results, we tested whether rabbit anti-SsEno serum provides passive 
protection against challenge infection with the same strain of S. suis in mice. As expected, and 
although a slight delay in the appearance of severe c1inical signs, passive immunization with anti-
SsEno serum did not confer significant protection against S. suis infection. As it has been shown 
that antibodies derived from hyperimmune sera against whole bacteria (inc1uding antibodies against 
the capsule) can prote ct mice against infection (5) and induce bacteria killing (4), it is possible that 
anti-SsEno antibodies are not opsonic, allowing bacteria to reproduce in high numbers to cause 
disease. On the other hand,antibodies against other fibronectin-binding proteins have already been 
described to enhance phagocyte killing in other bacterial species (27). To test this, we evaluated the 
capacity of the purified anti-SsEno IgGs to opsonize bacteria and promote their killing by murine 
phagocytes. Although most of the produced antibodies were of the Th 1 type, results obtained in this 
study showed that the anti-SsEno IgG subc1asses were not able to induce S. suis killing by mouse 
phagocytes. 
Since anti-SsEno has been shown to reduce bacterial adhesion and invasion to BMEC in 
vitro (9), we had expected a certain degree of protection against the CNS phase of infection. 
However, SsEno is not the only receptor involved in such process (32). It is possible that the high 
concentration of S. suis in blood, as a consequence of a lack of bacterial killing by leukocytes, may 
overcome the partial inhibition of bacterial-BMEC interactions mediated by anti-SsEno antibodies. 
In summary, although we demonstrated that SsEno elicits an important antibody response in 
convalescent pigs and immunized mice, this response as evaluated in the present study is inadequate 
for effective protection against S. suis infection. 
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Streptococcus suis is a well-recognized worldwide swine pathogen of emerging clinical 
significance in most countries with intensive swine industry (37). S. suis infections in pigs are 
associated with different clinical diseases such as meningitis, arthritis, endocarditis, septicemia and 
occasionally, other infections (37). Clinically healthy pigs can carry S. suis in their nasal cavities, 
tons ils, and upper respiratory tracts, contributing to the dissemination and transmission of this 
pathogen (29). In addition to its significant sanitary and economic impact in the swine industry, S. 
suis is also a zoonotic agent, responsible for septicemia and meningitis in humans (55). S. suis 
normally affect people in close contact with diseased pigs or with their pork-derived products (55). 
The number of S. suis infections in humans and the number of death caused by this pathogen 
dramatically increased in the last years and, although the hard work realized to eliminate this 
bacterial infection, the control of the disease is hampered by the lack of effective vaccines (55). In 
addition, as most of the pathogenic and etiologic agents of deadly diseases, S. suis is acquiring 
resistance to currently used drugs indicating that the development and formulation of vaccines is 
extremely necessary (36). 
Discovering virulence factors of pathogenic bacteria is an important key in understanding 
pathogenesis and for identification of targets for novel drugs and design of new vaccines (101). 
8acterial virulence factors can be divided into several groups on the basis of the mechanism of 
virulence and function (101). These are (i) membrane proteins, which play roles in adhesion, 
colonization, and invasions, promote adherence to host cell surfaces, are responsible for resistance 
to antibiotics, and promote intercellular communication, (ii) polysaccharide capsules that surround 
the bacterial cell and have anti-phagocytic properties, (iii) secretory proteins, such as toxin, which 
can modify the ho st cell environment and are responsible for sorne host cell-bacteria interactions, 
(iv) cell wall and outer membrane components, such as lipopolysaccharide and lipoteichoic acids, 
and finally (v) other virulence factors, such as biofilm forming proteins. Biofilm formation confers 
a selective advantage for persistence under environmental conditions and for resistance to 
antimicrobial agents and also facilitates colonization in the ho st by the bacteria. 
As described in this work, several putative virulence factors have been identified for S. suis 
(29). The capsular polysaccharide and the OFS are so far the only proven critical virulence factors 
since isogenic knock-out mutants for these proteins were shown to be avirulent and cleared from 
circulation rapidly in different models of infection (3, 10, 83). In addition, a muramidase-released 
ce Il-wall protein and an extracellular protein factor were originally associated with virulent serotype 
2 strains. However, isogenic mutants lacking these two proteins appeared to be as virulent as the 
wild-type strain. It is therefore not clear if these proteins are virulence factors per se or that their 
synthesis is only coincidentally associated with virulence (84). S. suis also produces a hemolysin, 
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member of the thiol-activated cytolysin family of toxins, named suilysin (40). The roles of these 
toxins in pathogenesis are varied and not fully understood, however, they aIl lyse eukaryotic cells 
that contain cholesterol (40). It has been described that suilysin is also able to lyse different type of 
host cells (29). Possibly, it might be involved in the dissemination of bacteria through the organism 
by disrupting several ho st barriers by affecting the cells forming these barriers (93). In addition, 
several other S. suis proteins that have a role as adhesins have also been described as a potential 
virulence factors (29). Finally, it has been recently described that, as for other bacterial pathogens 
such as S. aureus (64), S. suis is able to produce a biofilm which prote ct biofilm-grown S. suis from 
sorne antimicrobial agents su ch as penicillin G (6). It is important 'to note that most of these 
virulence factors have been tested as vaccine candidates against S. suis infections, however, the 
results obtained up to day have not been very succesful. 
AlI the se described (potential) virulence factors have a role in the pathogenesis of the 
infection caused by S. suis. However, as described in this work, the pathogenesis of S. suis 
infection is a complex process where many steps, most of tnem still unknown, are probably 
involved (29). It has been demonstrated that S. suis is a natural host of the tonsils of pigs and that 
sorne of the bacteria are able to cross the epithelial respiratory barrier and reach the bloodstream 
(29). In humans, bateria reach directly the bloodstream by lesions or minor abrasions in the skin 
(37). Once in the circulation; S. suis is able to evade the immune system permitting' its 
dissemination through the organism (8, 78, 79). In sorne cases, bacteria provoke septicemia and 
death (85). However, in case the host survives septicemia, bacteria are able to arrive to the target 
organs. In fact, S. suis is frequently isolated from brains of diseased pigs with clinical meningitis 
indicating that this pathogen has passed from the bloodstream to the CNS crossing the BBB (22). 
Many questions about the different steps of the pathogenesis of the infection caused by this 
pathogen and the molecules involved in those steps are still unresolved (29) (Fig 1). The first 
unresolved question is which mechanisms/molecules permit S. suis to evade the immune system of 
the host and travel in the bloodstream to finally arrive to the BBB, the other important question is 
how bacteria present at low levels on mucosal surfaces are able to traverse the host barri ers such as 
the respiratory barrier or the BBB to develop disease. (29). Many studies have been done in the last 
years to try to answer the se question marks. On one han d, several studies reported that, in contrast 
to nonencapsulated mutants, encapsulated S. suis is able to resist phagocytosis, indicating that 
capsule is an important factor that prote ct bacteria from phagocytosis (8, 78, 79). However, 
resistance to clearance from the bloodstream does not rely only on the presence of the capsule, since 
a weil encapsulated avirulent strain is eliminated from circulation within 48 h, whereas a virulent 
strain can stay in relatively high numbers in the blood for more than 5 days (29). These results 
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indicate that other important molecules are also responsible for this immune system evasion and 
that further research is necessary to determine the mechanisms by which S. suis avoids 
phagocytosis. On the other hand, one of the inost accepted proposed mechanisms used by this 
pathogen to cross the host barri ers is the adhesion to and subsequent invasion of the ho st cells 
forming these barriers (88, 93). It is commonly believed that the adhesion of microorganisms to 
ho st tissues represents a critical first step in the process of microbial infections. In fact, non-
adherent bacteria are readily eliminated from the body by such cleansing mechanisms as peristalsis 
and excretion (43). In contrast, bacteria that adhere to host tissues may remain extracellular or may 
be intemalized into an intracellular compartment (43). This cellular invasion enables the bacteria to 
escape host defense mechanisms; persist in the host and finally to cross ho st barriers (43). 
This ability to cross host barri ers ; has been observed in several pathogens including Gram-
positive and Gram-negative bacteria. Pathogens may cross the BBB transcellularly, paracellularly 
and/or by means of infected phagocytes (so-called Trojan horse mechanism) (47). Transcellular 
traversai of the BBB has been demonstrated for several bacterial pathogens, such as E. coli, group B 
Streptococcus, S. pneumoniae, L. monocytogenes, Neisseria meningitidis, Mycobacterium 
tuberculosis and furigal pathogens such as C. albicans and Cryptococcus neoformans (9, 46, 48). 
Paracellular penetration of the BBB has been suggested for the protozoans Trypanosoma sp (57). 
- This pathogen normally uses the fibrinolytic system in which bacterial-adhered plasminogen is 
converted to plasmin that is able to degrade the tight junctions forming the BBB. This destruction of 
the cell junctions permits the pathogen to cross the BBB between cells. Finally, the last proposed 
mechanism is the Trojan horse mechanism or the modified Trojan horse mechanism where infected 
phagocytes carry the pathogen through the BBB (47). This mechanism has been suggested for 
different pathogens such as L. monocytogenes and M tuberculosis (23). Other minor routes of 
bacterial entry into the CNS include mechanical spread from a contiguous source of infection such 
as sinusitis and mastoiditis. For example, S. pneumoniae has been shown to enter the CNS through 
non-haematogenous route in experimental animais after intranasal infection and otitis media (56, 
92). 
As it has always been observed in S. suis infected pigs with meningitis, it has been recently 
demonstrated that S. suis is found in the brain of mice with clinical signs of meningitis, indicating 
and corroborating that this bacteria is able to cross the BBB (22). Different mechanism used for S. 
suis to cross the BBB have been postulated. The first one is the adhesion to and invasion of BBB 
because although S. suis is a pathogen known to reside in extracellular niche, it has been 
demonstrated that S. suis has the ability to adhere to and, in sorne cases, invade different hostcells 
including those forming the BBB (88, 93). In addition, it has also been postulated that S. suis could 
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also use the "modified Trojan horse mechanism" in which bacteria are able to cross the BBB 
adhered to phagocytes such as monocytes (78, 79). In both ways, the adhesion of S. suis to host 
cells is extremely important. However, although the routes of entry seem to be known, the bacterial 
molecules responsibles for these adhesions are in most of the cases unknown. 
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Fig 1. Important unresolved questions about the pathogenesis of the infection caused by S. suis. Fig 
modified from (29) 
The adhesion of bacteria to the host cells mainly involves two molecules: the bacterial 
surface components, called adhesins, and the host receptors (43). One of the most known and 
studied host receptors is the extracellular matrix (ECM) (43). Host ECM components that are 
known to support bacterial adhesion include fibronectin, collagen, fibrinogenlfibrin, elastin, 
vitronectin, laminin (43). On the other hand, the subfamily of bacterial adhesins that bind to ECM 
molecules are collectively known as Microbial Surface Components Recognizing Adhesive Matrix 
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Molecules (MSCRAJVIMs) because more of the 90% of the adhesins responsibles for these 
adhesions are from this family of proteins (43, 70). However, and as it will be explained latter in 
this discussion, other bacterial adhesins subfamilies that participate in the adhesion of bacteria to 
ECM proteins have been reported in the last years (14). 
Although a high number of microbes have been shown to bind different host ECM 
components (43, 62,98), the adhesins responsible for these interactions have, in most cases, not 
been identified or characterized. In the case of S. suis, little was known, before this work, about the 
ability of this pathogen to bind to ECM proteins and the adhesins responsible for these adhesions. 
Only three works have been published about the ability of S. suis to bind to sorne ECM proteins. De 
Greef et al. identified in 1991 by "in vivo selected genes" the only fibronectin-fibrinogen-binding 
prote in (FBPS) described for this pathogen before this work (19, 20). They demonstrated that the 
recombinant FBPS was able to adhere to human fibronectin and fibrinogen, two of the main 
components of the ECM, and that this prote in seems to participate in the colonization of the organs 
specific for a S. suis infection in piglets, but not in the colonization of S. suis on the tons ils of 
piglets (19). Moreover, they showed that the jbps gene is present in ail known serotypes of S. suis 
[except for serotypes 32 and 34 that up to now can be considered as S. orisratti (38)] (19). 
However, the expression of FBPS in ail serotypes was not studied. Therefore, it is possible that 
although ail strains, except for serotypes 32 and 34, possess the fbps gene, not ail strains express 
FBPS. The second work about the adhesion of S. suis to sorne ECM prote in describes a 52 kDa 
IgG-binding protein that reacts with a large variety of IgGs and with human 19A, but also with other 
human plasma proteins including the ECM prote in fibronectin (80). However, the role of this 
. prote in in the pathogenesis of the infection caused by S. suis has never been studied so far. Finally, 
a last work about the adhesion of S. suis to fibrinogen has been recenty published. This work shows 
that fibrinogen enhances S. suis biofilm formation suggesting that S. suis has the potential to adhere 
to fibrinogen (6). Although these three works demonstrate that S. suis is able to bind to sorne ECM 
, proteins, an extensive research about the capacity of S. suis to bind to the ECM and particularly to 
the different proteins confonning this ECM was need to better understand sorne of the steps of the 
pathogenesis of the infection caused by this pathogens and the molecules that are involved. For this 
reason the first objective of this work was to study the capacity of S. suis to adhere to sorne of the 
most important ECM proteins presents in the host. 
Our results show, for the first time, that whole S. suis is able to specifically bind, in a dose, 
temperature and time-dependent manner, to different types of collagen and fibronectin, the 2 main 
components of the ECM. However, in this work, S. suis was not able to bind to any of the other 
ECM protein tested~ It is important to note that, although S. suis is mainly a swine pathogen, the 
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protein used for this first objective were from human origin because they were the only 
commercially available. In this work S. suis was not able to bind to collagen type IV, elastin, 
vitronectin, fibrin, laminin and fibrinogen. Although, as explained above, De greef et al. described a 
S. suis fibronectin-fibrinogen-binding prote in (19) and a recent work also demonstrated that S. suis· 
enhances the formation of a biofilm using fibrinogen (6), we can not detect any adhesion of S. suis 
to fibrinogen. The possible cause for this lack of adhesion in our work cou Id probably be the 
technique used in this study. The other two works described here used soluble fibrinogen whereas 
we bound fibrinogen to the ELISA plate weil. The adhesion of fibrinogen to a surface can probably 
modify its conformational structure and, as a consequence, the fibrinogen adhesion sites for bacteria 
can be hidder. In fact, differences in adhesion depending on the conformation of fibrinogen have 
also been reported for other bacteria. For example, S. gordonii is able to bind to immobilized 
fibrinogen, but not to soluble fibrinogen (51). In conclusion, it appears likely that fibrinogen 
expresses determinants that are recognized by bacteria only depending in the conformational form 
of the protein. 
As described before, we have demonstrated that S. suis is able to bind to collagen. 
Collagens are structural proteins of extracellular matrix that typically have triple helical domains of 
variable length (35). Collagens form, for example, the large fibers of connective tissues and 
networks in basement membranes, while sorne collagens are transmembrane proteins (35). The 
collagen family has been divided into two subgroups (35): i) the fibril-forming collagens with a 
long, continuous triple helix that gives the molecule a rigid, rod-like structure. These collagens form 
large fibrils that give structural integrity and tensil-strength to the tissues. Type l, II and V collagens 
are the most abundant protein in mammals forming extracellular matrix in bone, tendons, dermis 
etc, and ii) the network-forming collagens that have interruptions in their triple helix. Type IV 
collagen, belonging to this subfamily, is an important structural component of basement 
membranes. 
Different studies have shown the presence of collagen-binding receptors on sorne species of 
bacteria. The Dr fimbriae found on uropathogenic E. coli strains with the serotype 075 have been 
found to bind type IV collagen (99), while the enteropathogenic Yersinia enterocolitica and Y. 
pseudotubercolosis adhere to various collagen molecules through the YadA prote in (25). Within the 
genus Streptococcus, there are other species, mainly among the groups A, B, C, and G, which bind 
collagens (71). This binding has been postulated as a factor contributing to the development of a 
number of infections. For example, binding of S. mutans strains to collagen has been proposed to 
play a role in the pathogenesis of root caries (33), and the ability of S. pyogenes to bind collagen 
type IV may be an important virulence factor in determining post streptococcal glomerulonephritis 
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(49). In this work we demonstrated that S. suis binds to the most abundant co lIagen types in 
mammals, the types l, III, and V. However, and in contrast with other streptococci (49), S. suis has 
not the ability to bind to the collagen type IV. Differently to the other collagen types, collagen type 
IV is only found in thebasement membrane of the cell (30) and, as a consequence of its 
localisation, it has a different structure (30). This structural difference might hide receptors required 
for S. suis binding and could be responsible for this dissimilarity in the adhesion. Interestingly, 
although S. suis is not able to bind directly to this collagen type IV, we have demonstrated that it 
has the potential to adhere to this prote in via a surface-bound fibronectin mechanism. This 
fibronectin-mediated collagen recruitment has been previously described in other pathogens as a 
novel mechanism of colonization and immune evasion (21). In S. suis this mechanism could be of 
high importance since its route of entry in humans is through lesions or minor abrasions in the skin 
where the first proteins exposed to bacteria are the proteins forming thrombus, such as fibronectin, 
and the proteins of the basal lamina, including the type IV collagen (103). In addition, interaction 
via fibronectin with collagen found in specific tissues offers the pathogen multiple potential 
attachment sites such as fibronectin-mediated binding to collagen fibres that can allow the pathogen 
to colonize acellular tissue and collagen-binding integrins that may serve as subsequent receptors, 
th us rendering distinct cell types susceptible to S. suis attachment. 
On the other hand, we have also demonstrated that S. suis also binds to plasma (soluble) and 
cellular (solid-phase attached) fibronectin. Other pathogenic microorganisms have been reported to 
interact differentially with soluble versus solid-phase fibronectin. S. sanguis, group B streptococci 
and Yersinia sp. bind fibronectin adherent to a solid phase but do not bind soluble fibronectin (77, 
87). In contrast, S. aureus and S. mutans binds fibronectin in both phases (15, 73), which is similar 
to the situation with S. suis. It was speculated that the surface domains presented by soluble and 
sol id-phase fibronectin differ considerably (90). Since soluble fibronectin is ubiquitous in body 
fluids, it is logical that bacteria might evolve fibronectin-binding proteins which are not saturated 
by fibronectin in plasma, so that they may attach directly to tissue- or foreign body-associated 
fibronectin (15). In addition, bindingof soluble fibronectin may facilitate the extravasation or 
migration from oral compartments to distant regions of the body, and coating of the microorganism 
with soluble fibronectin may facilitate escape from ho st immune surveillance (15). 
Similar to collagen, fibronectin is also a high-molecular-weight glycoprotein that binds to 
membrane spanning receptor integrins (91). This adhesion helps maintain the shape of cells by 
lining up and organizing intracellular cytoskeleton, but in addition, permit bacteria to invade the 
cells by activating the cytoskeleton of the cell via fibronectin-attached integrins (l). In addition to 
integrins, fibronectin also bind other extracellular matrix components such as collagen and fibrin 
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indicating that microorganisms may bind to circulating fibronectin and become attached to tissues 
through fibronectin-fibrin, fibronectin-collagen, or fibronectin-fibronectin interactions (96). In the 
case of S. suis, its binding to fibronectin could have different important functions in the 
development of the infection. First of ail, it can impede that bacteria are rapidly cleared from the 
circulation since it permits bacteria to adhere to ECM-forming ce Ils, secondary, it can hide 
important antigens impeding bacterial recognition by the immune system (antibodies and 
complement) from the host, and as consequence, its elimination (98). Finally, this adhesion can also 
permit bacteria to bind to cell receptors such as integrins, activating the host signal transduction for 
intracellular polymerization and reorganization of actin filaments (98) and, as consequence, can 
permit S. suis to cross host barriers such as BBB by invading the host cells forming these barriers. 
In fact, it has been demonstrated that invasion of S. suis to PB MEC is an actin-dependent process 
(94) indicating the participation of integrins, of sorne ECM proteins such as fibronectin and, of 
probably, a fibronectin-binding adhesin of s~ suis in this process. It is important to remark that, 
although a fibronectin-fibrinogen-binding protein (FBPS) with capacity to bind to these ECM 
proteins has been described for S. suis before this work and a mutant lacking this protein was 
constructed (19), the ability of this mutant to bind to fibronectin compared to its parental strain has 
never been studied before. Our results indicate that the tbps knock-out mutant binds to fibronectin 
in a similar way th an its parental strain. In addition, it has also been demonstrated that the isogenic 
mutant for this protein binds to PBMEC cells at similar levels as those presented by the wild-type 
parental strain (94). These results indicate that other fibronectin-binding proteins are implicated in 
the fibronectin-adhesion process of S. suis. This is not the first case that more than one fibronectin-
binding protein is described for the same bacteria, for example, in the case of S. pyogenes, StbI 
protein or protein FI (34, 86), GAPDH (68), M3 (76), FBP54 (16), protein H (27), StbWOF (50), 
F2 (41), MI (18) and PFBP (75) have been identified among others as S. pyogenes surface 
molecules that bind to fibronectin. 
The bacterial ligands that allow binding to ECM proteins could be either a protein or other 
bacterial surface component (17). To determine which sort of molecules are responsible of the 
adhesion of S. suis to fibronectin and/or collagen, different treatments were done. The dramatic 
reduction in the binding of both, fibronectin and collagen, by trypsin-, pronase-, and proteinase K-
treated bacteria indicates that, in the case of S. suis, these adhesions are mediated by a protein. This 
conclusion is supported by the fact that heat treatments (60°C and 100°C) also decreased binding to 
ECM proteins. In other species, it has been proposed that bacterial capsule could also participate in 
the binding between pathogens and cells, probably via its ECM proteins (97). However, our 
hypothesis that proteins, instead of capsule, are the principal responsible of S. suis adhesion to 
fibronectin and collagens is supported by the fact that an unencapsulated mutant binds more to these 
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proteins than its encapsulated parental strain. Moreover, this unencapsulated mutant also has the 
ability to bind to other ECM proteins such as vitronectin and laminin indicating that capsule could 
be hiding the adhesins responsible for these adhesions. These results confirm that capsule does not 
participate in the S. suis-ECM protein adhesion and that, as showed before, proteins are the major 
responsible for these adhesions. In addition, cross-inhibition was observed between soluble 
fibronectin and collagen indicating that fibronectin and collagen binding domains exist on the same 
or nearby bacterial surface adhesins. Similar results were obtained with GBS by Tamura and 
Rubens (87). 
The second objective of this work was to identify and characterise the adhesins involved in 
the fibronectin and/or collagen binding activity of S. suis. Sorne bacterial adhesins are highly 
specific whereas other recognize more than one protein (98). ln an attempt to identify sorne S. suis 
collagen-binding proteins we have identified by "plasmid rescue" (82) (Annex 6, Fig 2) eight 
different genes that seem to be implicated in this adhesion (Annex 6 Table 1). To date, the best 
studied collagen-binding protein of Gram-positive cocci is the Cna surface prote in of S. aureus (74). 
The mature Cna protein (135 kDa) has a typical MSCRAMM structure (see below) containing two 
domains, the collagen type I-binding 500 aa A-region and a repeated B-region (74). However, in 
contrast to the fibronectin MSCRAMMs, no defined function has been described for the repeated 
domain ofthis collagen adhesin (74). In this protein, a 19-kDa subdomain within the A domain was 
found to be responsible for the majority of collagen binding activity (74). Although the eight genes 
identified in S. suis seem to participate in its collagen-binding activity, any of them has the typical 
bacterial collagen-binding protein structure described here neither any of them seem to participate 
in the export of the collagen-binding proteins to the surface of bacteria. These results indicate that 
other methods have to be used to identify the proteins responsible for the adhesion of S. suis to 
collagen and that, further research is necessary to determine the role of the genes identified in this 
work in the capacity of S. suis to bind to collagen. 
On the other hand, the identification of a new S. suis fibronectin-binding prote in was done 
by another approach. Briefly, a Iysate of bacterialproteins was passed through a human fibronectin-
coupled column and the proteins with affinity for fibronectin were eluted after washing the other S. 
suis molecules with no affinity for fibronectin from the column. The recovered S. suis fibronectin-
binding proteins were then visualised with coomasie blue staining and the amino-terminal sequence 
of a predominant S. suis fibronectin-binding protein of about 52 kOa was sequenced. Although we 
expected for a typical bacterial fibronectin-binding prote in with. high homology with other 
described streptococci fibronectin-binding protein, the BLAST analysis of the am ino-terminal 
sequence of this 52 KOa protein revealed that this protein is an a-enolase with more th an 93% of 
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similarity with other described bacterial enolases (66). a-enolase is one of the key glycolytic 
enzymes (1) found generally in the cytoplasm, nevertheless, its presence on the surface of cells is 
not without precedent. An a-enolase has been identified on the surface of many eukaryotic cells 
such as on the surface of neuronal, cancer and sorne haemopoietic cells (54, 59, 63). In addition it 
has also been described in the surface of several types of bacteria, including streptococci and 
staphylococci, fungi and nematode (5, 44, 45,60,67,81). The identity ofthis enzyme as a-enolase 
was confirmed by biochemical and a functionality tests. In fact we have demonstrated that this 
bacterial protein is able to convert the phosphoglycerate to phosphoenolpyruvate as it normally 
occurs in the cell glycolysis process (1). This new S. suis fibronectin-binding prote in was named 
SsEno for Streptococcus suis Enolase. It is important to note that this is the first time that the 
fibronectin-binding activity of an a-enolase is described. 
As SsEno is a predominant fibronectin-binding prote in of S. suis and as S. suis is mainly a 
swine pathogen we decided to test the capacity of this new described protein to adhere to porcine 
fibronectin. However, as explained before, porcine fibronectin is not commercially available so we 
decided to create a new protocol to purifY fibronectin from porcine blood plasma (Annex 1). Using 
the known high affinity of fibronectin for gelatine and a posterior HLPC purification (Annexl, Fig 
1,2 and 3) we obtained a high pure porcine blood plasma fibronectin (Annex 1, Fig 3). This prote in 
was used to demonstrate that SsEno has not only high affinity for human fibronectin but also a 
similar high affinity for porcine fibronectin (Annex l, Fig 4). These results indicate that this 
pathogen can use this ECM prote in to enhance its infection in both, swine and human hosts. 
Interestingly, recent studies demonstrate that other described streptococcal enolases have not this 
ability to bind fibronectin (2), suggesting that interaction of enolase with fibronectin may have 
different function in S. suis than in other pathogenic bacteria. 
The main function of surface enolases described before this work is their capacity to bind 
plasminogen (66). This feature was first demonstrated for eukaryotic surface enolases and later for 
prokaryotic enolases (66). We have demonstrated that, in addition to its fibronectin-binding activity, 
SsEno also binds to plasminogen as it has been previously described for ail the other bacterial 
enolases (2). Interestingly, SsEno binds to fibronectin with a similar affinity than to plasminogen, 
indicating that both functions could be of high importance for this pathogen. However, in contrast 
with the S. aureus enolase (7), SsEno has not the ability to bind to laminin, corroboring that this 
prote in can have different roles depending on the pathogen. As we observed cross-inhibition with 
. soluble fibronectin and collagen in the ELISA assay of the first objective, we test the capacity of 
SsEno to adhere to collagen. However our results showed that this protein does not possess this 
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binding activity (Anne x 5, Fig. 1) indicating that SsEno is not the surface protein responsible for the 
cross-inhibition between fibronectin and collagen. 
We have also demonstrated that in addition to its fibronectin and plasminogen-binding 
activity, SsEno has also IgG-binding activity (Annex 4, Fig 1). This is not the first time that it is 
described that a fibronectin-binding protein has IgG-binding activity. In fact, the fibronectin-
1 
binding protein 1 (Sfbl) of S. pyogenes, a main adhesin and invasion ofthis pathogen, is also able to 
bind to human, mouse, rabbit, pig and horse IgG (58). We have demonstrated in this work that 
SsEno is able to bind to porcine and human IgG and to IgY. This is the first time; to our knowledge, 
that the IgY -binding activity of a bacterial prote in is described. It remains to be determined whether 
these IgG-binding. activities of SsEno can contribute to the pathogenesis of the infection. It is 
commonly believed that the IgG-binding activities can favor bacterial immune evasion following 
infection by interfering with host clearance mechanisms (58). This hypothesis is supported by the 
fact that a-enolase is not only present in the cytosol and the surface of bacteria but it is also 
secreted by S. suis. This secrection can permit bacteria to evade host immunoglobulins since 
secreted SsEno binds to them before they recognize the pathogen. In addition, it has been 
demonstrated that S. sobrinus enolase stimulates an early production of interleukin-lO, an anti-
inflammatory cytokine, and not the pro-inflammatory cytokine IFN-y indicating that, in this specie, 
enolase acts in the suppression ofthe specific host immune response against S. sobrinus infec,tion as 
an immunosuppresive prote in (95). However, this enolase function has not been yet investigated in 
S. suis and further investigation is needed to confirm it. 
The enolase from microorganisms such as Saccharomyces cerevisiae (39) and 
Lactobacil/us rhamnosus (72) has also been described as a heat shock protein. A heat shock prote in 
is a specific prote in expressed and/or secreted by cells that permit its adaptation to extreme 
environments such as high temperatures (66). In our effort to characterize SsEno we have also 
described that SsEno is also heat shock protein (Annex 3, Fig 1). In S. suis, it can be proposed that 
upregulation of enolase is involved in thermal tolerance and growth control of bacteria. These 
results showed in this work confirm that a-enolase should not be more considered as a 
housekeeping enzyme since its expression varies depending on the pathophysiological, metabolic or 
developmental conditions of cells. Furthermore, these results confirm that SsEno is a 
multifunctional prote in that can participate in the different steps ofthe pathogenesis of the infection 
caused by this pathogen depending on the function it develops in each moment. 
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To be a fibronectin-plasminogen and IgG-binding prote in, SsEno has to be present on the 
surface of S. suis. In fact, we have shown by several methods that SsEno is present in the surface of 
ail the described S. suis serotypes (Annex 2, Fig 1) corroborating its role as possible adhesin. Up to 
now, three types of streptococcal fibronectin-binding adhesins have been identified (14). The first 
ones are the MSCRAMM (microbial surface component recognizing adhesive matrix molecules) 
proteins, which are the most abundant type (more than 90% of the bacterial fibronectin-binding 
proteins) (70). This adhesin contains a signal sequence at N-terminal and a LPXTG motif at C-
terminal domain which is recognized by a transpeptidase called sortase (69). As explained before, 
sortase is a multifunctional protease-transpeptidase that specifically c1eaves the LPXTG sequence in 
a protein and catalyzes the transfer of the processed prote in to the free amino group of pentaglycine 
cross-bridges in peptidoglycan. The second type of fibrqnectin-binding protein is the choline-
binding proteins (32). This sort of proteins lacks the LPXTG motif but contained carboxy-terminal 
choline-binding repeats that interact with the phosphorylcholine of the lipoteichoic acid of Gram-
positive bacteria. Final!y, the last type described is the new denominated anchorless-proteins (14). 
These types of protein lack the conventional leader sequence, the LPXTG motif and the choline-
binding sequences. Tt is important to note that up to now, the mechanism used for these last type of 
proteins to reach the surface ofbacteria is still unknown. We have demonstrated (Annex 8, Fig. 2) 
that the ability of a S. suis mutant strain lacking the srtA to interact with fibronectin is reduced 
compared to the wild-type strain. However, it still possesses more than 70% of its fibronectin-
binding activity, indicating that, although surface proteins anchored by sortase A are required for a 
normal level of bacterial binding, other proteins different than MSCRAMM are the principal 
adhesins involved in the interaction between S. suis and fibronectin. The amino acid sequence 
analysis of SsEno shows that this protein does not possess an N-terminal signal sequence and an 
anchor carboxyl terminus LPXTG motif, the crucial domains for translocation through the cell wall 
and for anchoring surface proteins to the Gram-positive bacterial cell wall (26). Furthermore, 
repeats typical of choline-binding proteiris such as those described for the choline-binding protein 
of S. pneumoniae (102) are also not present on SsEno. Ail these features classify SsEno as one of 
the new anchorless-type adhesins and confirm our previous results indicating that the major S. suis 
fibronectin-binding protèins do not belong to the MSCRAMM family of proteins. In addition to its 
surface localisation, SsEno is also present in al! the other subcel!ular compartiments of the bacteria 
and.it is also secreted to the medium. It is largely unknown how glycolytic enzymes like enolase 
and GAPDH that lack a signal peptide required for secretion and peptidoglycan-anchoring motifs 
are transported. to and associated with bacterial surface structures or which factors influence this 
process. Tt also remains open as to whether these proteins are secreted across the bacterial cell 
membrane by the general secretory (Sec)pathway. One study suggested that the secretion of the 
Listeria monocytogenes enolase, which also binds plasminogen, is SecA2-dependent (52). Another 
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study speculated that surface GADPH and enolase do not come from inside the bacteria but are 
'scavenged' from other cells that have undergone programmed cel! death through allolysis (31). 
However, further research is necesary to finally understand this mystery. 
As mentioned above, the pathogenesis of S. suis infection is poorly understood at present. 
Once in the bloodstream, S. suis resists phagocytosis and killing by neutrophils and monocytes (8, 
12, 78). In the event that S. suis fails to cause acute fatal septicemia, bacteria are able to reach the 
CNS (22) via different mechanisms that are only partially elucidated and produce meningitis. One 
of the mechanisms proposed to cross the BBB is the adhesion to, and posterior invasion of the brain 
microvascular endothelial cells (BMEC) (4, 13, 93) and/or choroid plexus epithelial ce Ils (88, 89). 
As fibronectin-binding proteins have been described as important virulence factors that participate 
in adhesion to and invasion of host cells for other pathogens (14), the third objective of this work 
was to determine the role of SsEno in the pathogenesis of the infection caused by S. suis. SsEno is 
the major S. suis fibronectin-binding protein described up to now, so we proposed that the 
interactions of SsEno to fibronectin may be an important key in this mechanism. In addition, this 
hypothesis is corrobored by the fact that S. suis adhesion to and intracellular invasion ofPBMEC 
increases in more than 500% and 700% respectively when bacteria are precoated with fibronectin 
(94), indicating that this S. suis-fibronectin adhesion is an important step for the development of the 
infection. An important tool to demonstrate the role of a fibronectin-binding protein (SsEno in the 
case of S. suis) in the pathogenesis of the infection caused by this pathogen is the construction of a 
knock-out mutant. However, as SsEno is an essential enzyme that participates in the glycolysis and 
gluconeogenesis of the bacteria (1), the production of a knock-out mutant for this protein was not 
possible. Another method cou Id be a knock-out mutant for the export system of this prote in to the 
bacterial surface however, aS this mechanism is still unknown, this approach was also not possible. 
The alternative method that we used to determine the role of this adhesin in the adhesion to and 
invasion to host ce Ils was by blocking the SsEno function with specific antibodies againts this 
protein. Our results show that the "inactivation" of SsEno with specific antibodies against this 
adhesin significatively decreases the adhesion to and the invasion of S. suis to these host ce lis 
corroborating that the S. suis fibronectin-adhesion is an important stepof the infection and 
demonstrating that the adhesion of S. suis to fibronectin via its SsEno is important for this process. 
On the other hand, although the adhesion to and invasion of S. suis to PBMEC was not 
increased by the addition of exogen?us plasminogen, a certain role of the plasminogen-binding 
activity of SsEno in the pathogenesis of the infection caused by S. suis cannot be ruled out. It has 
been previously demonstrated that plasminogen adhered to S. suis is able to acquire plasmin activity 
when it is incubated with BMEC (42). As a consequence, bacterium is able to hydrolyse ECM 
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proteins, such as fibronectin, and destabilise the cells forming barriers. Once bacteria de grade the 
ECM, cells loss their stability and start to die by anoikis (28). Anoikis is a type of cell death that 
produces "holes" in the barriers. These "holes" can be used by pathogens to facilitate their 
penetration through biological membranes (28). To demonstrate this hypothesis, future work using, 
for example, a transwell system could be done (Fig. 2). This system permits to determine if the 
presence of a substance in the medium (in our case plasminogen) enhance bacteria to cross a 
monolayer of BMEC. This method consists in, as it is shown in Fig 2, two compartments separated 
by a porous membrane where cells, in this case BMEC, grow. Once cells form a monolayer, both 
compartments are physicaly separated implicating that if you put bacteria in the upper compartment 
and after a period of time you recover bacteria from the inner compartment is because bacteria have 
crossed the ceIl monolayer intracellularly (invading cells) or intercellularly (by broking the cell 
junctions). The transwell method also permits to know which method is using bacteria to cross the 
cell monolayer by measuring the transendothelial electricaJ resistance (TEER). If bacteria cross the 
cell monolayers by invading cells, cells monolayer integrity is Dot disturbed and the TEER will not 
change. In contrast if bacteria broke the junctions between cells, TEER will be modified. 
s. suis + plasminogen 
-
Upper compartment 
- 1 - 1 - 1 - 1 --
••••••••••••••• 
r 
Inner compartment 
S. suis recovery???? 
"""" 
B 
, 
BB monolayer 
(TEER) 
Fig 2. Transwell system. Upper and inner compartments are separated by a porous membrane where 
BMEC grow to a confluent monolayer of cells producing a stable TEER. S. suis with or without 
plasminogen can be introduced in the upper compartment and invasion can be measured by recovering or 
not bacteria from the inner compartment. Changes in TEER indicates if the bacteria cross the monolayer 
bv invasion or bv brokin!.! the iunctions between cells. 
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As a result of its critical role in the infection process, bacterial adherence to host tissues 
represents a potential target for the development of new antimicrobial agents. As explairied before, 
different types of vaccine against S. suis infections have been developed or are currently under 
investigation. At present, bacterins (commercial and autogenous) have been used in the field to 
prevent S. suis disease. However, disappointed results are usually obtained since these vaccines do 
not induce high levels of antibodies and they are serotype-specific (37). Recently, we have 
demonstrated that a surface expressed protein (Sao) confers protection against an experimental 
infection in mice and pigs (53)(Annex 7). However, this protection was not complete, which 
indicates that other proteins should probably be combined with Sao to optimize the protective 
capacity. 
Agents that can block adherence, such as specific antibodies, may prove to be effective in 
combating infectious disease. In fact, fibronectin-binding proteins have been suggested as potential 
vaccine targets for preventing bacterial infections because antibodies directed aga in st such adhesins 
may prevent bacterial attachment and inhibit colonization (100). As SsEno is the major fibronectin-
binding prote in described for S. suis up to now, the last objective of this work was to test its 
potential as vaccine candidate in a septicemia and meningitis model in the mouse (22). SsEno has 
been chosen as a good vaccine candidate because: i) it is present in the surface of aIl the 35 different 
serotypes described up to day for S. suis (Annex 2, Fig 1) , ii) it participates in the adhesion to and 
invasion of S. suis to the host cells, iii) it is a highly conserved prote in without antigenic variation 
(24), and finally iv) it is a highly immunogenic prote in that elicits elevated antibody levels in sera 
from pigs. This is not the first time that an enolase has been tested as vaccine candidate to protect 
hosts from different organism. It has been demonstrated that anti-enolase antibodies are able to 
protect mice against Plasmodium falciparum infection (65). However, recombinant enolase from 
Candida albicans induced only a modest protection against disseminated candidiasis (61). Toour 
knowledge, this is the first time that a protection test against streptococci using enolase as antigen to 
elicit an immune response has been 'done. The results obtained in this work show that, although the 
good immune response elicited by SsEno [ail SsEno-specific IgG isotypes (IgG l, IgG2a, IgG2b and 
. IgG3) were induced], these antibodies are not able to protect mice in an experimental infection with 
S. suis. As it has been shown that antibodies derived from hyperimmune sera against who le bacteria 
can protect mice against infection (11) and induce bacteria killing (8) we hypothesized that this lack 
of protection is due to the fact that anti-SsEno antibodies are not opsonic, permitting bacteria to 
reproduce in high numbers and cause disease. To verify this hypothesis we evaluated the capacity of 
the purified anti-SsEno JgGs to opsonise bacteria and promote their killing by the murine 
phagocytes. The results obtained in this work showed that, although SsEno elicits an important 
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immune response in convalescènt pigs and immunized mice, the produced anti-SsEno IgGs are not 
able to induce the S. suis killing by mouse phagocytes being this response inadequate for protection 
against S. suis infections. 
[n conclusion, although we have not found the "good" vaccine candidate against S. suis 
infections, this work is important because it provides new advances in the study of the infectious 
process produced by S. suis and permits a better comprehension of the pathogenesis of the infection 
caused by this important pig and human pathogen (Fig. 3). In fact, we have described for the first 
time that the pathogen S. suis is able to adhere to fibronectin and collagen, the two main 
components of the ECM. In addition, we have identified new genes that participate in the adhesion 
of S. suis to collagen. Moreover, we have also identified and characterized a new S. suis 
multifunctional adhesin with fibronectin-plasminogen and IgG-binding activities that participates in 
. the adhesion to and invasion of this pathogen to the endothelial cells forming the BBB which can 
permit bacteria to cross this host barrier to the CNS and produce meningitis. Tt is important to 
remark that this is the first time that the fibronectin and the IgG-binding activities of a bacterial (X- . 
enolase are described. Finally, we have also described that SsEno is a heat shock protein that could 
be involved in thermal tolerance and growth control ofbacteria. 
Upper respiratory tract 
bloodstream 
2- Fibronecti n-mediated 1 CNS 
adhesion to and invasion of '--____ --' 
S.suistoBMEC 
~ 
~ 2 
1- Fibronectin-mediated 
phagocytosis evasion 
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., 
àsEnoissEnoS) ~ 0 tJ 
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3- Plasmin degradation of ECM 
proteins fonning tigh junctions 
4- BMEC anoikis 
S. suis entrance to CNS 
• S. suis ~ fibronectin 1 integrin ~ Plasminlogen l Tigh junction ~Phagocyte 
Fig 3. Potential roles of SsEno in the pathogenesis of the infection caused by S. suis. The new described 
multifunctional SsEno adhesin can participate in the pathogenesis of the infection caused by S. suis by several 
ways, As fibronectin-binding protein, this prote in can permit the evasion of S. suis from the immune system cens 
since fibronectin-coated S. suis can not be recognised by these cens as an exogen particle and, as consequence, it is 
not phagocytosed and killed by these cens (1). In addition, the SsEno adhered fibronectin can also be recognised 
by the integrins on the surface of several cells such as the BMEC, producing the activation of its cytoskeletton and 
permitting the invasion of this pathogen to these cells (2). This mechanism is considered as one of the ways by 
which bacteria is able to cross sorne host barriers such as the BBB. Finally, the plasminogen-binding activity of 
this protein can permit bacteria to adhere to plasminogen that, in presence of plasminogen activators normally 
secreted by host cells, is converted in the protease plasmin. This protease is able to degrade the ECM-forming 
junctions between cells (3) provoking anoikis (4) and as consequence, holes in the barriers by where bacteria can 
traverse to the CNS (5), 
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v. GENERAL CONCLUSIONS 
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• Streptococcus suis adhere to sorne of the components of the ECM such as plasma and 
cellular fibronectin and collagen types 1, III and V. However, although S. suis can not 
directly bind to collagen type IV, this pathogen can use plasma fibronectin as a bridge to 
permit this adhesion. This mechanism can be considered as a new mechanism of 
colonisation and evasion. 
• The adhesins involved in these adhesions are mostly proteins. However, although most of 
the bacterial fibronectin-binding proteins are MSCRAMMs, in the case of S. suis these type 
of adhesins are responsible of less th an 30 % of these adhesions. The other 70 % of 
adhesion can be do ne by choline-binding proteins or by the new denominated anchorless-
proteins. 
• The major S. suis fibronectin-binding protein described up to day is the surface D-enolase. 
As expected, this fibronectin-binding prote in is not an MSCRAMM but an anchorless-
binding adhesion. 
• SsEno adheres to human and porcine fibronectin indicating that this protein could enhance 
the infection ofthis pathogen in both hosts 
• In addition to its fibronectin-binding activity, SsEno is also responsible of the adhesion of 
S. suis to plasminogen and to IgG from human, porcine and chicken origin. 
'. SsEno is also a HSP confirming that this protein can not be more considered as a 
housekeeping enzyme. 
• SsEno participates in the adhesion to and invasion of brain microvascular endothelial cells 
(BMEC), the ce Ils forming the BBB, which implies that this prote in can be considered as a 
new virulence factor that participate in the pathogenesis of the infection caused by S. suis 
• Although SsEno is a highly conserved immunogenic protein present in ail the described 
serotypes of S. suis, this prote in does not develop an effective immune response able to 
protect host from S. suis infections. These results suggest that antibodies against other S. 
suis components are the responsible of the solid immunity developed in pigs that have 
undergone infections caused by this pathogen and that new efforts have to be done to 
finally developed the effective vaccine. 
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• Despite the fact that sorne of the steps involved in the pathogenesis of S. suis meningitis 
remains to be solved, our findings in this work suggest that adhesion of S. suis, via SsEno, 
to the fibronectin present in the cells forming BBB represent a key step in the development 
of the disease and provide a little advance in the comprehension of the pathogenesis of the 
infection caused by this important pig and human pathogen. 
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ANNE X 1 
Purification of plasma porcine fibronectin 
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One of the main objectives of this work was to study tht? capacity of the swine pathogen S. 
suis to bind to sorne of the most important ECM proteins. One of the main results of this work is 
that S. suis is able to specifically bind to fibronectin. As explained before, the adhesion of bacteria 
to fibronectin helps bacteria in the pathogenesis of the infection caused by these pathogens (2). In 
one hand, bacteria can use their fibronectin-binding proteins to bind to. soluble fibronectin 
facilitating their evasion from host immune surveillance. On the other, since fibronectin binds to 
membrane cell receptor proteins called integrins, fibronectin-coated bacteria are able to bind to 
these cell receptors permitting the activation of the cell cytoskeleton and, as consequence, the 
posterior invasion to these cells. Both mechanisms help bacteria to survive in the host and to 
develop an infection (2). 
Although S. suis. is mainly a swine pathogen, the fibronectin used in the first objective of 
this was a commercial human plasma fibronectin. However, to test the capacity of SsEno to bind to 
fibronectin we decided to test both, the human and the porcine plasma fibronectin. As this porcine 
fibronectin is not commercially available, a simple protocol for its purification from porcine serum 
was designed. 
The first step consisted in a pre-purification of fibronectin from porcine plasma using the 
high affinity of this protein for gelatin (1) (Fig. 1). Briefly, a nitrocellulose membrane was coated 
with porcine gelatin for 2 hours before its incubation with porcine blood plasma. Blood plasma is 
the liquid component of blood, in which the blood cells are suspended. It makes up about 55% of 
total blood volume. It is composed of mostly water (90% by volume), and contains dissolved 
proteins including fibronectin among other components. Plasma fibronectin is synthesized and 
secreted into the bloodstream by hepatocytes and found at 300-500 )lg per ml in plasma (3). The 
porcine blood plasma used in this work was prepared simply by spinning a tube, of fresh blood until 
the blood cens fan to the bottom of the tube. The blood plasma was then recovered and kept at -
20°C until its utilization. 
As explained, porcine blood serum was incubated for 2 hours with the gelatin coated 
nitrocellulose membrane. After that, membrane was washed three times with PBS to eliminate ail 
the proteins that did not bind to gelatin and the gelatin attached proteins (including fibronectin) 
were eluted using Urea 8M. 
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Fig 1. Porcine plasma fibronectin purification. Porcine plasma fibronectin was purified from porcine fresh 
blood using gelatine-coated nitrocellulose membranes. After two hOUTS of incubation, non attached proteins 
were washed and fibronectin was recovered by elution with Urea 8M. 
After this first step, different proteins, including the 250 kDa fibronectin protein, 
were obtained (Fig. 2) 
250 kDa 
150 kDa 
100 kDa 
75 kDa 
50 kDa 
37 kDa 
25 kDa 
porcine plasma fibronectln 
other plasma proteins 
Fig 2. Proteins 
recovered after the 
first step of the 
purification of porcine 
plasma fibronectin. 
Plasma fibronectin was 
incubated with gelatin-
coated nitrocellulose 
membranes and the 
proteins with high 
affinity for gelatin were 
eluted using Urea 8M, 
separated with 10% 
SDS gel and stained 
with coomasie blue. 
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To purify fibronectin from aIl the other proteins obtained in step l, we performed a High-
performance liquid chromatography (HPLC). HPLC is a form of colurnn chromatography used 
frequently to separate, identify, and quantify compounds. This method utilizes a colurnn that holds 
chromatographie packing material (stationary phase), a pump that moves the mobile phase(s) 
through the colurnn, and a detector that shows the retention times of the molecules. Retention time 
varies depending on the interactions between the stationary phase, molecules being analyzed, and 
the solvent(s) used. The binding buffer used was 20 mM Tris HCl, pH 8. The elution buffer used 
was 20 mM Tris-HCl, 1 M NaCl. We tried different elution buffer pHs and different times of 
elution to find the best protocol. The different pH used were pH 4, pH 7 and finally pH 10. We also 
tried as elution times 15, 30 and 45 minutes. The protocol that worked best was that with pH 7 and 
45 minutes of elution (Fig. 3). In these conditions we obtained 2 peaks. The first one did not contain 
fibronectin whereas the second one contained high pure fibronectin (Fig.3) 
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Fig 3. Porcine fibronectin purification. The recovered proteins of the step 1 were separated using 
HPLC. With an elution time of 45 minutes and an elution buffer pH 7 two peaks were obtained. By SDS-
PAGE and coomasie blue staining we concluded that the second peak con tains a high pure (2: 99% of 
purity) porcine plasma fibronectin. 
XXV111 
The obtained purified porcine plasma fibronectin was used to test the adhesion of SsEno to 
tbis fibronectin by Western blot. Results obtained showed in Fig 4 demonstrate that in addition to 
its adhesion to human fibronectin, SsEno also adheres to porcine fibronectin, indicating that S. suis 
can use the fibronectin-binding activity of SsEno as a mechanism to colonize, adhere to and invade 
cells from both hosts, buman and swine. 
A B c D 
+--SsEno 
J 
Fig 4. SsEno is able to adhere to human and porcin fibronectin. S. suis proteins, including SsEno (arrow) 
were detennined by SDS-PAGE (12.5%) followed by Coomasie blue staining (B). Proteins were transferred 
to a nitrocellulose membrane and the fibronectin-binding activity of SsEno was detennined by Far western 
blot using commercial human (C) and porcine plasma purified (D) fibronectin. Molecular mark ers (A) were 
250,150,100,75,50,37,25 and 17 kDa. 
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ANNEX2 
SsEno is present in ail the 35 described serotypes for S. suis 
xxx 
Streptococcus suis is a major porcine pathogen worldwide that, in addition, can be 
transmitted to human beings by close contact with sick or carrier pigs (5). S suis causes meningitis, 
septicaemia and septic shock among other diseases in both pigs and human (5). Moreover, it can 
also produce the death (5). Human infection with S suis occurs mainly among certain risk groups 
that have frequent exposure to pigs or pork (5). Outbreaks ofhuman S suis infection are uncommon, 
although severa) outbreaks havè occurred in Asia in recent years (7). In July, 2005, the largest 
outbreak of human S. suis infection occurred in Sichuan province, China, where 204 peoplewere 
infected and 38 of them died. There have been more than 400 cases of human S. 'suis infection 
worldwide, most of which have occurred in China, Thailand, and the Netherlands, and these 
infections have led more than 70 deaths (7). 
Among the 35 serotypes described, the serotype 2 has always been considered the most 
virulent and the most frequently isolated serotype from diseased animais (3). However and as 
explained in this work, the situation may be different depending the geographical location and also, 
• throughout the time. The percentage of S. suis serotype 2 strains isolated from diseased animais in 
North America remained relatively low compared with those reported in sorne European countries, 
such as France, Italy and Spain, where most of isolates recovered from diseased animais belong to 
serotype 2 (1, 9). In thisregard, it may be hypothesized that European and North American 
serotype 2 strains of S. suis possess a different virulence potential (3). In addition, under specific 
circumstances, sorne strains belonging to other serotypes of S. suis appear highly virulent, as it is 
the case for serotype 14 in UK (4), serotypes 1/2 (unpublished observations M.Gottschalk) and 5 (2) 
in Canada and serotype 9 in central Europe (9). In contrast of what occurs in swine, except for two 
human S. suis infection cases caused by serotype 1 (although not serologically confirmed), two 
cases of septicemia caused by serotype 14 and one case caused by serotype 4, ail other human S. 
suis infections are attributed to serotype 2 (6, 8). 
At the present time, vaccination of pigs to prevent swine infections but also human 
infections is generally carried out with autogenous bacterins but results are equivocal. Up to day, 
several S. suis virulence factors have been tested as vaccines candidates, however, most of them 
protected only against a homologous strain ofthis pathogen. 
We have demonstrated in this work that SsEno is a S. suis multifunctional adhesin with 
fibronectin-binding activity. It has been demonstrated that agents that can block adherence, such as 
specific antibodies, may prove to be effective in combating infectious disease. In fact, fibronectin-
binding proteins have been suggested as potential vaccine targets for preventing bacterial infections 
because antibodies directed against such adhesins may prevent bacterial attachment and inhibit 
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colonization (10). As SsEno is an important fibronectin-binding protein of S. suis, we can 
hypothesise that it can be an interesting candidate to be used as a vaccine against S. suis infections. 
However, to be a good candidate for a vaccine, SsEno had to be present at the surface of all the 
serotypes described for this pathogen. 
To test the presence of SsEno in the surface of ail the described S. suis serotypes, the 
reference strain of each serotype was grown ovemight onto sheep blood agar plates at 37°C and 
isolated colonies used as inocula for 5 ml of Todd-Hewitt broth (THB; Difco Laboratories), which 
was incubated for 8 h at 37°C with agitation. Working cultures were prepared by transferring 10 III 
of 1/1000 dilutions of 8-h cultures into 30 ml ofTHB which was incubated for 16 h at 37°C with 
agitation. Stationary phase bacteria were washed twice in PBS (pH 7.3). Bacterial pellet was then 
resuspended in THB until an OD600 nm value of 0.4 was achieved, which corresponded to 5 X 108 
CFU/ml. Twenty-five microlitres of this dilution was blotted in a nitrocellulose membrane and air-
dried. The membrane was theil blocked in Tris buffered saline (TBS) containing 2% case in for 1 h 
with agitation, then incubated 2 h in the specific rabbit anti-SsEno antibodies produced as described 
in this work. The membrane was then washed in TBS, and incubated 1 h with the anti-
rabbitlhorseradish peroxydase conjugate (Jackson Immunoresearch), diluted 1/2000 in TBS. The 
membranes were th en washed again in TBS before the addition of the 4-chloronaphtollhydrogen 
peroxyde based revelator for 15 min, washed in water and dried. 
The results obtained demonstrated that this prote in was present in the surface of all the 
reference strains of the 35 S. suis described serotypes (Fig. 1) corroborating that this protein was an 
interesting candidate to be used as an antigen in a protection assay against a S. suis infection. 
Fig. 1. SsEno is present at the surface of ail the described S. suis serotypes. The same 
concentration of each one of the reference strains of the 35 serotypes of S. suis were grown in THB 
before being blotted in a nitrocellulose membrane. The detection of SsEno was done with rabbit 
anti-SsEno antibodies. Each square represent a serotype of S. suis. PBS was used as a negative 
control. 
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ANNEX3 
Characterisation of SsEno as a heat shock protein (HSP) 
XXXIV 
In adapting to extreme environments such as high temperature or glucose deprivation, cells 
often secrete or express specific proteins known as heat-shock proteins (HSPs) (5). It has been 
demonstrated that vascular endothelial ce Ils in a similarly stressful situation such as chronic 
hypoxia respond by upregulating the expression of a unique set of five ceU-associated stress 
proteins (Mr 34,36,39,47 and 57) in a time- and oxygen concentration-dependent manner (3). The 
52-kDa prote in has been identified as a-enolase. This was the first time that an a-enolase was 
identified as a HSP. It is proposed that in a hypoxic situation, upregulation of a-enolase may . 
provide protection to cells by increasing anaerobic metabolism (1). Later, it has been demonstrated 
that in Saccharomyces cerevisiae several HSPs were also induced at elevated temperatures. One of 
these HSPs, HSP48, was also ide~tified as a-enolase (4). Finally, it has been demonstrated that the 
HtrA surface protease in gram-positive bacteria is involved in the processing and maturation of 
extracellular proteins and degradation of abnormal or misfolded proteins (2). Inactivation of htrA in 
S. mutans has been shown to affect the tolerance to thermal and environmental stress and to reduce 
virulence (2). This inactivation also resulted in a reduced ability to withstand exposure to low and 
high temperatures, low pH, and oxidative and DNA damaging agents (2). In addition, the htrA 
mutation affected surface expression of several extracellular proteins including enolase and 
glyceraldehyde-3-phosphate dehydrogenease, two glycolytic enzymes th~t are known to be present 
on the streptococcal cell surface (2). 
As we have identify the S. suis enolase (SsEno), we investigated if a change in growth 
tempe rature could also influence the production of SsEno as it has been described in the other 
. works described before (2, 4). The ability of strain 166' of S. suis serotype 2 to respond to a heat 
stress via SsEno was assessed by growing the organism at 37°C in Todd-Hewitt broth (THB) and 
then shifting the temperature to 42°C for 2 h. Optical density was recorded in order to measure cell 
growth. One ml of each culture was centrifuged for 5 min at 12 OOOxg and the supematant was 
discarded. The same quantity of prote in for the stressed and unstressed ce Ils was subjected to SDS-
PAGE using a 10% gel. The identity of the SsEno as hsp was confirmed by immunoblotting using 
the specific polyclonal antibody against SsEno. 
The results obtained showed that after 2 h growth at 42°C compared with the control 
culture grown at 37°C an increase in expression of the 52-kDa prote in, determined as SsEno by 
Western blot using the purified rab bit anti-SsEno IgG, was observed as expected for a Hsp (Figure 
1 ). 
xxxv 
Regarding this results we can conc1ude that, in addition to a fibronectin and plasminogen-
binding protein, this enzyme has also heat shock activity that, as it has been demonstrated for other 
pathogens, could be involved in the thermal tolerance and the growth control in this pathogen. 
However, further research is necessary to confirm this hypothesis. 
A 1 2 3 B 1 2 3 
Fig. 1. SsEno is a heat shock protein. Cells were grown at 37°C and the tempe rature shifted to 42°C 
for 2 h. Coomassie blue-stained gel (A) and nitrocellulose blot incubated with polyclonal anti-SsEno 
antibody (B) showed the heat shock activity of SsEno. Lane l, molecular marker (kDa); lane 2, cells 
kept al 37°C; lane 3, ce Ils shifted to 42°C. 
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ANNEX4 
Characterisation of SsEno as an IgG-binding protein 
XXXVll 
The expression of bacterial surface proteins that interact nonspecifically with 
immunoglobulins (Igs) from different mammalian species has been described for many 
microorganisms (2). Nonimmune binding to Igs is generally mediated by the Fc fragment of the Ig 
molecules (2). However, few of these proteins can also bind the F(ab')2 fragment through an 
alternative binding pathway (2). The consistent presence of these Ig-binding proteins in many 
pathogenic bacteria suggests that these molecules might be required for bacterial survival during the 
infection process. 
8ased on their binding activities with IgG from various host species, different types of IgG-
binding proteins have been proposed. Well-known examples of such proteins are protein A from S. 
aureus (3) and protein G (6) from group C and G streptococci, both of which preferentially bind 
IgG. Sorne group A streptococcal proteins have been purified and extensively characterized: protein 
Arp (1), which preferentially binds IgA; protein H (4), which binds IgG; and prote in Sir (7), which 
binds IgA and IgG. These various Ig-binding proteins are valuable as immunochemical tools and as 
model systems with which to study the interactions between Ig and specific receptors. In addition, 
sorne reports have demonstrated an association betw~en expression of Ig-binding proteins by group 
A streptococci and the ability ofthese microorganisms to elude ho st defenses (5). 
Sorne Ig-binding proteins were shown to bind other plasma proteins, such as album in and 
fibronectin (5). [n fact, it has been described that fibronectin-binding protein 1 (SfbI) of S. 
pyogenes, a main adhesin and invasin, also binds to human IgG in a nonimmune fashion through 
the Fc component (5). This binding affected Fc-mediated phagocytosis by macrophages and 
antibody-dependent cell-mediated cytotoxicity. SfbI was also reactive with mouse, rabbit, pig, and 
horse IgG (5): 
As SsEno has been described in this work as an important S. suis fibronectin-binding 
prote in, the ability of this protein to bind to IgG was also tested. We tested IgG from different 
species, the two main host of S. suis (pig and human) and chicken IgG (lgY). 
Results showed in Fig 1 demonstrate that, in addition to its fibronectin- and plasminogen-
binding and heat-shock activities, SsEno is also able to adhere to human, porcine and chicken IgGs. 
In fact, this is the first time that the IgY -binding capacity of a bacterial protein is demonstrated. 
The chicken. immune system has been studied for many years and these studies have 
contributed substantially to our understanding of the fundamental concepts of immunology and the 
development of different immunoglobulin classes. It is thus surprising that only a small fraction of 
the antibodies presently used in laboratories are of avian origin. A laying hen produces more yolk 
antibodies than a rab bit can produce during the same time period, and the animal care costs are· 
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lower for the chic ken compared to the rabbit. Chicken antibodies offer many advantages to the 
traditional mammalian antibodies when used for the detection of mammalian antigen. Due to the 
evolutionary difference chicken IgY will react with more epitopes on a mammalian antigen, which 
will give an amplification of the signal. Chicken antibodies can also be used to avoid interference in 
immunological assays caused by the human complement system, rheumatoid factors, human anti-
mouse IgG antibodies or human and bacterial Fc-receptors. The antibodies can be purified in large 
amounts from egg yolk, making laying hens highly efficient producers of polyclonal antibodies. 
However, up to day it does not exist a rapid and simple protocol for their purification. Our results 
open the door for a new method for IgY purification using SsEno as a ligand. 
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ANNEX5 
Characterisation of SsEno as a collagen-binding protein 
xli 
ln the first objective of this work we have observed a cross-inhibition with soluble 
fibronectin and collagen in the ECM binding assay, indicating that fibronectin and collagen binding 
domains exist on the same or nearby bacterial surface adhesins. To test if SsEno is one of the 
proteins responsible, for this' cross-inhibition between both proteins an ELISA binding assay 
between collagen and SsEno was done to test if SsEno is also responsible of the collagen-binding 
activity of S. suis. 
Purified rSsEno binding to immobilized collagen (Sigma) was determined by ELISA. 
Briefly, Maxisorp® flat-bottom mierotiter 96-well plates (Nunc, VWR, Mississauga, ON, Canada) 
were coated with 1 00. ~l of seriaI dilutions collagen in 0.1 M carbonate coating buffer (0.15% 
[wtlvol] Na2C03, 0.1% [wtlvol] MgCl2 - 6H20, 0.3% [wtlvol] NaHC03 [pH 9.6]) and incubated 
overnight at 4°C. Casein-coated wells served as a control for non-specific adhesion of rSsEno. 
Fibronectin and plasminogen coated wells served as a positive control for specific adhesion (Fig. 1 
A and B). The plates were washed three times with PBS containing 0.05% (v/v) Tween 20 (PB ST, 
pH 7.3), and 200 ~l of 3% (w/v) non-fat dry milk in PBST was added to each weIl to prevent non-
specific binding. After 1 h at 37°C, the wells were washed three times with PBST. Next, 100 ~l of 5 
~g ml-lof rSsEno was added and the plates were incubated for 2 h at 37°C. After several washes 
with PBST, optimally diluted rabbit anti-SsEno IgG were added to each weIl and the plates were 
incubated for Ih at 37°C. The wells were washed three times with PBST and specific horseradish 
peroxidase-iabelled IgG (Jackson Immunoresearch Laboratories) was added. Plates were then 
incubated for 1 h at 37°C with the secondary antibody and 3,3',5,5'-tetramethylbenzidine (Zymed, 
San Francisco, CA, USA) was used as the enzyme substrate according to the manufacturer's 
instructions. The reactions were stopped by adding 25 ~l of H2S04 (IN) and were read at 450 nm 
using a microplate reader (Uvmax; Molecular Deviees, Menlo Park, CA, USA). 
Results showed that SsEno does not possess collagen-binding activity (Fig. 1 C) and that, as 
consequence, it is not the responsible of the cross-inhibition between fibronectin and co Ilagen. 
These results also indieate that other collagen-binding proteins are responsible of the adhesion of S. 
suis to collagen. 
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Fig. 1. Representative ELISA analysis for the binding to 5 ug/ml SsEno binding to immobilized 
collagen. Binding was evaluated after 2 h. Fibronectin and plasminogen was used as positive controls for 
adhesion. Data are expressed as means ± standard deviations of at least three experiments performed in 
triplicate. 
xliii 
ANNEX6 
Identification of genes associated with the collagen-binding 
activity of Streptococcus suis using random insertional 
mutagenesis 
xliv 
As explained before, the ECM proteins h~ve been identified as an important host 
receptors involved in the bacteria-host adhesion (5). We have identified for the first time in this 
work that S. suis is also able to bind to collagen. Collagen is a polypeptide substance comprising 
about one third of the total protein in mammalian organisms (3). It is the main constituent of skin, 
connective tissue, and the organic substance of bones and teeth (3). In fact, different forms of 
collagen are produced in the body but aIl consist of three alpha-polypeptide chains arranged in a 
triple helix (1). The predominant form is Type 1 collagen. This fibrillar form of collagen represents 
over 90 percent of our total collagen. Type II collagen is the form that is found exclusively in 
cartilaginous tissues. It is usually associated with proteoglycans or "ground substance" and therefore 
functions as a shock absorber in our joints and vertebrae. Type III collagen is also found in our skin 
as well as in blood vessels and internaI organs. In the adult, the skin contains about 80-percent Type 
1 and 20-percent Type III collagen. In newborns, the Type III content is greater than that found in 
the adult. It is thought that the supple nature of the newborn skin as well as the tlexibility of blood 
vessels is due in part to the presence of Type III collagen. During the initial period of wound 
healing, there is an increased expression of Type III collagen (2). Type IV collagen is found in 
basement membranes and functions as a filtration system. Because of the complex interactions 
between the Type IV collagen and the noncollagenous components of the basement membrane, a 
meshwork is formed that filters cells as weil as molecules and light. Finally, type V collagen is 
found in essentially ail tissues and is associated with Types 1 and III. In addition, it is often found 
around the perimeter of many ce Ils and functions as a cytoskeleton. 
Although we have described that S. suis is able to bind to collagen, up to now any coll agen-
binding protein has been identified for this pathogen. The main objective of this project was to 
identify the S. suis collagen-binding proteins or the genes involved in this binding process. 
To permit its identification, a Tn917 mutant library produced from S. suis serotype 2 strain 
pl/7 was used (4). This library consists in about 1800 mutants each of one containing only one 
transposon insertion. For the identification of each different mutant, each bacteria composing the 
bank was named: letter (from A to P), number (l to 12), letter (A to H). 
Each mutant was tested for its ability to bind to collagen compared with their parental strain 
using a similar ELISA than those that is reported in the article 1 of this work. Brietly, collagen was 
coated to ELISA plate wells and after bloc king non specific binding to the weil with skimmed milk, 
each mutant was tested for its ability to bind to collagen using an specific polyclonal anti-S. suis 
antibody. 
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ELISA results of ail 1800 mutants were illustrated in Fig. lA. These results showed that 
only ten from the initial 1800 mutants have less than 30% of adhesion to collagen type 1 (red bar) 
compared with the parental strain Pl/7 (Fig lB). From them, only the ElA mutant has a significant 
reduction of adhesion to collagen type V (green, Fig 1 C). As explained in the introduction, different 
types of collagen were used because each one represents a different way that can be used by,S. suis 
to bind to the ho st tissues. It is important to note that an ELISA where each one of the ten mutants 
selected in the first step (Fig. lA) were coated to the plate and incubated with S. suis serotype 2-
specific rabbit antiserum was done. This ELISA was used as a control to verify that ail mutants 
react in a similar form with the antibody used in this work and that differences in adhesion are not 
due to differences in bacterial recognition by this specific antibody. Figure lB demonstrates that ail 
these ten mutants were recognized by the specific antibody against-S. suis in a similar form 
corroborating that the observed decrease in the adhesion to collagen is directly linked with the 
transposon insertion in the genome (Fig. lB). 
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Fig. 1. Adhesion of Tn917 mutants to collagen. Only 10 mutants have Jess than 30% of adhesion to 
collagen compared with strain PI/7 (A). Ali these 10 mutants react with specifie anti-S. suis 
polyclonaJ antibody in a similar way (B). ELISA results of the adhesion of the 10 mutants with 
collagen type 1 (in red) and to collagen type III (in green) 
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ELISA results of ail 1800 mutants were illustrated in Fig. 1 A. These results showed that 
only ten from the initial 1800 mutants have less than 30% of adhesion to collagen type 1 (red bar) 
compared with the parental strain P 1/7 (Fig 1 B). From them, only the ElA mutant has a significant 
reduction of adhesion to collagen type V (green, Fig 1 C). As explained in the introduction, different 
types of collagen were used because each one represents a different way that can be used by S suis 
to bind to the host tissues. It is important to note that an ELISA where each one of the ten mutants 
selected in the first step (Fig. 1 A) were coated to the plate and incubated with S suis serotype 2-
specific rabbit antiserum was done. This ELISA was used as a control to verify that ail mutants 
react in a similar form with the antibody used in this work and that differences in adhesion are not 
due to differences in bacterial recognition by this specific antibody. Figure 1 B demonstrates that aH 
these ten mutants were recognized by the specific antibody against-S suis in a similar form 
corroborating that the observed decrease in the adhesion to collagen is directly linked with the 
transposon insertion in the genome (Fig. lB). 
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Fig. 1. Adhesion of Tn9J 7 mutants to collagen. Only 10 mutants have less than 30% of adhesion to 
collagen compared with strain P 1/7 (A). AlI these 10 mutants react with specifie anti-S. suis 
polyclonal antibody in a similar way (B). ELISA results of the adhesion of the 10 mutants with 
collagen type 1 (in red) and to collagen type III (in green) 
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Once isolated from the rest of mutants, the Tn917 mutated genes from the 10 strains with 
decreased adhesion to collagen were identified by Plasmid rescue (Fig 2). 
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Fig. 2. Diagram of 
plasmid rescue 
technique. The genes 
targeted" and mutated 
with Tn917 were 
identified by digestion 
of genomie DNA of 
each strain with 
EcoRl restriction 
enzyme, ligation of 
fragments with T4 
ligase, transformation 
to E. coli, isolation of 
Tn917 containing 
plasmids by resistence 
to ampieillin and 
finally, sequeneing of 
the gene using 
specifie primers of the 
Tn917. " 
Plasmid rescue is a technique in which transposon disturbed genes can be identified by 
digesting the bacterial genome with a specific restriction enzyme (in our case Eco RI), relegation of 
the fragments obtained and transformation of the obtained "plasmids" in a host bacteria such as E. 
coli. As transposon contains a resistance gene for an antibiotic such as ampicillin, only bacteria 
containing DNA fragments with the transposon can grow in the presence of antibiotic. Once 
bacteria are isolated by this technique, the genes can be sequenced using specific primers localized 
in the transposon. Later, biocomputacional analysis using a BIast server can be used to identifY the 
genes corresponding to the sequence obtained after sequentiation. 
Our results revealed that different genes could be implied in the adhesion of S. suis to 
collagen. The genes identified are listed in Table 2. From aU the genes identifie d, none of them has 
a typical bacterial collagen-binding protein sequence. Moreover, non of them can be identified as a 
known gene involved in the export of adhesins to the surface. Regarding the literature any 
relationship between these genes and collagen has been found, so further research is necessary to 
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find the concrete role of these genes in the adhesion of S. suis to collagen. In addition, in 2 of the 
ten mutants was not possible to identify the gene by this method and other methods have to be do ne 
to determine which gen had been mutated by the transposon. 
NOM Cnl CnV Fn identification 
E1A 14% 50% 26% plasmid 
E5A 25% 85% 77% Excinuclease ABC 
HiOB 30% 75% 68% ORF2 (Aro operon) 
L2S 12% 80% 80% plasmid 
M9C 20% 83% 97% Auxin effiux protein 
Mi0C 12% 85% 96% Copper-translocating P-type 
ATPase 
NiiE 15% 82% 93% a/~ hydrolase fold 
Ni0H 13% 93% 89% Surface protein, anchor region 
S. suis FlpS gene (arginine 
Deim operon) 
P12D 15% 79% 86% Bacteriocin operon component 
SenE 
Q8A 17% 100% 100% Transglutaminase-like 
Table. 2. List of genes identified by plasmid rescue and Blast. 
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ABSTRACT 
Sao is a Streptococcus suis surface prote in recently identified as a potential vaccine 
candidate. In this study, recombinant Sao in combination with Quil A provided cross-protection 
against S. suis serotype 2 disease in mouse and pig vaccination protocols. Subcutaneous 
immunization of mice elicited strong immunoglobulin (Ig) G antibody responses. Ali four IgG 
subclasses were induced"with the IgG2a titer being the highest followed by IgG l, IgG2b and IgG3. 
Challenge of the mice with S. suis strain 31533 resulted in a mortality of eighty percent in the 
control group which received Qui! A only. In contras t, ail the mice immunized with Sao survived. 
In a pig vaccination protocol, intramuscular immunization with Sao also elicited significant 
humoral antibody response, and both IgG 1 and IgG2 subclasses were induced with a predominance 
of IgG2 production. In vitro assay showed that Sao-induced antibodies significantly promoted the 
ability of porcine neutrophils in opsonophagocytic killing of S. suis. An aerosol challenge of the 
pigs with S. suis strain 166 resulted in clinical signs characteristics of S. suis infection in diseased 
pigs. The vaccine group showed significantly better survival, lower clinical score and less S. suis 
recovery from postmorterm tissue samples compared with the control group. Furthermore, this 
study also revealed that although challenge S. suis strains express Sao size variants, recombinant 
Sao conferred cross-protection. These data demonstrate that recombinant Sao formulating with Quil 
A triggers strong opsonizing antibody responses which confers an efficient immunity against 
challenge infection with heterologous S. suis type 2. 
INTRODUCTION 
Streptococcus suis is an important pathogen of swine causing meningitis, septicaemia, 
arthritis, endocarditis, pneumonia and substantial economical losses in the swine industry 
worldwide (17, 23, 47). It is also an important zoonotic agent for humans in contact with diseased 
pigs or their products, causing life-threatening diseases as reported in a recent outbreak in China 
(43). Thirty-five serotypes have been described so far (17). Serotype 2 is the most prevalent type in 
association with diseases in most countries. The pathogenesis and virulence attributes of S. suis are 
not weil defined and attempts to control the infection are hampered by the lack of an effective 
vaccine (22). 
Different types of vaccines have been developed or are presently under investigation. At 
present, inattivated commercial autogenous vaccines are used in the field, but results have been 
inconsistent (20, 35). Furthermore, safety data for autogenous vaccines are lacking, which has 
liability implications for the use of this type of material (19). Attenuated or avirulent live S. suis 
strains have been tested and results were also equivocal (6, 26, 53). In addition to bacterins and live 
vaccines, a number of purified bacterial components have been developed as vaccine candidates. 
The capsule polysaccharide is a critical virulence factor of S. suis. However, a vaccine based on 
capsular material was unsatisfactory due to its poor immunogenicity (13). A vaccination strategy 
using purified suilysin (27), or muramidase-released prote in (MRP) and extracellular prote in factor 
(EF) (54) from S. suis serotype 2 have been shown to protect pigs from homologous and 
heterologous serotype 2 strains. However, a substantial number of virulent strains in sorne 
geographic regions do not express these proteins (14, 16,45). 
We recently identified a surface prote in (Sao) which is highly conserved among S. suis 
species (37). Convalescent swine sera have high titers of antibody against this prote in, suggesting 
that Sao is a pote nt immunogen that is expressed during S. suis infection. These findings made the 
Sao a candidate for use in a subunit vaccine. However, in a convenient test, immunization of piglets 
with recombinant Sao mixed with the oil-in-water Emulsigen® triggered a predominant production 
ofIgG1, and these antibodies lacked opsonophagocytic function and did not confer protection (37). 
This suggested that the quality of the type 1/type 2 immune response bias was inappropriate to 
mediate protection against S. suis. It is known that ho st protection against infection caused by S. 
suis, a highly encapsulated microorganism, is mediated primarily by opsonophagocytosis which is 
mainly associated with a Th1-type immune response characterized by IgG2a production (5, 17). 
Vaccine formulation and components, such as adjuvants, can dramatically influence a vaccine-
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induced antibody response including bias to type 1 or type 2 responses which may have a 
significànt effect on the protective efficacy of a vaccine (l, 31, 44). Evidence from vaccination 
using surface antigens of other Gram-positive bacteria indicated that the efficiericy of antibody-
mediated opsonophagocytqsis and protection can be dramatically improved by using Thl-directing 
adjuvants to promote a Thl-type immune response (2, 36). We therefore hypothesized that Sao may 
be protective in a vaccination protocol involving optimal adjuvant and higher antigen dosage. ln 
this study, the efficacy of recombinant Sao in combination with Quil A was demonstrated by 
protection against S. suis infection and disease in mice, as weil as in pigs, the target species of this 
vaccine candidate. 
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MATERIAL AND METHODS 
Bacterial strains 
Three S. suis strains of serotype 2 were used in this study. Strain S735 was used to clone the 
sao gene and to produce the protein (37). This strain is the reference strain and was originally 
isolated from a diseased pig in the Netherlands (28). Strains 166 and 31533 originated from pigs 
with meningitis (4, 33). Strain 31533 was chosen for challenging miee and strain 166 was used for 
challenging pigs. Bacteria were grown on plates made of Todd-Hewitt broth (Difco, Detroit, MI, 
USA) containing 2% .agar or in Iiquid cultures of Todd-Hewitt broth. 
Immunization and challenge of mice 
Recombinant Sao was produced and purified as previously described (35). Six-week-old 
female CD-1 miee were randomly assigned (according to their body weight) to two groups often, 
and immunized subcutaneously twice at a 2-week interval with either 20 IJ,g of purified Sao mixed 
with 20 IJ,g of Qui1-A (Brenntag Biosector, DK-3600 Frederikssund, Denmark) adjuvant or 20 IJ,g of 
Quil-A only as a control in 100 IJ,I of phosphate-buffered saline (PBS) per mouse. Ten days after the 
second vaccination, the animaIs were challenged intraperitoneally with 1 x 108 CFU per mouse of 
log-phase S. suis, strain 31533, in 1 ml of Todd-Hewitt broth. This challenge model was confirmed 
to reproduce septie shock and meningitis similar to those induced by S. suis in pigs (unpublished 
data). Miee were monitored daily for c1inical signs such as abnormal behaviour, rough hair coat, 
ataxia and mortality, until day 14 after the infection. Blood samples were collected prior to each 
vaccination and the challenge for determining antibody responses. Guidelines from the "guide to the 
care and use of experimental animaIs" of the Canadian Council on Animal Care were followed 
during the experiment, which followed a protocol that had been approved by the University of 
Montreal committee on animal care. 
Immunization and challenge of pigs 
Pigs were used to perform the immunization and protection experiment at the Vaccine and 
Infectious Disease Organization (VIDO, University of Saskatchewan, Saskatoon, Canada) in 
accordance with princip les outlined in the "guide to the care and use of experimental animaIs" of 
the Canadian Counci1 on Animal Care using a protocol that was approved by the University 
Committee on Animal Care. Four week-01d piglets with average weight of7.79 kg from a herd that 
is free of S. suis serotype 2 were randomly assigned to two groups oftwelve. AnimaIs were injected 
intramuscularly twice at a 2-week interval with 1 ml of either 200 IJ,g purified Sao mixed with 400 
IJ,g Qui! A or 400 IJ,g Quit A only in physiologieal saline as a control. Two weeks after the second 
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injection, the immunizedand control animais were challenged by aerosol of 1 ml (6.8 x 10 6 CFU) 
of a log-phase culture of S. suis strain 166 as previously described (39). Blood samples were 
collected prior to each injection and challenge for determination of antibody responses. Pigs were 
monitored for body temperature, c1inical signs and mortality for ten consecutive days after 
challenge. A daily clinical score (from 0 to 8) was derived as the sum of attitude and locomotion 
scores for each pig based upon signs of nervous, musculoskeletal or respira~ory disease as follows. 
Attitude: 0 = normal attitude and response to stimuli; 1 = inactive and slow to respond, and oculo-
nasal secretions; 2 = only responsive to repeated stimuli; 3 = recumbent, nonresponsive, unaware of 
surroundings; 4 = dead. Locomotion: 0 = normal gait and posture; 1 :::: slight incoordination, 
lameness and/or joint swelling but rises without assistance; 2 c1early uncoordinated or lame but 
stands without assistance; 3 :::: severe lameness and/or severe ataxia; 4 dead. Pigs having a clinical 
score greater than 2 on either scale were euthanized by lethal injection. Postmortem examination 
procedure was conducted for ail pigs. Brain, tracheobronchiallymph node and grossly affectedjoint 
samples from ail pigs and blood samples from euthanized pigs were cuItured for bacteria recovery. 
Enzyme-linked immunosorbent assay (ELISA) 
Titers of Sao-specific total IgG and IgG subclasses in mouse and swine sera were 
determined by ELISA as previously described (37). Briefly, Polysorb plates (Nunc-Immunoplates, 
Rochester, NY, USA) were coated ovemight at 4°C with 100 Jll per weil of the purified 
recombinant Sao at a concentration of 0.3 Jlg/ml in carbonate buffer. The plates were incubated 
with seriai dilutions of test sera in PBS containing 0.05% Tween-20 (PBS-T) for 1.5 h at room 
temperature. For determination of antibodies in mice, bound antibodies were detected by incubation 
with peroxidase-conjugated goat anti-mouse IgG, IgG l, JgG2a, IgG2b or IgG3 antisera (Serotec, 
Kidlington, Oxford, UK) for Ih at room temperature. For determination ofswine totallgG, bound 
antibodies were detected by incubation with peroxidase-conjugated goat anti-swine IgG(H+L) 
antisera (Jackson Immuno Research Laboratories, Inc., West Grove, PA) for 1 h at room 
temperature. For swine IgGI and IgG2 detection, mouse anti-porcine IgGl or IgG2 (Serotec) were 
used as the primary antibodies, and peroxidase-conjugated goat anti-mouse IgG(H+L) (Serotec) was 
used as the secondary antibody. The plates were developed with TMB substrate (Zymed, S. San 
Francisco, CA, USA). Absorbance was measured at 450 nm in an ELISA reader (Power Wave 340, 
Bio-Tek Instruments, Inc.,Winooski, VT, USA). The serum dilution that resuIted in an OD450 
reading of 0.1 after background subtraction was considered the titer of this serum. 
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Opsonophagocytosis assay 
To investigate the role of Sao-specific antibody in protection, total IgG was purified using a 
, 
prote in-A column (Pharmacia, Uppsala, Sweden) from sera pools of control or Sao-vaccinated pigs 
after the second immunization. Porcine neutrophils were isolate'd from pigs that belonged to a high 
health status herd. Complete normal serum from the healthy pig was used as a source of 
complement. An opsonophagocytosis assay was then performed as previously described (Chabot-
Roy, 2006). Briefly, S. suis 166 strain was suspended in complete normal porcine serum containing 
25 Ilg/ml of the purified IgG from either Sao-vaccinated pigs or control pigs, and pre-opsonized for 
30 min at 37°C. Neutrophils at a concentration of 5 xl 06 cells/ml were mixed with 1 xl 04 CFU/ml 
of the bacterial in microtubes and incubated 90 min at 37 oC with 5% CO2• The neutrophil cells 
were Iysed with sterile water and viable bacterial counts were performed on THA plates. Tubes with 
bacteria al one were treated similarly and used as controls. The tests were performed eight times. 
Results are expressed as percentage of killed bacteria. 
Western blot 
Fifty microliters of S. suis culture supematants were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SOS-PAGE) in 8% acrylamide gel. Proteins transferred to 
nitrocellulose membrane (Bio-Rad, Mississauga, Ontario, Canada) were detected by incubating 
ovemight at 4 Co with 1/200 dilution of the pooled sera from the mice which received two doses of 
Sao or from the control animais. in TBS-0.05% Tween- 20 containing 5% skim milk. Sao-specific 
antibody was detected with peroxidase-conjugated goat anti-mouse IgG (Serotec), and visualized 
using 4-chloro-I-naphthol (Sigma, St. Louis, MI, USA) as the substrate. 
Polymerase chain reaction (PCR) and sequences 
S. suis cell pellet from 5 ml ovemight culture was suspended in 1 ml of Iysis buffer (50 mM 
Tris-HCl, 5 mM EDTA, 3% SOS, 1 mg/ml RNase, pH 8.5) and transferred to a 2 ml screw cap tube 
containing 0.5 g of O.I-mm glass beads (BioSpec, Oklahoma, USA). The suspension was 
homogenized for 3 min at maximum speed using the Mini-Bead Beater (BioSpec). The sample was 
centrifuged for 3 min at 16000 x g in a microcentrifuge, and then the supematant wasused to 
extract the genomic ONA following standard procedure. The complete saD gene was amplified from 
the genomlc ONA using pSIF (5'-ATGAATACTAAGAAATGG-3') and pSIR (5'-
AATTTACGTTTACGTGTA-3') primer pair, and the ONA fragment flan king the repeating region 
in saD was amplified using pS2F (5'-GAAATATCGAACCCCCTAAAG-3') and pS2R (5'-
CTTCGACTGTACCATTTTGGT-3') primer pair. The PCR was performed for 5 min at 94 oC, 
followed by 30 cycles of 1 min at 94 oC, 30 s at 46°C, and 1 min at 72 oC in a thermal cycler 
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(Eppendorf Scientific Inc, Hamburg, Germany). The amplicons were analyzed on 0.8% agarose gel 
and sequenced using the same primers. 
Statistics 
Comparison between antibody titers and percentage of killed bacteria was do ne using t test. 
The clinical scores were transferred by ranking, and the significance of the difference between 
groups was determined by t test. Survival distributions were evaluated with chi-square analysis 
using the Kaplan-Meier method and the significance of the difference was tested using the Log-rank 
test. Fisher Exact Test was applied to compare the proportion of postmortem tissues from which S. 
suis was lecovered. A P value of < 0.05 was taken as significant. 
A 
Ivi 
RESULTS 
Sao-specific IgG and IgG subclasses 
Subcutaneous immuniza~ion of mice with Sao in combination with Quil A elicited a 
significant humoral IgG response after primary immunization. The second immunization boosted 
the specific antibody response which was significantly higher than the level after the primary 
immunization (P<O.OOI) (Fig. lA). Furthermore, ail four tested IgG subclasses were induced in 
Sao-immunized mice, with the IgG2a titer being the highest followed by IgG l, IgG2b and IgG3 as 
measured in the sera nine days after the second vaccination. The IgG2a titer was significantly 
higher than the titers of other IgG subclasses, including IgG 1 (P<0.05) (Fig. lB). In contrast, the 
Sao-specific IgG and its subclasses in sera of the mice before vaccination and the mice in control 
group were below the Iimit of detection. 
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Fig. 1. Serum antibody responses in mice immunized with Quit A (open cycles) or Quit A plus 
recombinant Sao (solid cycles). (A) Total Sao-specific serum IgO. (8) IgO subclasses in sera nine days 
after the second immunization. Antibody titers for individual mice are shown, with the average titer (n=IO) 
represented as a bar. *, P<0.05; **, P<O.Ol; ***, P<O.OOI. 
Similar patterns of immune responses were revealed in pigs that intramuscularly received 
200 /lg of Sao in combination of 400 /lg of Quil A. Primary immunization of pigs triggered a strong 
antigen-specific IgG response. The serum IgG titer was significantly higher th an that in control pigs 
received only Quit A and the pigs before immunization (P<O.OI). After a second dose of the 
vaccine, a significant increase in IgG level (P<O.OO 1) was seen in Sao-immunized pigs (Fig. 2A). 
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Assessment of IgG subc1asses demonstrated that while both IgG 1 and IgG2 subc1asses were 
induced in sera of Sao-immunized animaIs, the IgG2 response significantly dominated the IgG 1 
response (P<O.05) (Fig. 2B). 
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Fig. 2. Serum antibody responses in pigs immunized with Quil A (open cycles) or Quil A plus 
recombinant Sao (solid cycles). (A) Total Sao-specific serum IgG. (B) IgG subclasses in sera thirteen days 
after the second immunization. Antibody titers for individual pigs are shown, with the average titer (n=12) 
represented as a bar .• , P<0.05; •• , P<O.OI; ••• , P<O.OOI. 
Protection of mice against S. suis strain 31533 
Sixteen hours after administering the challenge infection with S. suis 31533, all mice in the 
non immunized control group exhibited c1inical signs, such as ruffled hair coat suggesting fever and 
slow response to stimuli. Beginning about four days after the challenge, eight of ten mice in this 
group successively developed severe central nervous system signs such as running in circ1es and 
opisthotonos. All eight of the ill mice died, or met criteria for humane euthanasia due to the severity 
of their condition. In contrast, most of the mice in Sao-vaccÎnated group showed only mild and 
transient rough hair after the challenge, and all mi ce survived the S. suis infection, resulting in 
complete protection from cause-specific mortality (P<O.OOl) (Fig. 3). 
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Protection of pigs against S. suis strain 166 
One pig in Sao-immunized group was humanely killed because of an unrelated disease and 
this pig was excluded from analysis of the effects of vaccination on disease. Aerosol challenge of 
the pigs with S. suis 166 strain resulted in diseases characteristic of S. suis infection. The mean 
accumulated c1inical scores of two groups are presented in Fig. 4A, and clinical signs were 
significantly less severe in the Sao-vaccinated group compared with the control group (P<O.05). 
The body temperature data showed no significant difference between the two groups, although the 
Sao-vaccinated group tended to have lower temperatures (data not shown). In the control group, 
three pigs died and four more were euthanized. due to high clinical scores prior to the end of the 
experiment, resulting in a survival rate of 42%. In contrast, only two pigs in Sao-vaccinated group 
were euthanized with a survival rate of 82%. Comparison of survival curves showed that survival 
time in the Sao-vaccinated group was significantly longer than that in the control group (P<O.05) 
(Fig. 48). 8acterial culture of samples from blood, brain, tracheobronchial lymph node and joint 
wasdone to monitor the infection level and the recovery of bacteria with colonial morphology 
typical of the challenge strain was summarized in Table 1. Although the number of organs with 
detectable bacteria in the Sao-vaccinated group was less than in the control group, only the 
proportion of positive braintissue samples from immunized pigs was significantly lower than from 
control pigs (P<O.OI) (Table 1). 
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Fig. 4. Protection of pigs immunized with Quil A (open circles) or Quil A plus recombinant Sao (solid 
circles) following challenge with S. suis 166. (A) Clinical scores (daily mean and standard deviation) of 
pigs after challenge. (8) Survival of pigs after challenge. The data are reported for eleven pigs in the Sao-
vaccinated group and twelve pigs in the control group, respectively. *, P<O.05. 
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No. of S. suis recovery/total no. of samples examined 
Sample P value 
Quil A Quil A + Sao 
Blood 4/9a 1/11 0.13 
Brain 10/12 2/11 0.003 ** 
Lymph node 8/12 6/11 0.68 
Joint 4/12 2/11 0.64 
Table 1. Bacteriological analysis of postmortem samples from pigs immunized with Quil A or Quil A 
plus recombinant Sao. a Postmortem blood samples could not be obtained from three pigs that died before 
they were observed. **, P<O.Ol. 
Functional activity of Sao-induced antibodies 
To determine the nature of protection, serum antibodies obtained from Quil A plus Sao-
vaccinated pigs were compared with antibodies from pigs that received Quil A only for their ability 
to promote opsonization phagocytosis and killing of S. suis 166 by porcine neutrophils in vitro. As 
shown in figure 5, antibodies from Sao-vaccinated pigs mediated significantly more efficient 
opsonophagocytic killing of S.suis than antibody from pigs that received adjuvant alone (P<O.OO 1). 
Quil A Qui! A + Sao 
Fig. 5. Effect of antibodies on opsonophagocytic killing of S.suis by porcine neutrophils. The antibodies 
were purified from pooled sera of pigs immunized with Quil A or Quil A plus Sao. Data are expressed as 
mean percentage ± standard deviation of killed bacteria and are representative of eight independent 
experiments. *, P<O.OOI. 
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Immune recognition of Sao protein and its variants 
Specificity of Sao-induced antibodies was demonstrated by western blot with sera pooled 
from Sao-immunized mice, which recognized the 8ao prote in of wild type S. suis strains as weil as 
the recombinant 8ao (Fig. 6). In contrast, sera from non immunized control mice did not react with 
the proteins (data not shown). However, size variation of 8ao was noted among the S. suis strains. 
WhiIe S. suis 8735 strain, from which the 8ao prote in antigen was produced, expressed an apparent 
110 kDa 8ao protein similar in size to the antigen, strain 166 and 31533 expressed 8ao variants of 
approximately 100 kDaand 93 kDa, respectively (Fig. 6). 
a b c 
Genetic analysis of Sao variants 
d Fig. 6. Western blot showing the variation in 
Sao protein of S. suis. Culture supernatants of S. 
suis strain S 735 (lane a), strain 166 (lane b), 
strain 31533 (lane c), and the purified 
recombinant Sao that was used for immunization 
(lane d) were separated bySDS-PAGE and th en 
transferred to membrane. Blot was detected with 
sera pooled from mice after the second 
immunization with recombinant Sao. The 
molecular masses are indicated on the left. 
The genes encoding 8ao variants were analyzed by PCR. As shown in Fig. 6, the size of saD 
varied among S. suis strains 8735, 166 and 31533, and corresponded to the size of the 8ao variants 
observed in the western blot. One of the features of 8ao p~otein is the presence of ten repeats of a 
27-amino-acid sequence separated by 3-amino-acid spacers near the C-terrninal (37). Analysis of 
the PCR fragments spanning the repeating region of saD suggested that a variable number of the 
repeats accounted for the size differences of saD (Fig. 7). Indeed, DNA sequence analysis revealed a 
deletion of 270 bp nucleotide sequence corresponding to three repeats plus the spacers in strain 166 
and a deletion of 450 bp sequence corresponding to five repeats plus the spacers in strain 31533, 
compared with the sequence of saD in strain 8735. 
a 
101 
Full-iength 
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500 
Fig. 7. peR amplification 
products of the fulJ-length of sao 
gene of S. suis and the DNA 
fragments tlanking the repeats 
of sao. The variations of complete 
saD were correspondingly revealed 
in the differences of the DNA 
fragments spanning the repeats. 
Lanes: (a) 1 kb DNA ladder (Life 
Technologies), (b) strain S735, (c) 
strain 166, (d) strain 31533 and (e) 
100 bp DNA ladder (Invitrogen). 
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DISCUSSION 
In our continued effort to search for S. suis protein(s) useful in the development of a 
vaccine, a highly immunogenic surface protein, Sao, was identified from a virulent strain (S735) of 
S. suis serotype 2. In a convenient pig immunization protocol, Sao in combination with Emulsigen 
triggered a predominant production of IgG 1 that did not confer the protection against S. suis 
challenge infection (37). In this study, we first used a mouse model to test the protective efficacy of 
recombinant Sao in combination with Qui! A and found that the experimental vaccine induced a 
predominant generation of IgG2a which confers protection against S. suis infection. This prompted 
us to further evaluate the protective capacity of Sao in combination of Qui! A in pigs, the target host 
of this potential vaccine. Indeed, it significantly protected the pigs against S. suis infection and 
disease. 
Induction of the appropriate type of antigen-specific immune responses is crucial for the 
success of vaccines. The IgG subclass produced as a consequence of immunization reflects the type 
of immune responses. In mice, serum IgG 1 is associated with Th2-type response, whereas serum 
IgG2a is associated with a Th 1-type response which is particularly effective at mediating bacterial 
opsonophagocytosis (49). Of the mouse IgG subclasses, IgG2a is the most effective at binding to 
the FcyRI on phagocytic cell (42, 49). Thus, it is likely that predominant IgG2a production in this 
CUITent mouse vaccination protocol contributed most to the observed protection. However, it is also 
possible that IgG2a is not the only effector of protection induced by vaccination with Sao. Sorne 
studies have shown that IgG2b and IgG3 are also associated with Th 1-type immune response and 
are critically involved in bacterial opsonophagocytosis and protection against infection of Gram- ! 
positive pathogen (9, 32, 41, 48). In this pig immunization and challenge protocol, the Sao-induced 
immune response was characterized by predominant IgG2 production. Although the concept of 
"Th lITh2" balance is not yet weil documented in pigs, recent evidence showed that porcine IgG2 
had greater complement activating ability than did IgG 1 (11). 
Adjuvants play an important role in the efficacy of vaccines. The type of adjuvant used can 
direct the type of immune response generated to an administered antigen (44). It has been 
previously shown that an appropriate adjuvant is essential in determining the outcome of 
vaccination, and that protection following vaccination was obtained only after switching immune 
responses to a predominantly Th 1 type, such as the vaccines against Streptococcus pneumoniae (2, 
40), Mycobacterium tuberculosis (38), Chlamydia pneumoniae (3) and Brucella abortus (21). The 
adjuvant Quil A has been shown to enhance the antibody levels, and more importantly to shift 
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response towards type l, thus resulting in the induction of both bactericidal and opsonophagocytic 
antibodies (12, 30, 31, 51). In this modified pig protocol, it appears that Sao combined with Quil A 
triggered an adequate immune response bias which consequently led to protectiop. To determine the 
nature of protection, Sao-induced antibodies were analyzed for their ability to promote 
opsonophagocytic killing of S. suis in the presence of white blood cells, an important 
immunological correlate of protective immunity against S. suis (7). We found that antibodies 
purified from the sera of pigs that received two doses of Sao vaccine in combination of Quil A 
exhibited strong opsonic capacity. Given our previous study in that Sao combined with Emulsigen® 
triggered a predominant production of IgG 1 and these antibodies lacked opsonophagocytic function 
(37), this result indicated that Sao in the present formulation may more adequately induce protective 
antibodies that' are capable of triggering leukocyte effector. The enhanced level of opsonizing 
antibodies is likely related to the predominant generation of IgG2, detected by using Quil A 
adjuvant. However, it should be emphasized that the type of immune response induced could be . 
also affected by the antigen dose (10, 15, 52). Comparing with our previous study in which 100 
Ilg/per pig of Sao was used, a dosage of 200 Ilg was applied in this trial. Although the exact 
factor(s) crucial in directing the immune response toward the adequate bias was not defined, this 
study did provide a basis of suitable formulation for further clinical evaluation of Sao prote in as a 
vaccine candidate for control of S. suis disease in pigs. 
S. suis strain S735, from which the saD gene was originally clone d, was not used for 
challenging the animais due to the controversial report about its virulence in experimental infection 
models (8, 50). We have previously confirmed that a Sao-specific antibody raised in rabbit cross-
reacted with ceillysates of S. suis strain 31533 (unpublished data) and strain 166 (37). Thus, they 
were chosen for challenging animais to investigate the cross-protection of recombinant Sao against 
heterologous S. suis field strains. The sera from the animais immunized with recombinant Sao 
recognized size variants of Sao expressed by S. suis field strains, suggesting that differences in Sao 
among the S. suis strains used in this study do 
not alter the immune recognition of the recombinant Sao-elicited antibody. One of the features of 
Sao protein is the presencé of a region of ten repeats near the C-terminal (37). Variation of repeat 
numbers has been commonly observed in bacterial proteins, such as EF of S. suis (46), the M-
prote in of Streptococcus pyogenes (18, 24, 25, 29), and alpha-like protein of group B Streptococcus 
(34). Therefore, we assumed that the size difference of Sao occurred due to variation in the number 
of répeats. This was confirmed by DNA sequencing. It has been proposed that the size variation of 
Gram-positive bacterial proteins, such as M-protein, is a mechanism by which organisms cao 
escape from the host immune system (18, 24, 25, 29). However, our study shows that Sao-specific 
antibody cross-reacted with Sao variants and moreover, Sao vaccine off ers cross protection against 
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S. suis expressing Sao variants. This discrepancy may result from the structural difference between 
Sao and M-protein. In M-protein, the highly variable repeat region presents in N-terminal halve and 
the highly conserved region in C-terminal halve (29). As aC-terminai anchored protein, the N-
terminus extends outwards from the cell and epitopes close to the C-terminus may be masked by 
other cell wall components. As a result, variation in the N-terminus alters the ability of certain 
antibodies, originally produced in response to the parent protein, to bind to the mutant molecules or 
opsonize the mutant organisms (29). Different from the M-protein, the variable repeat region in Sao 
is located in C-terminal halve and the conserved region in N-terminal halve (37). Therefore, 
deletion of sorne repeats does not render them inaccessible to antibody binding. 
In summary, we have shown that recombinant Sao in a vaccine formulation with Quil A 
higgers strong opsonizing antibody responses which confer protection against experimental S. suis 
infection. In addition, Sao protects from challenging strains expressing Sao size variants. These 
findings suggest that Sao is a potential candidate for development of a subunit vaccine against S. 
suis infection. However, an optimum vaccine formulation remains to be further studied. 
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ANNEX 8: ARTICLE V 
Disruption of srtA gene in Streptococcus suis results in decreased 
interactions with endothelial cells and extracellular matrix proteins 
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experiments and the laboratory work conceming the adhesion of SrtA mutants with the 
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ABSTRACT 
Streptococcus suis, a major pathogen of swine, is an emerging zoonotic agent which causes 
meningitis and septic shock. In this study, we investigated the ability of S. suis mutant Strain 
(SRT ~A) lacking the sortase A gene (srtA) to interact with host ce Ils and extracellular matrix 
(ECM) proteins, as weIl as its virulence in a mouse infection model. We demonstrated that mutant 
SRT~A had reduced capacity to adhere to and invade porcine brain microvascular endothelial cells 
compared to the wild-type strain. In addition, mutant SRT~A also showed significantly less 
adherence to plasma fibronectin, cellular fibronectin and collagen type 1. However, disruption of 
srtA had little effect on the virulence of S. suis in a mouse intraperitoneal model of infection. These 
results indicate that surface proteins anchored by sortase A are required for a normal level of 
bacterial binding. However, other factors may also be important for S. suis virulence and interaction 
with ho st tissues. 
lxx 
INTRODUCTION 
Streptococcus suis serotype 2 is an important swine bacterial pathogen associated mainly 
with meningitis but also with other diseases such as endocarditis, arthritis, septicemia, and 
pneumonia (12). Among 35 described serotypes, S. suis serotype 2 is the serotype mostfrequently 
recovered from diseased animais (12). Recently, serotypes 32 and 34, unlike other serotypes, have 
been shown to be more related to Streptococcus orisratti (14). As a zoonotic agent, S. suis has been 
isolated from human cases of meningitis, endocarditis, and toxie shock-like syndrome (27, 29). A 
recent, unprecedented outbreak in China resulted in >200 human cases that were directly Iinked to a 
concurrent outbreak of S. suis infection in pigs. Ofthese human cases, 20% were fatal (29). 
Our understanding of S. suis virulence factors remains limited. While a few factors have 
been shown to be critieal for virulence, others are considered as putative although their precise role 
in S. suis related pathogenesis has yet to be clearly defined (11). In addition, the multistep 
pathogenesis of men ingitis caused by S. suis is poorly understood (11). Most bacterial infections are 
initiated when bacteria adhere to host tissues. Likewise, initial interactions between S. suis and host 
tissues are also thought to be important for infection. In particular, interactions between S. suis and 
porcine brain mierovascular endothelial cells (PB MEC) from the blood-brain barrier (BBB), whieh 
separates the central nervous system (CNS) from the bloodstream (10, 16), are thought to comprise 
a key step in the pathogenesis of S. suis induced meningitis (25). 
The extracellular matrix (ECM) is a complex structural network beneath epithelial and 
endothelial cells and surrounding connective tissue cells (22). Recently, it has been established that 
S. suis binds to several immobilized serum and ECM proteins such as plasma and cellular 
fibronectinsand collagen types l, III, and V. Moreover, the adhesin(s) responsible for the se 
interactions are proteinaceous in nature (8). However, the mechanisms underlying interactions 
between these proteins and S. suis have "not been elucidated. In other Gram positive bacteria, many 
cell surface proteins possessing a Leu-Pro-X-Thr-G1y (LPXTG) motif have been repoited to 
mediate bacterial interaction with host ce Ils, namely ECM, and th us play an important role in 
virulence (19). These specific proteins are covalently anchored to the cell wall by sortase A (SrtA), 
a membrane-bound thiol transpeptidase enzyme (19, 20). Five sortases of S. suis have been 
described thus far: SrtA, SrtB, Srte, SrtD and SrtE (21). Of the five sortases, SrtA (recently 
classified as a class A sortase) has been shown to play a critieal role in anchoring LPXTG proteins 
to S. suis cell wall (7,21). 
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It is not clear whether SrtA and LPXTG proteins of S. suis are important for virulence and 
initial interactions between bacteria and ho st cells. In this study, we investigated the effects of a 
disruption of srtA gene on the capacity of S. suis to interact with PBMEC and ECM components 
and subsequently be virulent in an experimental mouse model of infection. 
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MATERIALS AND METHODS 
Bacterial strains and growth conditions 
S. suis serotype 2 reference strain NCTC 10234 and its mutant SRT~A, with targeted 
disruption of srtA as generated by allelic exchange via double crossover (21), were used in this 
study. Bacteria were grown ovemight onto sheep blood agar plates at 37 oC and isolated colonies 
were incubated in Todd-Hewitt broth (THB; Difco Laboratories, Detroit, MI, USA) for 8 h at 37 oC 
with agitation. Working cultures were obtained by inoculating 10 III of a 10-3 dilution of these 
cultures in 30 ml of THB and incubating for 16 h at 37 oC with agitation. Bacteria were washed 
twice in phosphate buffered saline (PBS) pH 7.3, and were appropriately diluted in cell culture 
medium before infection. An accurate determination of the number of colony forming unit per ml 
(CFU/ml) in the final suspension was made by plating onto THB agar using Autoplate® 4000 
(Spiral Biotech, Norwood, MA, USA). S. suis mutant SRT~A was grown in the presence of 5 !tg 
ml-lof chloramphenicol (Sigma-Aldrich, Oakville, ON, Canada). Both strains showed similar 
growth rates (data not shown). 
Cell culture 
The PBMEC/CI-2 cellline (24)was cultivated as previously described (Vanier et al., 2004). 
Briefly, cells were grown in a 1:1 mixture oflscove's modified Dulbecco's medium and Ham's F-
12 (Invitrogen, Burlington, ON, Canada) supplemented with 7.5% (v/v) heat inactivated fetal 
bovine serum, penicillin-streptomycin (Invitrogen), sodium bicarbonate, L-glutamine, human 
transferrin (MP Biomedicals, Solon, OH, USA), N-acetyl-cysteine, hypoxanthine, porcine heparin, 
human recombinant fi broblast growth factor-basic (Sigma-Aldrich), and ~-mercaptoethanol 
(BioRad Laboratories, Mississauga, ON, Canada). Flasks (BD FalconTM; BD Biosciences, 
Mississauga, ON, Canada) and 24-well tissue culture plates (Primaria, BD FalconTM) were 
precoated with 1 % (w/v) type A gelatin from porcine skin (Sigma-Aldrich). Cells were maintained 
at 37 oC with 5% C02 in a humid atmosphere. For assays, PBMEC were trypsinized by adding a 
trypsin-EDTA solution (Invitrogen) and diluted in culture medium at 8 x 104 cells/ml. The cell 
suspension was distributed in tissue culture plates and incubated to confluence. Before the 
experiments, medium was removed from the plates and replaced by medium without antibiotics. 
Adherence and invasion assays 
For adhesion assay, bacteria were pelleted, washed twice with PBS, and resuspended at 106 
CFU/ml in fresh cell culture medium without antibiotics as previously described (25, 26). Confluent 
cell monolayers were infected with 1 ml aliquots of bacterial suspension. Plates were centrifuged at 
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800 x g for 10 min and incubated for 2 h at 37 oC with 5% C02. The monolayers were washed five 
times with PBS, and incubated with 200 III of 0.05% trypsin-0.03% EDTA for 10 min at 37 oc. 
After the addition of 800 III of ice-cold deionised water, ce Ils were detached and disrupted by 
scrapping the bottom of the weil. Seriai dilutions of this cell Iysate were plated onto THB agars to 
enumerate viable bacteria. An invasion assay to quantify intracellular bacteria was performed in a 
similar manner as the adhesion assay, with one exception. Following the initial infection period, 
cells were washed twice with PBS and incubated with 1 ml of cell culture medium containing 100 
Ilg/ml of gentamicin and 5 Ilg/ml of penicillin G (Sigma-Aldrich) for 1 h at 37 oC with 5% C02 
(Vanier et al., 2004; Vanier et al., 2007). Levels of adhesion and invasion are expressed as the total 
number of CFU recovered per weil. 
Binding of S. suis to ECM proteins 
Bacteria grown to a late exponential-phase were washed three times in PBS, resuspended at 
a concentration of 108 CFU/ml in 0.2% (v/v) formaldehyde, and incubated ovemight at 4 oC. An 
enzyme linked immunosorbent assay (ELISA) was performed as previously described (8) using 
microtiter plates (Maxisorp, Nunc, VWR, Mississauga, ON, Canada) that had been coated ovemight 
at 4 oC with 100 III of plasma fibronectin (1 to 10 Ilg/ml) (Roche Diagnostics Corp., Indianapolis, 
IN, USA), cellular fibronectin (20 Ilg/ml) (Sigma-Aldrich), or collagen type 1 (1 to 12.5 Ilg/ml) (BD 
Biosciences) in 0.1 M carbonate coating buffer (pH 9.6). Wells were washed three times with PBS 
containing 0.05% (v/v) Tween 20 (PBST, pH 7.3), and blocked with 200 III of3% (w/v) non-fat dry 
milk in PBST. After 1 h at 37 oC, wells were washed three times with PBST and formaldehyde-
killed bacterial suspensions (100 Ill) were added. Plates were incubated for 2 h at 3~ oC and washed 
three times. A 100 III volume of S. suis serotype 2-specific rabbit antiserum (13) (diluted 1/3000 in 
PBST) was then added to each weil. Plates were incubated for 1 h at 37 oC and were washed three 
times. A volume of 100 III of horseradish peroxidase-Iabelled anti-rabbit IgG (Jackson 
Immunoresearch Laboratories Inc., West Grove, PA, USA) (diluted 1/8000 in PBST) was added 
and plates were incubated for 1 h at 37 oc. After washing three times with PBST, 3,3',5,5'-
, TetraMethyIBenzidine (Zymed, Invitrogen) was used according to the manufacturer's instructions. 
Reactions were stopped by adding 25 III of H2S04 (1 N) and then read at 450 nm using a 
microplate reader (UVmax; Molecular Devices, Sunnyvale, CA, USA). Uncoated and casein-coated 
wells served as background and non-specific adhesion of S. suis to protein coated control wells, 
respectively. In addition, controls were performed to ensure that S. suis serotype 2- specific rabbit 
antiserum recognized wild-type strain and SRT ~A equally. 
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Intraperitoneal mouse virulence model 
A total of 40 female CD1 6-week-old mice (Charles River Laboratories, Wilmington, MA, 
USA, 10 animais per group) were infected intraperitoneally with either 1 ml of S. suis strain NCTC 
10234 or 1 ml of mutant SRT~A (approximately 108 CFU in PBS). The CD1 mouse model was 
recently shown to be an excellent model of S. suis infection causing septic shock and meningitis (6). 
Body weight changes (due to an excessive production of pro-inflammatory cytokines) were 
recorded daily post-infection (p.i.) (6). Survival and development of clinical signs of meningitis 
were recorded over a 10-day period. In addition, bacterial numbers in blood and homogenized brain 
samples were determined by plating on sheep blood agar plates using Autoplate® 4000 at different 
timepoints p.i . Experiments involving mice were repeated twice (total number of 20 animais per 
group) and were conducted in accordance with the guidelines and policies of the Canadian Council 
on Animal Care and the principles set forth in the Guide for the Care and Use of Laboratory 
Animais, Animal Welfare Committee of the Université de Montréal. 
Statistical analysis 
All data are expressed as means 't standard deviations (error bars). Data were analyzed by 
twotailed, unpaired t test. Unless specified, ail assays were repeated at least three times. Statistical 
analysis of the survival data was performed with the LogRank test. A P value of S 0.05 was 
accepted as the minimal level of significance. 
lxxv 
RESULTS 
srtA gene contributes to the interactions between S. suis and endothelial cells 
As shown in Fig. 1, adhesion and invasion levels of mutant SRT ~A were strongly reduced 
to 16 ± 24% and 17 ± 12%, respectively, compared to those of the wild-type strain (considered as 
100%) when 106 CFU ml-l bacterial suspensions were used. Similar results were obtained with 
different concentrations ofbacteria (data not shown). The complemented mutant SRT~A (Osaki et 
al., 2002) showed adhesion and invasion values of 88 ± 17% (P = 0.008 compared to the mutant 
SRT~A) and 47 ± 4% (P = 0.004 compared to the mutant SRT~A), respectively. These results 
confinn that sortase A is at least partially invol~ed in S. suis-specificadhesion to and invasion of 
endothelial cells. 
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Fig. 1. (a) Adhesion to PBMEC by mutant SRTAA compared to the wild-type strain NCTC 10234. (b) 
Invasion of PBMEC by mutant SRTAA compared to the wild-type strain NCTC 10234. Adhesion and 
invasion are expressed as a percentage of the adhesion and invasion levels achieved by the wild-type strain 
NCTC 10234. Asterisk denotes values that are significantly different (P < 0.05) from those ofNCTC 10234. 
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srtA gene contributes to adherence of S. suis to ECM proteins 
An ELISA binding assay was used ta detennine. whether the mutant SRT ôA had altered 
capacity ta bind plasma and cellular fibronectins and collagen type I. As shawn in Fig. 2 (a), 
SRTôA had reduced binding ta plasma fibronectin by (P < 0.05) compared ta the wild-type strain. 
A similar decrease in adhesion ta cellular fibronectin was also observed (data not shawn). Binding 
ta collagen type 1 by mutant SRTôA was also diminished (P < 0.05; Fig. 2 (b». Adhesion ta 
fibronectin and collagen type 1 by bath strains was dependent on the prote in concentration (Fig. 2). 
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Fig. 2. Binding to different concentrations of plasma fibronectin (a) and coUagen type 1 (b) by 
mutant SRTAA compared to the wild-type strain NCTC 10234. Asterisk denotes values that are 
significantly different (P < 0.05) between the two strains. 
Effect of srtA gene disruption on virulence 
AnimaIs from bath groups showed only limited weight loss (0 ta 10% of initial weight) 
between day (d) 0 and d 5, with maximum loss observed at d 2 p.i. (data not shawn). In addition, 
weight gain from d 6 ta the end of the experiment was not significantly different between groups (P 
> 0.05; data not shawn). With respect ta cumulative survival, COI mice infected with SRTôA had 
slightly longer median survival (2 d), although this was not statistically significant (P > 0.05) 
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compared to mice infected with the wild-type strain (1 d) (Fig. 3). Both strains displayed a similar 
mortality rate, with 80% of ail animais dying within 10 d. Morbidity also did not differ between the 
groups; one mou se in each group developed clinical signs of meningitis (i.e. spatial disorientation). 
Blood and brain samples collected from infected animais during the first 2 d p.i. showed no 
significant differences in bacterialload between the two groups (data not shown). 
Fig. 3. Kaplan-Meier survival analysis of CDl mice infected with the wild-type strain NCTC 10234 
or the mutant SRTAA (P = 0.56 for survival times between both groups). Six-week-old CDl mice were 
inocùlated i.p. with 108 bacteria, and survival was monitored over a lO-day period. Data are expressed as 
mean percentage of live animaIs in each group (n=20). 
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DISCUSSION 
In this study, we demonstrated that the mutant SRT I1A strain of S. suis has markedly 
impaired interactions with PBMEC in vitro. These findings provide evidence that sortase A of S. 
suis is involved in adhesion to and invasion of ho st cells and are consistent with those reported for 
other Gram-positive pathogens, such as Streptococcus pneumoniae (15), Streptococcus sanguinis 
(28), and Streptococcus agalactiae (17). Our results also showed mutant SRTI1A has reduced 
binding to ECM proteins, suggesting that SrtA of S. suis may anchor LPXTG-containing microbial 
surface components which recognize adhesive matrix molecules (MSCRAMM) that mediate 
binding to plasma and cellular fibronectins and to collagen type 1. These findings are in agreement 
with previous studies on S. agalactiae (17) and S. gordonii (3), showing that SrtA-expressing 
strains bind in significantly higher numbers to fibronectin compared to isogenic srtA mutant strains. 
Together these results suggest that LPXTG proteins anchored by SrtA are at least partially involved 
in the interactions between S. suis and host tissues. 
Few LPXTG proteins of S. suis have been identified. Among these, the opacity factor of S. 
suis (OFS) and surface antigen one (Sao) have been recently described (1, 18). OFS is an opacity 
factor involved in virulence but not in colonization (1). Sao is an immunogenic prote in that is 
expressed on the bacterial surface and confers protection to immunized animais (18). Moreover, 
surface expression of sorne LPXTG proteins is downregulated after disruption of the srtA gene (21). 
Indeed, mutant SRTI1A of S. suis has reduced expression of more than 15 major prote in spots as 
visualized with two-dimensional polyacrylamide gel electrophoresis. Frorri the se protein spots, a 
previously described prote in, the muramidase-released prote in (MRP), as weil as other newly 
described proteins similar to 5'-nucleotidase, and encoded by the genes sntA, sntB, and sntC, were 
identified. In European S. suis strains, MRP is considered to be a virulence marker (11). Howevèr, 
MRP alone is not necessary for virulence in swine and is absent in most North American virulent 
strains (12). Other putative S. suis LPXTG proteins and their role in virulence have yet to be 
identified. Moreover, the precise LPXTG proteines) invo\ved in S. suis-host interactions are unclear 
and warrant further investigation. 
It should be noted that a deficiency of sortase A did not completely abolish interactions 
between S. suis and PBMEC or ECM proteins, suggesting that other factors may also contribute to 
S. suis mediated pathogenesis. This is in agreement with our previous observations (26) 
demonstrating that non-proteinaceous cell wall components, such as \ipoteichoic acid (LTA), are 
also invo\ved in interactions between S. suis and PBMEC. Other pathogens, such as S. pyogenes, 
lxxix 
have been shown to possess multiple types of adhesins (LTA and proteins) that mediate interactions 
with host cells (4). Non-LPXTG proteins (non-MSCRAMM) might also be involved in binding to 
ECM proteins. Notably, S. suis possesses non-MSCRAMM ECM-binding proteins such as FBPS 
(5), a 52-kDa IgG-binding prote in (23), and a recently described Enolase (9). In a previous study, 
bacteria coated with plasma fibronectin showed high levels of adhesion to and invasion of PB MEC, 
suggesting that S. suis uses plasma fibronectin as a bridge between bacteria and the host cell surface 
(26). Results obtained in the present study suggest that non-MSCRAMM as well as LPXTG-
containing MSCRAMM ECM-binding proteins may be involved in the se host-pathogen 
interactions. 
Disruption of srtA gene had little effect on, the virulence of S. suis in a mouse 
intraperitoneal model of infection. Our findings are consistent with those reported by Kharat and 
Tomasz (2003) showing that a srtA mutant of S. pneumoniae was as virulent as the wild-type strain 
in mice. Paterson and Mitchell (2006) demonstrated using a competitive infection model that srtA is 
a factor required for fitness rather than virulence of S. pneumoniae. It is not known whether a 
similar function can be attributed to srtA in S. suis infection, lndeed, there were no significant 
differences in levels of bacteremia between the wild-type and mutant strains. Survival of bacteria in 
blood is a critical step that enables the bacteria to disseminate throughout the ho st and ultimately 
gain access to the CNS. There is much evidence that the capsule is an important virulence factor 
that promotes bacterial resistance to phagocytic clearance (11). Recent results in our laboratory 
obtained using a coagglutination assay showed that the mutant SRT ~A is encapsulated 
(unpublished observation), which may explain its normal bacterial loads in blood. A high-grade 
bacteraemia was shown to be required for S. suis to subsequently reach the CNS, thus suggesting a 
critical role of the capsule for bacterial survival and dissemination in blood during S. suis invasion 
of the BBB (2). 
Lastly, other class C sortases genes (srtB, srtC, srtD and srtE) (7) may also contribute to S. 
suis-host interactions. In S. suis NCTC 10234 strain, three class C sortases genes (srtB, srtC, srtD) 
cluster together and are associated with LPXTG proteins (21). It is possible that these accessory 
class C sortases, which are present in about 50% of virulent S. suis strains (T. Sekizaki, unpublished 
observations), might specifically anchor the flanking LPXTG-containing proteins. Studies are 
ongoing in our laboratory to verify the role of other S. suis sortases in bacterial interactions with 
ho st ce lis and proteins. 
We conclude that S. suis SrtA anchors LPXTG-containing surface proteins, thus playing an 
important role in bacterial colonization of host cells and adhesion to ECM proteins. However, 
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anchorage of LPXTG proteins alone is not sufficient for virulence in mice. Together, these 
observations suggest that although LPXTG-containing surface proteins participate in multiple steps 
of the pathogenesis of S. suis infection, other npn-LPXTG proteins, including secreted, membrane-
bound and non-proteinaceous components, are likely to be involved in cell colonization, ECM 
binding, and virulence. 
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